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ABSTRACT 
Jacob Edward Wulff: Methods for Adapting Global Mass Spectrometry based Metabolomics 
to the Clinical Environment 
(Under the direction of Lloyd J Edwards) 
Metabolomics is a maturing field with successful application to research areas such as 
biomarker discovery and mechanisms of disease. With the ability to profile hundreds or even 
thousands of biochemicals simultaneously, many of which are also used in various laboratory 
diagnostics, the technology has the potential to replace a battery of clinical tests with a single 
test. However, the current state of global analysis presents several challenges for the clinical 
environment. This dissertation addresses two of these challenges. First is handling of missing 
values with respect to comparing an individual sample against a reference population. Second is 
the semi-quantitative nature of the liquid chromatography mass spectrometry. 
The first paper explores basic properties of metabolites, specifically the statistical distribution 
of metabolite concentrations and correlation between them. In human sample sets covering three 
different sample material appropriate for clinical testing, raw ion counts are shown to be vastly 
non-normal and consistently having a heavy right skew. Natural log-transformation is effective 
at removing this skewness and inducing Gaussian behavior, though departures from normality 
may persist in the tails of the distributions. Correlation between library-matched metabolites 
after removing artifact related features is also shown to be of only moderate degree in most 
cases.  
In the second paper, application of the log transformation is used to account for missing 
values in estimating population parameters of a reference cohort. Missing values are largely 
 
iv 
 
attributed to the true level falling below the detection limit of the instrument. Combining this 
assumption with the Gaussian model leads to two parametric approaches being introduced for the 
estimation of population parameters. These methods are shown to outperform standard 
imputation approaches in the field using a combination of simulations and real metabolomic 
datasets.  
The third paper addresses merging multiple global LC-MS metabolomic sets of the same 
biological sample type together. Typical normalization methods meant to account for sample to 
sample variation are presented and compared to alternative approaches using technical replicates 
and within batch scaling. Concentrations from targeted analysis of eight clinical biomarkers are 
used to show the superiority of these alternative approaches.
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CHAPTER 1: LITERATURE REVIEW 
1.1. Introduction to Metabolomics 
Metabolomics is the field concerned with the study of small molecule biochemicals, 
collectively known as metabolites, which are the intermediates and end products of metabolism. 
The metabolome refers to the entire set of such small molecules present in a biological organism, 
or specific part thereof. Metabolomic analysis is thus tasked with identifying, measuring and 
understanding the metabolome. This requires a combination of analytical chemistry, 
biochemistry and biology. Metabolites are generally defined as having molecular weight < 1k 
Daltons (Da; grams/mol) which helps to differentiate metabolomics from areas that focus on 
certain classes or species such as proteomics or lipomics [1-3]. Metabolites include a diverse 
background of chemical compounds including amino acids, carbohydrates, nucleotides, peptides 
and lipids among others. Such a diverse set of compounds present an analytical challenge to 
measure but offer a wealth of information. Indeed, because metabolites are directly involved 
with cellular function, information drawn from a metabolomic study will tend to be more 
phenotypic rather than genotypic [4, 5]. Beebe and Kennedy [6] as well as Koen et al. [7] 
illustrate the importance of incorporating metabolic knowledge along with genetic and 
phenotypic information. In this way metabolomics may be seen as compliments to other omics 
fields such as proteomics, genomics or transcriptomics. Metabolomics offers a wide range of 
applications from cancer research to bioprocessing. For the purposes of the proceeding document 
our interest is focused on clinical application and disease screening. Inborn Errors of 
Metabolism, a large class of congenital disorders resulting in impaired metabolic function, will 
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have a large presence throughout the document due to the available data; however, the 
majority of the principles discussed are generalizable to other applications of metabolomics. 
The work contained in this dissertation focuses on High Performance Liquid 
Chromatography Mass Spectrometry (HPLC-MS) which is the most popular method for 
obtaining high-throughput metabolomic data [8, 9]. A brief summary of this technology is 
provided here to help familiarize the reader with some the background of the paper.  
1.2. Chromatography and Mass Spectrometry 
Chromatography is used to separate dissolved compounds in complex mixture by exploiting 
the differential partitioning between two phases: the mobile phase and the stationary phase. The 
mixture to be separated is injected onto a fluidized bed containing the stationary phase, typically 
beads that are functionalized with lipophilic organic molecule. The mobile phase, a liquid state 
typically composed of an inert solvent, dissolves the mixture and is pumped through the 
stationary phase. Dissolved components partition between the liquid and surface of the stationary 
phase. Interaction with the surface varies by compound, causing the individual compounds to 
pass through the stationary phase at different. This is usually in the form of lighter compounds 
moving through more quickly while heavier compounds move more slowly and leads to a 
separation of the compounds over time. Chromatographic systems are identified by the type of 
mobile phase used. Gas chromatography (GC) refers to a gaseous mobile phase, usually a noble 
gas such as helium, while liquid chromatography (LC) refers to a liquid mobile phase, which is 
most commonly an aqueous solution containing an organic solvent (acetonitrile, methanol, etc.), 
acid (formic, phosphoric, etc.), and/or salt.  
As the different compounds elute from the chromatogram they are injected into the mass 
spectrometer (MS). The MS system consists of three main components: an ion source, a mass 
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analyzer and a detector. The ion source ionizes the individual molecules of the compound. These 
ions are then passed to the mass analyzer, which separates them according to their mass to 
charge (m/z) ratio. Finally, the detector tracks the individual m/z ratios and the number of ions 
associated with each. MS can be used to identify a compound based on the resulting profile of 
m/z ratios. When an individual molecule is ionized, the chemical bonds holding the molecule 
together may break, leading to a fragment ion. The number of ways in which a compound may 
fragment and the proportion of molecules that form those fragments relate directly to the 
structure of the parent molecule in addition to the ionization state of the parent molecule and type 
of fragmentation chemistry that is employed. This leads to one of the fundamental powers of 
MS: Different molecules produce different fragmentation spectrums. By cross-referencing the 
fragmentation pattern of an unknown compound against a library of known spectrums the 
compound may be identified. It should be noted that sources of ionizations can be divided into 
two broad categories which also correspond to instrumentation used. Hard ionization methods, 
such as Electron Impact (EI), lead directly to the fragmentation of parent compounds and are 
well suited for GC systems. Soft ionization, which includes the popular Electrospray Ionization 
(ESI) and other atmospheric pressure chemical ionization methods, ionizes the compound in 
such a way that a charge is supported by the molecule without fragmentation. While it is possible 
to measure the m/z ratio of parent molecules in this state it is not possible to identify the 
compound without the daughter ion spectrum. Therefore, soft ionization methods usually involve 
another step to force the fragmentation. Tandem Mass Spectrometry, or MS-MS, involves 
multiple steps of the mass spectrometry process with fragmentation occurring in between [10]. 
Soft ionization techniques are well suited for LC systems. 
In addition to the ion source, MS can be used to produce either positively or negatively 
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charged ions. Compounds, depending on their physical and chemical properties, may ionize and 
fragment much better in one ion mode over the other. Due to the wide range of physical and 
chemical diversity spanned by metabolites, it is advisable to incorporate multiple instrument 
conditions into the analysis in order to maximize coverage of the metabolome. The same mass 
analyzer paired to the same chromatography system can be used in both modes; however, the 
mobile phase will in most cases need to be different in order to facilitate positive ion formation 
or negative ion form [11]. 
GC-MS has been around for decades and by nature it is best suited for volatile compounds, 
or those that can be easily derivatized to a volatile state [12]. However, non-volatile and low 
vapor pressure, non-derivatizable compounds may fail to ionize under GC conditions. Despite 
these shortcomings, GC remained popular for many years until the development of high pressure 
pumps and other hardware for LC systems in the 1980s and 1990s. These advancements led to a 
superior level of sensitivity for the LC-MS system [13] making HPLC-MS the standard in 
metabolomic analysis.  
Alternatives to the pairing of mass spec and chromatography do exist but tend to suffer from 
a much lower coverage of the metabolome in comparison, particularly with HPLC-MS. The 
majority of alternatives, in practices, are focused on specific compound classes or other niche 
roles in which LC-MS does not perform as well. For example, capillary electrophoresis (CE) is a 
separation technique that offers tremendous potential in terms of sensitivity and has been 
successfully coupled to MS for the purpose of metabolomics analysis [14]. But combination with 
ESI is not trivial and hence the full potential of CE-MS has yet to be realized. In its current state 
CE-MS is best suited for the measurement of highly polar compounds [15, 16]. Issaq et al. 
provides a good overview of the separation techniques available in metabolomics [17].  
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The main competition to LC-MS for identification of metabolites would be Nuclear Magnetic 
Resonance Spectroscopy (NMR). NMR exploits the electromagnetic spin of specific nuclei 
containing an odd number of electrons to produce a spectrum of the number of differently 
bonded target nuclei and the relative proportions of each. In a similar manner to the MS 
spectrum, the NMR spectrum can be used to identify compounds. NMR has a number of 
advantages over LC-MS, namely that it does not require chromatography to separate compounds 
and, as it does require the breaking of chemical bonds, it is non-destructive to the sample. NMR 
has successfully been used in many metabolomics studies [18, 19] but the sensitivity is far 
inferior to that of HPLC-MS [20, 21]. For more on NMR see Larive et al. [22] and for a general 
overview of the analytical methods in metabolomics see Verpoorte et al. [23]. 
1.3. The Mass Spectrum 
As mentioned above, the MS process results in the breaking of chemical bonds, producing 
multiple ion features per compound. Consider a simple example with pentane, which is a five-
carbon chain with chemical formula C5H12. When ionized in a mass spectrometer any of the C-
C bonds may be broken and so the possible m/z ratios correspond to an ion with either 1, 2, 3 or 
4 carbons. Note that in metabolomics the majority of analytes involved are too small to stably 
support more than a single charge, so the m/z ratio is generally equivalent to the fragment’s 
mass. The relative heights of the peaks associated with each m/z relate to the relative stability of 
the ion (or corresponding neutral fragment) in question and serve to differentiate compounds 
with similar mass from one another. 2-methylbutane is a four-carbon chain in which the second 
carbon in the chain has a single carbon branch in place of a hydrogen. The chemical formula is 
identical to that of pentane, C5H12, but the branched structure of 2-methylbutane causes the 
four-chain carbon ion (peak centered around 57 m/z) to form more readily than it does with 
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pentane. Figure 1.1, curtesy of Chemguide 
[24], displays the fragmentation mass 
spectra of these two compounds. Global 
profiling will capture thousands to tens of 
thousands of features related to hundreds to 
thousands of metabolites. 
Separation of the ion features is 
performed by the mass analyzer with an 
emphasis on both resolution and sensitivity. 
Resolution refers to the ability to distinguish 
between two peaks, while sensitivity refers 
to the ability to detect an ion source. Among 
the most popular in metabolomics are quadrapole, linear ion trap (LIT), orbitrap, time-of-flight 
(TOF), and Fourier-transform (FT) [25]. MS-MS in inherent to some analyzers, like the ion traps 
and FT, allowing for multi-stage ionization within the same instrument. Some can be joined 
together, such as quadrapole-TOF configuration, to produce a similar multi-stage process and 
origination of the phrase “tandem MS”. Other analyzers can only operate in the traditional MS 
setup. For more specifics on the use of mass analyzers in metabolomics see Vékey [26]. 
1.4. Ion-centric vs. Chemo-centric 
Being able to associate fragment features back to their parent compound requires more 
advanced instrumentation, such as MS-MS and/or pattern recognition software. When these 
resources are available, analysis may performed at the compound level which is referred to here 
as the chemo-centric approach. Measurement will be carried on the quantitation, or quant, ion. 
Figure 1.1: Mass Spectrums of pentane and 2-
methylbutane. Both produce same mass fragments but 
at different relative proportions. 
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This quant ion may be the parent ion itself, typical for MS-MS, or it may be a pre-determined 
daughter peak used to signify presence of the compound. In the latter case, the quant ion is 
usually the most dominant peak in the compound’s spectrum. Minor peaks may also be used to 
confirm identification of the compound; however, these peaks are not used to quantify the 
compound. Absent the resources for the chemo-centric approach, data analysis must be carried 
out on all ion features without regard to parental origin. There are clear implications of the 
approach used on the resulting data. If an ion-centric approach is taken, the number of features 
can be up to 10,000 [27] whereas a chemo-centric approach will yield a much lower number of 
distinct biochemicals [28, 29]. Ion fragments associated with same parent molecule will 
extremely correlated, and thus resolution of these fragments into a single feature preferentially 
removes the most correlated variables. Finally, structural identification features allows for the 
removal of known contaminants which constitute the majority of features produced in MS 
metabolomics [30]. Removing these features not only reduces the size of the data but also likely 
alters characteristics of the data since these features are entirely the result of sample processing 
and lack any biological qualities as is the case with metabolites. It is worth pointing out that a 
chemo-centric approach does not by itself identify compounds by name. Naming requires 
referencing observed spectrums against an internal database, which can be very costly and time 
consuming to maintain in-house. Much of published literature has involved ion-centric data 
likely due to the challenges inherent to compound identification [31]. A few public and 
commercial databases are available [32-34]; however, precise matching can be difficult if the 
conditions (instrumentation, sample preparation, processing, etc.) in the study do not match those 
used to develop the library. Therefore, chemo-centric data may contain a mix of named and un-
named biochemicals.  
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1.5. Data Structure and Routine Analysis 
A metabolomics dataset is an array of n experimental sampling units, or more plainly just 
samples, and m metabolites (chemo-centric) or features (ion-centric). Orientation is arbitrary, but 
in these papers the convention is that the rows are the samples and the columns are the features. 
As such, denoting such a set as Y(n×m) gives  
 Y = ൥ 
y11
⋮
…
⋱
y1m
⋮
yn1 … ynm
 ൩ 
in which the sets of individual yji′𝑠 are the observed value of the i
th feature in the jth subject, i ϵ 
{1, …, m} and j ϵ {1, …, n}. In the case of MS, which is the focus of this dissertation, these 
observations are ion counts derived from the area of a peak associated with the metabolite or 
feature in question.  Ion counts vary dramatically between metabolites with average values 
ranging from the tens of thousands up to hundreds of millions or even billions, and hence are 
treated as continuous variables for statistical analysis purposes. On occasion it may be useful to 
consider the matrix as a collection of features or samples. This amounts to segmenting the data 
into a series of columns (features): 
 Y = [  y.1 ⋯ y.m] 
 or a stack of rows (samples): 
 Y  = ൥ 
y1.
⋮
yn.
 ൩ 
From here on the notation 𝒚௜ and 𝒚௝ are used to generically indicate all the observed values for 
either the ith feature in the data or the jth subject. That is yi = y.i = ൛y1i, …, yniൟ
'
 and yj = yj. = 
{yj1, …, yjm}.  
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Generally, a complete metabolomic set, illustrated in Figure 1.2, will also include details on 
the samples and features, respectively. The meta-data, labeled here as Dn×d, contains sample 
details most notably the study design information such as group assignments as well as potential 
factors of interest and possible covariates. Similarly, in certain cases the features may be grouped 
or associated in some way such as by biochemical pathway function or molecular mass. This sort 
of feature annotation, designated as Aa×m, is more likely to occur with chemo-centric data.  
The material, or matrix, that makes up a metabolomic sample is generally biofluid (plasma, 
serum, urine, saliva, sweat, etc) or tissue (muscle, heart, liver, etc.) from either plant or animal 
specimens, although technically any organic substance is permissible with the MS. Regardless of 
whether the dataset contains metabolites or the ion features, statistical analysis can be performed 
in roughly the same manner. However, the chemo-centric allows for the identification of artifacts 
and contaminants, which are features related to sample collection and processing and instrument 
performance [28]. For example, plasticizers, which include phthalates, can easily leach into the 
sample through contact with the test tube or other similar storage device. As another example, 
sample material derived from biopsy specimens can be contaminated by gel used during sonic 
Figure 1.2: Metabolomic Data Components. Set of metabolomic data comprises three matrices: sample details (D), 
observed feature values (Y) and feature details (A).  
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disruption of preserved tissue samples [35]. By identifying and removing these artifacts, a 
greater level of reproducibility is achieved [36].  
Common univariate statistical tests used in metabolomic studies include the t-test and 
ANOVA. Certain studies have even used the z-score to assess individual samples in a population 
[37]. Such applications are an important theme for this dissertation and the z-score itself will be 
discussed further in Chapter 4.  Due to the large number of variables, some form of adjustment 
should be made whenever univariate p-values are being produced, with some form of false 
discovery rate (FDR) method being most practical [27]. Popular multivariate methods are 
principle components analysis, linear discriminant analysis, and partial least squares regression 
among others [38]. 
1.6. Metabolomics Workflow 
The process of obtaining metabolomic data from a sample is intensive. There are six distinct 
phases in the metabolomics workflow which is shown in Figure 1.3. The first phase, sample 
collection, includes all activities related to obtaining physical specimens such as hypothesis 
formulation, experiment design, etc. Once the samples are collected, the samples are sent to the 
facility where metabolite data is obtained. All actions that take place in between sample 
collection and data analysis can be collectively referred to as pre-analytical. Here, the pre-
analytical aspects have been divided i nto four phases to impart some understanding of the 
complexity and influence these steps have on data analysis. The descriptions provided here are 
intended to give a general understanding of the purpose served by each phase. For further 
information on these topics several texts and articles available [39-43].  
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Sample preparation addresses two main goals. The first goal is to freeze or reduce metabolic 
activity. As intermediates of cellular function, metabolites often have rapid intracellular 
conversion and steps must be taken to preserve the status of the metabolome at the time the 
sample is obtained. This is known as “quenching”. The second goal is to lyse the cells contained 
in the sample to maximize recovery. As metabolites are contained within the interior of the cell, 
disrupting the cellular structure is helpful (or even necessary) in order to obtain measurable 
levels of the metabolites. This is known as “extraction”. Quotations are used because the  
description given here is an oversimplification. Specific workflows will vary depending on 
instrumentation, sample material and metabolite groups of interest. For example, derivatization is 
done in GC-MS but not in LC-MS or NMR. Instead these methodologies involve reconstitution. 
Figure 1.3: The metabolomics workflow. A metabolomics experiment begins with sample collection. Phases in 
green are collectively referred to as pre-analytical.  
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Other actions that may take place in between sample collection and data collection include, but 
are not limited to, addition of chemical solvents, homogenization, centrifugation, lyophilisation, 
storage, etc. This makes it challenging to completely describe the sample preparation process 
concisely. Instead the focus here is on the primary purpose of sample preparation. For more 
complete details on the sample preparation process see Metabolome Analysis by Villas-Boas, 
Roessner, Hansen, Smedsgaard, and Nielsen [39] or Collection and Preparation of Clinical 
Samples by Chetwynd, Dunn and Rodriguez-Blanco [43]. 
After the samples have been prepared, the samples are processed through the instrumentation 
of choice. This produces data records associated with each sample. But before analysis can 
begin, this data must be compiled and organized in way that allows the spectral information to be 
combined across samples. This is the pre-processing phase and include peak alignment, baseline 
correction (NMR data), binning of features (ion-centric), or metabolite identification (chemo-
centric) [38, 44-46]. The conclusion of these steps produces a data set consistent with that shown 
in Figure 1.2. 
The final phase before data analysis is processing which involve manipulating certain 
characteristics of the data in order to maximize analysis results. Handling of missing values, 
which plays an important role in this dissertation, is one such step and is discussed in more detail 
in section 1.7.3 and is the subject of Chapter 3. Two other steps common to metabolomics are 
transformations and normalizations. Based on the orientation defined in Figure 1.2, 
transformations refer to operations applied to the columns (metabolites/features) while 
normalizations are applied to the rows (samples). A larger discussion on transformations can be 
found in section 2.3 and normalization is the subject of Chapter 4. Briefly, the intent of 
transformations is to improve some feature of the biochemicals whereas normalizations serve to 
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reduce variation between samples due to endogenous effects [31]. This purpose helps marks the 
distinction between pre-processing and processing. Pre-processing steps are necessary to make 
these feature values comparable between samples. In contrast, data processing can be regarded as 
optional, but generally useful to enhance the signal or other characteristic of the dataset for 
analysis. This leads to some ambiguity to the term “raw” data. The rawest forms of the data is 
that prior to any pre-processing steps. This includes the individual scans from the mass 
spectrometer, of which multiple scans are required to cover the entire chromatographic peak for 
a given metabolite. However, because these scans cannot be meaningfully resolved without pre-
processing steps, the pre-processed data is sometimes referred to as “raw” data since this is data 
from which optional transformations or normalizations can be made. Plainly, this amounts to the 
difference between “raw scan” data versus “raw peak” data. In this dissertation the latter 
definition of raw is used. While pre-processing can influence the data, it is not the subject of the 
present document. Therefore, in this dissertation the term “raw data” implies the resulting data 
given whatever pre-processing steps have been selected.  
Normalization seeks to remove sources of systematic variation by dividing feature values of 
samples according to some metric associated with this variation. In biological organisms many 
processes are subject to tight physiological control. Homeostasis therefore affects many matrices, 
including plasma and cerebral spinal fluid [47]. But some matrices are subject to a high degree of 
sample-to-sample variation due to endogenous characteristics. Such is the case with urine, where 
volume levels can vary greatly depending on water consumption, diet, exercise and other 
physiological condition [47] Creatinine levels have long been associated with kidney filtration 
and are a common normalizer for urine, although osmolality has also been used [47, 48]. In cell 
culture studies metabolite levels can similarly be influenced by the amount of cellular material 
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present [21, 49]. Cell specific normalizers are cell count, protein concentration and DNA 
concentration [21]. Universally available normalizers, many of which are adopted from other -
omic fields, include total ion count, median ion count or housekeeping metabolites [49]. 
Normalization of this type is commonly used due the fact that it can be used in any matrix and is 
easy to calculate. However, it is susceptible to individual outliers and in cases where the 
experiment affects a large proportion of the variables, such normalization can actually remove 
the signal from the data. Many modifications have been made to total ion count for this reason, 
and improved normalization methods remain an active area of research [50]. Regardless of the 
normalizer, the underlying assumption is always the same: certain factors, pre-processing steps 
or biological, related to a sample cause an elevation or suppression of variable levels across the 
whole spectrum. The procedure is popular in proteomics where all variables are of the same class 
(proteins) but in metabolomics, where the variables span a number of classes and functions, the 
effectiveness is less clear. 
1.7. Clinical Utility and Challenges 
As stated previously, Inborn Errors of Metabolism (IEM) form a class of genetic diseases 
involving disorders of metabolism. In most cases a genetic defect leads to the coding of defective 
enzymes, which in turn inhibit the conversion of various substrates required for proper metabolic 
function. Individual symptoms and disease pathology can vary greatly depending upon the 
defective gene and resulting enzyme involved. Alkaptonuria, for example, is caused by a 
mutation in the gene responsible for creating the enzyme homogentisate oxidase (HGD) [51]. 
This results in a defective version of the enzyme homogentisate 1,2-dioxygenase, preventing the 
body from processing the amino acids phenylalanine and tyrosine [52, 53]. Buildup of the 
intermediate homogentisic acid occurs, the oxidated form of which is called alkpton, damaging 
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cartilage and heart valves which can negatively impact quality of life. Major symptoms may not 
present until the 3rd or 4th decade of life as it can take over 30 years for homogentisic acid to 
accumulate to dangerous levels in the body. Medium-chain acyl-CoA dehydrogenase (MCAD) 
deficiency presents in early childhood causing hypoglycemia and liver dysfunction [54]. Fatty 
acid beta-oxidation provides energy to the body after glucose and glycogen are depleted. A 
deficiency of the MCAD enzyme can quickly lead to fatty acid catabolism during periods of 
increased energy needs. Infants are particularly susceptible, and it is believed that prior to 
expanded newborn screening MCAD deficiency was responsible for a number of SIDs case [55, 
56]. Comparing the symptoms and pathology of alkoptonuria and MCAD deficiency helps 
illustrate how different one IEM case can be from another. As a whole, IEMs can affect any 
organ and can occur at various stages of life. There is no single diagnostic test to identify 
someone as having an IEM. Instead, diagnosis of an IEM begins physicians who suspect a case 
ordering a targeted test covering biochemicals that best fit the observed symptoms or to rule out 
a possible candidate. Based on the results of this first round testing, a second round of tests will 
likely be ordered. And so on. This amounts to essentially a guess-and-check approach to 
diagnosing IEMs which may be time consuming. 
Recently, global metabolomics have been used to identify a wide range of IEMs [37, 57]. In 
these studies, samples of human plasma and urine from subjects with known IEMs were profiled. 
In the majority of IEM cases, metabolites that were informative of the subjects underlying 
disease were significantly expressed when compared to control group, thus demonstrating a 
proof-of-concept for using global metabolomics as a screen for IEMs. However, several items 
related to the instrumentation and data processing of LC-MS metabolomics complicate the 
clinical utility of this technology. First is the need for a normal reference population through 
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which outlier metabolites can be identified. MS data is inherently semi-quantitative and are 
subject to run-to-run instrument variation. Yet it is infeasible to run a large set of control samples 
with every run of the instrument. Thus, practical application requires the ability to bridge 
different instrument runs together. Effectively dealing with these missing values and day-to-day 
instrument variation as part of the data analysis, particularly in a clinical environment, serves as 
the motivation for this dissertation. Second is that global MS metabolomics suffers from a high 
rate of missing values, which complicate patient assessment in a clinical setting. The purpose of 
this dissertation is to identify the optimal statistical methodology and data processing steps 
related to these issues when applying global MS based metabolomics in the clinical setting. 
1.7.1.  Relative Quantitation 
Although MS is a very common analytical tool, it is not inherently quantitative. This means 
the ion count values returned by the mass spectrometer are not directly indicative of 
concentration. Instead the quantitation is relative, which is to say that the relative ion counts 
between samples run together can be inferred. For example, suppose the observed ion counts for 
creatinine in two samples analyzed in the same batch are 100,000 and 130,000. From this it can 
be inferred that the second sample contains approximately 30% more creatinine than the first 
sample, although the exact amount of either is unknown. Determining the exact amount involves 
elaborate methods. For instance, the gold standard method utilizes a stable isotope dilution assay 
which incorporates spiking known concentrations of the purified isotope associated with the 
compound of interest along with process controls to monitor extraction efficiency and matrix 
effects [58-60]. This is the process behind targeted analysis, so named because it focuses on the 
analytes of specific compounds (i.e. targets) and the instrumentation is typically optimized for 
these compounds. The challenges of targeting high throughput data is obvious. When utilizing 
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the global approach, all the metabolites detected may not be known up front. Even if they were, 
identifying associated isotopes, obtaining purified reserves and fitting the full dilution assay 
structure into workflow. As a result, global methods currently exist separately from targeted 
methods. A consequence of this is that separate runs of high-throughput MS, or “untargeted”, 
datasets cannot be directly compared. Overcoming this limitation so that samples can be 
compared across multiple batches is one goal of this dissertation. 
To better understand the semi-quantitative nature, it is helpful to explain how the ion counts 
returned by MS relate to the true concentration. The mass spectrometer is attempting to ionize 
the individual molecules of any given metabolite. The ion count is dependent on two things. One 
is the number of molecules present which depends not just on concentration but also molar mass, 
the number of molecules for a given mass of the compound. A smaller, lighter compound will 
thus have more molecules than larger, heavier compound when both are present at the same 
concentration. The second item influencing ion counts levels is the propensity of the molecule to 
stably carry a charge. This is referred to as ionization efficiency and is dependent on many things 
including chemical structure, meaning it will vary by biochemical, but sample handling and 
instrumentation. Here, instrumentation refers to the specific components, such as mobile and 
stationary phases, ionization method and even sample material. Some of these factors are static, 
i.e. molar mass, or can be controlled with choice of instrument, i.e. ionization method. But others 
will vary from run to run of the instrument. Certain components of the mass spectrometer, like 
the column/stationary phase, degrade over time and must be replaced, the exact solution of the 
mobile phase may vary from lot to lot, various sample preparation steps are performed manually, 
etc. While the instrument and sample processing can be monitored for performance in various 
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ways to indicate when components are needing to be replaced, these items induce variability 
causing the ionization efficiency to vary from run to run.  
Rocke and Lorenzato presented an analytical chemistry model with two sources of error to 
more accurately estimate instrument error [61]. The argument for two components is based on 
empirical experience in which low level concentrations tend to have a near constant error rate but 
at higher levels the error tends to increase as the concentration does. This phenomenon was 
answered by two error components: a linear component and a component that is multiplicative of 
the concentration. This premise forms the basis of model 1.1. Letting y୨୧ be the observed ion 
count and xji be the true concentration of metabolite j in subject i, the model used here is as 
follows: 
yji = α + cixjie
ηji  + εji model 1.1 
with ηji ~ N(0, ση
2),  εji ~ N(0, σε2). Both errors are independent and identically distributed random 
variables with εji being the linear error component and ηji representing the proportional error 
term. The intercept α represents the ion count returned when no amount of the metabolite is 
present and is analogous to the background level of the instrument. The coefficient ci represents, 
generally, the overall ionization efficiency of the system for the biochemical in question. This 
model accounts for the observed behavior in analytical methods since at low levels εji tends to 
dominate the observed error as smaller values of xji results in less contribution from ηji. 
However, as xji increases the greater the impact of ηji causing this term to dominate at high 
concentrations. This is also compatible with the relative assumption between samples as the 
expected value of between any two samples i and i' for a given feature is 
 E[yji] = α + cixji 
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 E[yji'] = α + cixi'j 
α is mostly a nuisance parameter and many pre-processing steps involve removing counts that 
are not at least 3x to 5x above the baseline level. Therefore, this term may often be assumed as 
small enough to be ignored. Ignoring the intercept term gives the expected ratio of sample i to 
sample i' as xji xji'⁄  which is consistent with relative quantitation. 
While ci is certain to vary from feature to feature, it is unknown if α, ση or σε do. Background 
and error can theoretically vary from feature to feature, though careful monitoring of instrument 
performance should indicate when this occurs and trigger remedial steps. After all, it is not 
uncommon for background levels to increase over time in MS instruments. This would imply, 
since features are processed over time within a sample and samples are then processed 
sequentially through the instrument, the background could vary not only by feature but by 
sample as well. This quickly leads to a model with more unknowns than observations, requiring 
additional assumptions to solve. Since instrument drift often tends to be linear, assuming 
linearity and examining the levels of housekeeping features, spiked in during sample preparation, 
in quality control samples interspersed through the instrument run provides an easy way to 
monitor for such drift. Significant inflation of either error component would lead to large 
increases in the variation of housekeeping markers, which would be grounds for re-analysis. 
Hence it is reasonable to treat the background and error components as fixed. 
Lastly, to extend the model to multiple instrument runs, all model components related to 
instrument performance should be adjusted accordingly. As a result, considering, hypothetically, 
the same set of samples run over multiple days gives 
yjik = αk + cjkxjie
ηjik  + εjik model 1.2 
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where k ϵ {1, …. } indexes the instrument run. ηjik ~ N(0, σηk
2 ), and εjik ~ N൫0, σεk2 ൯. Obviously, 
from run to run the concentration of the sample does not change. The slope and ionization factor 
can change though, as can the distribution of the errors and background. Examining the expected 
value of the same sample from one run to another gives: 
 E ቂyjikቃ  = αk + cjkxji ∗ 𝑒
σηk
2 ଶ⁄  
 E ቂyjik'ቃ = αk' + cjk'xji
∗ 𝑒
σ
ηk'
2 ଶ⁄
. 
Again, ignoring the intercept terms leads to, on average, a proportional relationship between the 
two runs with the second run differing by a factor of (cjk 𝑒σηk
2 ଶ⁄ )/(cjk'𝑒
σ
ηk'
2 ଶ⁄
) compared to the first 
run. Combination of multiple instrument runs can be accomplished by estimation of this ratio. 
This is the subject of Chapter 4. The effect of the varying background from run to run may result 
in some features, particularly those of low level, being lost or having more missing values (see 
section 2.1.2.) in certain runs as their detectability fails to rise sufficiently above the background 
level. Different error variances may result in certain runs being more precise than others; 
however, if all runs are deemed to be acceptable then combined error should also be acceptable 
provided the ratio (cjk 𝑒σηk
2 ଶ⁄ )/(cjk'𝑒
σ
ηk'
2 ଶ⁄
) is adequately accounted for. 
1.7.2.  Missing Values 
Not all of the yji's will have an observed ion count. Compared to other omics fields the rate of 
missing values in global MS metabolomics data is quite high [33, 62-64]. Theoretically, missing 
values can be caused by a number of technical issues, such as ion suppression [65], but the 
technology used is very similar to that used in proteomics where the missing rate is much lower 
[66]. The major difference is that metabolite species are of a much lower molecular mass and 
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abundance (average ion count) than proteins, and metabolomics workflow is optimized to these 
molecules. In a well-functioning instrument in which technical issues are minimal, missing 
values can largely be attributed to the true value falling below the background level of the 
instrument [62, 64]. In extreme cases the metabolite may be completely missing from the 
sample, a situation most likely to hold for drug metabolites or other xenobiotics. This detection 
limit depends on certain physical and chromatographic properties of each chemical compound 
meaning that it will vary from compound to compound.  
Missing values can technically occur for other reason [67, 68]. If the analytes of two 
compounds elute close together with one peak being relatively large peak and the other being 
relatively small, the dominate peak may prevent the lesser peak from being recorded. In this case 
the missing value is not due to the abundance of a neighboring compound and un-related to the 
level of the lost compound. Another possibility is that a peak is missed because it occurs in-
between scan intervals or because a certain scan records poorly, in which case missingness is 
also unrelated to the true intensity level (this can be avoided by increasing the scan rate, but 
doing so may negatively impact other areas of instrument performance). A literature survey 
returned no studies on the proportion each of these contribute to the overall missing rate. Given 
the wide range technological methods used in the field this is likely to depend the analytical 
approach and type of instrumentation. But it is increasingly of interest to treat missing values in 
MS as limit of detection [69], and in a well-functioning MS system this would theoretically be 
the dominant reason for such occurrences.  
Due to the prevalence of missing values, addressing them forms an important step in the 
analysis workflow. From the experience of the authors, in large chemocentric MS analysis 
almost every sample is guaranteed to experience a missing value in at least one feature and 
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roughly half of the features will experience some amount of missing data. The spirit of high 
throughput metabolomics is the ability to identify a large quantity of metabolite features at once. 
Imagine in a study comparing healthy subjects to some disease in which a feature is found only 
to be present in the disease subjects. Such a feature would hold enormous research value, not just 
for disease identification but also potential treatment. So, in one sense low filled compounds can 
be the most alluring to researchers. Any step which reduces the number of identified features 
chips away at the potential and attraction of global metabolomics.  
However, data quality is also important to obtaining confident, reproducible results. Filtering, 
which removes features when the proportion of missing values is above a certain percentage, is a 
compromise that mitigates the impacts of missing values and is gaining some popularity. 
Removing the most sparsely populated compounds improves reproducibility, but still runs the 
risk of removing potential markers from being discovered. And because global metabolomics 
operates on the front line of biomarker discovery, markers that are missed at this stage may never 
be recovered later on. Whether filtering is applied liberally or conservatively, missing values 
persist to some degree and must be dealt with somehow during statistical analysis. With global 
metabolomics functioning mostly as a biomarker screening tool, researchers often desire a 
complete dataset from which to work and try various approaches. Imputation, which involves 
inserting a value in place of the missing observations, is therefore common. For example, 
average imputation replaces the missing values in a given feature with the mean of the observed 
samples in that feature. Similarly, minimum imputation, which is analogous to LOD, replaces 
missing values with the observed minimum. Numerous other types of imputations methods have 
been used in metabolomics, with none being found to be universally “best”. In fact, the optimal 
approach is likely specific to goals and study design [62-64]. Here it is important to note that the 
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clinical setting differs in several critical ways from the usual biomarker discovery setting. First, 
in contrast to the group-based designs of biomarker discovery, clinical analysis involves 
comparing one patient against a control population or set of reference values derived from such a 
control population.  Second, interest is only in the patient sample which means that imputation of 
control population to achieve a complete data set is not strictly necessary. All that is needed are 
accurate measures of relevant parameters that are derived from the control population. This is a 
novel issue for high through put metabolomics and is the subject of Chapter 5.  
1.7.3.  Metabolite Distribution 
As a maturing field of study, there exists several fundamental unknowns in metabolomic 
data. Among these include the distribution of metabolites themselves. Under the proposed ion 
intensity model 1.1, yji has error components that are both normal and log-normal. In the 
previous section it was discussed how these components influence the distribution for a fixed 
level abundance level. But, the overall distribution of yji will also depend on the distribution of 
xji, the true concentration of the population. Since metabolomics studies often involve factorial 
designs leading to t-tests and ANOVA while simultaneously employing a low number of 
samples, normality is a convenient assumption. There is biological reason to believe metabolites 
are normally distributed. Many biological matrices, including blood/plasma, are subject to 
homeostasis. Tight process regulation could easily lead to a normal behavior. Clearly though, the 
ion intensity model and log-normal behavior of η makes the validity of such an assumption 
questionable. If xji is normal than the product xjie
ηji  is not strictly normal or log-normal, though 
may still be close to normal if ση2 is small relative to the population variance σi2. Some 
examination of normality has been done [27], though it has primarily used ion-centric data which 
contains a high proportion of artifacts [30]. Since these features are closely tied to the 
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performance of the instrument, it is likely that most influential error component is σε2 which 
indicates a normally distributed variable. It is the experience of this author that in chemo-centric 
data metabolites are most accurately described as log-normal. There is some existing evidence to 
support the use of log transformation with metabolites [70, 71]. This could be explained partially 
by the property of the log-normal distribution that holds the product of two log-normal 
distributions, which would the case for xjie
ηji if xji is log-normal, is another log-normal with 
variance equal to the sum of the individual variances. This combined variance would help to 
diminish the relative contribution of σε2. By establishing the distribution of metabolites, the door 
is opened for parametric approaches to handling missing values and is hence a natural place for 
the papers in this dissertation to begin.  
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CHAPTER 2: DISTRIBUTION AND CORRELATION 
2.1. Overview 
Global metabolomics has been developed as a screening platform. This primary function can 
be attributed to cost and difficulty in obtaining sample material, which in turn leads to 
metabolomics having experimental designs with small sample sizes [1]. Another characteristic of 
metabolomic sets are the frequent use of factor designs such as water-stress conditions in plants 
[2] or disease staging [3]. This approach fits well with the semi-quantitative nature of MS where 
only relative difference between samples are meaningful. One cannot use global MS to answer 
how many days of drought it takes phenols or flavonoids to fall below a certain mg/dl 
benchmark, for example. This would be more appropriate for targeted analysis [4].  
However, it is possible through global metabolomics to examine what biochemicals have 
significantly higher or lower levels in water stressed plants compared to non-stressed plants. The 
low sample size, semi-quantitative nature and group-based comparisons combine to position 
global metabolomics primarily as a tool for identifying the most promising candidates from 
hundreds, or even thousands of features. This group-based approach to biomarker identification 
has naturally led to wide spread use of two sample t-test and ANOVA, which have become the 
go-to statistical procedures for metabolomics. The hypothesis tests here involve the means of the 
groups, which for the simple two group setting is 
H0i: µ1i = µ2i 
HAi: µ1i ≠ µ2i 
For i = 1, …, m. The features can then be ranked by p-value. However, an underlying 
32 
 
assumption to these univariate methods is a normal distribution. Normality is also central to 
certain multivariate procedures including MANOVA and linear discriminant analysis. Yet, 
biochemicals themselves are not biologically constrained to a Gaussian behavior [5, 6]. 
Generally, this concern would be avoided by using non-parametric equivalents, such as 
Wilcoxon rank sum or Kruskal Wallis, but the lower power of these tests coupled with the low 
sample size make this option undesirable or even impractical. Focusing for a minute on the 
Wilcoxon test, the hypothesis tested is 
H଴: Distribution of Group 1 = Distribution of Group 2 
HA: Distribution of Group 1 ≠ Distribution of Group 2 
In metabolomics though, it is possible to have as few as three observational units per group [7]. 
A comparison of two such groups using the Wilcoxon test gives the lowest possible obtainable p-
value as 0.1, and this is before any adjustments for multiple comparisons are made. Hence 
parametric hypothesis testing is preferred, and normality is, therefore, a desirable trait. Yet little 
research has been devoted to the distributional behavior of metabolites. Vinaixa et al. [1] have 
previously assessed normality in ion-centric datasets, finding the majority of the features from 
four separate data sets “pass” for normal. Three different types of sample material were covered 
by these sets: two retina, one serum and one cell culture. Given the differences between ion-
centric and chemo-centric data (Section 1.9) [8], it is natural to extend this discussion to the 
chemo-centric setting. This chapter does so using LC-MS metabolomic data with a variety of 
assessment tools and transformations. The results suggest that metabolites can be reasonably 
regarded as log-normal, which is to say that normality is achieved following a natural log 
transformation.  
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Another item of interest is the dependence or association between metabolites. While 
univariate approaches have historically dominated in metabolomics, certain multivariate 
procedures, most notably principal component analysis, are also used widely in metabolomics. 
Correlation plays an extremely important in multivariate statistics. For example, variable 
correlation can have significant impact on the power and Type I error rate of MANOVA [9], 
correlation plays a fundamental role when choosing between LASSO and Elastic Net [10], and 
many network analyses, including Gaussian graphical models, rely on correlation or partial 
correlation. Literature on correlation analysis has been small and inconsistent in metabolomics. 
Vinaixa et al. [1] commented that LC-MS metabolomics is “multi-correlated” to the point that 
certain features border on being collinear, whereas Camacho et al. [11] observed “the large 
majority of metabolite pairs showed little or no correlation”. Clearly this is an issue for which 
greater understanding is beneficial. 
This chapter is devoted to examining the distribution of metabolites, specifically focusing on 
normality, and correlation. Three separate cohorts comprising samples of human plasma, urine 
and cerebral spinal fluid (CSF) were profiled using LC-MS based chemocentric metabolomics. 
Each set is composed of between 30 and 40 healthy individuals creating reasonably large sets of 
single populations with which to explore metabolite properties. All three sets were indexed 
against a propriety library allowing for biochemical identification and arrangement by 
biochemical pathway [8, 12]. This level of annotation allows for further assessment within and 
between the different types of datasets.  
2.2. Assessing Normality 
Normality is one of the richest subjects in statistics with the literature spanning from the 
early 1900s to the present day [13, 14]. Summary measures can be used to assess normality. 
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Most of these metrics revolve around the concepts of skewness and kurtosis. Skewness attempts 
to measure the amount of asymmetry while kurtosis relates to the amount of overall “tailedness”, 
“shoulderdness”, or “peakedness” of a distribution [15, 16]. Skewness is most commonly 
expressed numerically as the third standardized moment, which for Yi a random metabolite 
feature, is defined as: 
𝛾௜ = E ൥
 ൫𝑌௜ − µ௜൯
3
σi3
 ൩ 
where µ௜ and 𝜎௜ are respectively the mean and variance of 𝒚𝒊. Similarly, kurtosis is the fourth 
standardized moment:  
 ν௜ = E ൥ 
൫𝑌௜ − µ௜൯
4
σ௜4
 ൩ 
Other definitions of these statistics exist, such as skewness based on the standardized difference 
between the mean and median [17, 18], but all are geared toward the same fundamental concepts 
of skewness and kurtosis. A recent summary of skewness and kurtosis measures is given in Cain 
et al. [19] though both are usually covered in most elementary statistics books. The definitions 
above are specifically shown because they are prominently used in formal hypothesis tests and 
considered the most recognizable.  
The range of γi is the entire real line. Values of γi < 0 indicate a distribution in which the left 
tail is longer or heavier while γi > 0 indicates the right tail is so. Distributions, which include the 
normal, in which γi = 0 are said to be non-skewed. For kurtosis, νi is strictly greater than 1. For 
any normal distribution νi = 3, and as a result the term excess kurtosis subtracts 3 from the usual 
kurtosis value in order to index against the normal. A value of νi < 3, also known as leptokurtic, 
are taken to imply longer tails and a thinner central peak than a normal. Values of νi > 3, or 
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platykurtic, indicate shorter tails and wider shoulders than a normal.   
For a given sample, inference about the normality of the population can be made from the 
corresponding sample statistics γ̂i and νොi, which are found by substituting the sample mean and 
standard deviation in place of their population level parameters and averaging over the sample. 
Interpretation is subjective, but a general rule of thumb is -1 < γ̂i < 1 and 2 < νොi < 4. However, 
statistics meant to address skewness or kurtosis are mathematical constructs and need not 
correspond exactly to any philosophical interpretation [20, 21]. For example, γi does not adhere 
to any strict rule or direction when one tail is very long and the other is very heavy. It has been 
shown that statistical tests based on these measures can be misleading [22]. As a result, skewness 
and kurtosis are not often used without other diagnostics. 
Graphical approaches to assessing normality include simple stem and leaf plot, histogram 
and the quantile-quantile plot. This plot compares the observed quantiles of the sample against 
their expected value under a normal distribution. The main attraction to graphical approaches is 
the visual format and, like summary statistics, the ability to indicate where deviation from 
normality is occurring. However, interpretation can be subjective and is challenging to 
implement in omic datasets containing hundreds to thousands of features.  
In contrast to summary and graphical methods, hypothesis testing provides a concrete 
framework for determining if a sample is normal that can be applied easily to large datasets, 
though the informational value behind a test statistic and p-value is limited beyond a simple 
decision tool. All normality tests surveyed in this review utilize the same null hypothesis, namely 
for yi = {y1i,…,yni}
' 
H଴i : F൫yi൯= φ ൬
𝒚𝒊 − µ௜
𝜎௜
൰ 
where φ(t) is the cumulative distribution function of the standard normal distribution. Some 
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measure of discrepancy is calculated between the observed sample and what would be expected 
under H଴i. A consequence leads to a well-known dilemma with normality testing: major 
departures from normality may not trigger rejection if the sample size is small while minor 
departures may be deemed “significant” if the sample size is very large [23, 24]. But in terms of 
formal decision making, normality tests provide the only option and for that reason are quite 
widely used when determining normality. 
Normality tests can be broadly classified depending on the mechanism used to detect 
departure from normality. Here we choose a classification scheme similar to Baringhaus et al. 
[25] which separates tests based on (1) the empirical distribution function (EDF), (2) correlation, 
(3) moment, (4) empirical characteristic function (ECF) and (5) miscellaneous approaches. In the 
descriptions that follow let Xn be a random vector of size n with 𝑥௝ the jth element of Xn, x(j) the 
jth ordered element of Xn, xത = n-1 ∑ xj1j=1  the sample mean and  s = ට(n-1)
-1 ∑ (xj − xത)
2n
j=1  the 
sample standard deviation. 
2.2.1.  EDF Tests 
As the name suggests these tests make use of the empirical distribution function and includes 
those from Kolmogorov-Smirnoff, Cramer-von Misses and Anderson-Darling. Using the 
notation above while letting Vj = φ ൬
x(j) − xത sൗ ൰ and defining: 
F෡n(t)=
1
n
෍ I(Vj ≤ t)
n
j=1
, 0 ≤ t ≤ 1 
each of the three tests can be written using the function: 
 Rn(t) = √n (F෡n(t)  −  t) 
For the tests above, we have: 
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Cramer – von Mises: 
න Rn2(t)
1
଴
dt 
Kolmogorov – Smirnoff: sup
t |Rn(t)| 
Anderson – Darling: 
න Rn
2(t)
t (t-1)൘ dt
1
଴
 
Cramer-von Mises (CM) is the oldest of these test with Cramer introducing his version of the test 
statistic in 1928 [26]. Von Mises, working independently, produced a very similar test statistic in 
1931 [27]. Being so similar in content and introduced so closely together in time, the test has 
come to share the names of both individuals. Shortly after introduction of the CM test, 
Kolmogorov introduced a different test statistic in 1933 with important contributions made in 
subsequent years by Smirnoff regarding the distribution of the variables involved [28-31]. The 
result came to be known as the Kolmogorov-Smirnoff test (KS) and has become a stalwart of 
normality testing. Use of this test continues into the present day and it remains a fixture in many 
introductory statistics books despite arguments that it should not be used as a normality test due 
its poor performance [32, 33]. In its defense, KS can be used to test that two samples are derived 
from the same distribution and it is able to handle ties, which many of the more statistically 
powerful tests do not tolerate well. Worth noting is that as a normality test KS specifically tests 
that the data is Standard Normal and thus use of this test requires centering and standardizing the 
sample. Lilliefors went on to extend KS to test for normality without specifying the mean or 
variance [34]. Anderson and Darling (AD) introduced their test in 1952, which gives more 
weight to the tails of the distribution than KS does [35]. More recently, Vasicek provides another 
EDF test using a test statistic based on the sample entropy of the density function [36]. Of the 
EDF tests mentioned here, AD is generally regarded as the most powerful and therefore the most 
advisable [37, 38].  
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2.2.2.  Correlation Tests 
These tests compare the observed ordered statistics from the sample against their expected 
value under a standard normal distribution. Letting z(1) ≤ z(2) ≤ … ≤ z(n) be the ordered statistics 
of n independent draws from a standard normal. Under H଴ the ordered sample statistics can be 
modeled as a linear function of the z(j)'s such that 
x(j) = µ + σmj + εj 
where mj=Eൣ z(j) ൧ and the εj's represent random error satisfying Eൣεj൧=0 and cov(ε')=σ2Σ̇ for all j 
ϵ {1, 2, …, n} with Σ̇ being the covariance matrix of z =൫z(1), …, z(n)൯
'
. When the sample is 
derived from a normal distribution the ordered sample vector x = {z(1), …, z(n)} will be closely 
linear with the vector of ordered standard normal expectations, m = {m(1), …, m(n)}. Therefore, 
the square of the correlation coefficient ρ2 provides a measure of assessing normality. In practice 
calculating 𝑚௝ is not trivial and the choice of what to use for m leads to the various tests in this 
category. For w the chosen representative of m we have 𝜌ଶ as 
ρ2(w, x)=
⎝
⎛ ∑ (wj − wഥ)(x(j) − xത)
௡
j=1
ට∑ (wj − wഥ)
2n
j=1 ∑ (x(j) − xത)
2n
j=1 ⎠
⎞
2
 
In terms of w better known correlations tests can be written as: 
Shapiro-Francia (SF) w = m  
Shapiro-Wilk (SW) 
 w = Σ̇
ି1m
ቛΣ̇ିଵmቛ
൘  ‖a‖=Euclidean Norm of a 
de Wet-Venter (DW)  wj = φ
-1 ቀj n+1ൗ ቁ  
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Weisberg-Bingham 
(WB) 
 wj = φ-1 ቌ
j- 38
n − 34 +1
൙ ቍ  
Smith-Bain (SB)  wj = φ-1 ቌ
j − 12 n
൘ ቍ  
Each of these tests are shown to be asymptotically equivalent but in large sample sizes values of 
w are easily calculated for DW, WB and SB [25]. Practical estimation of m was also extended by 
Royston for n ≤ 2,000 and then by Rahman and Govidarajulu for n ≤ 5,000 [39-41]. The 
expected values of normal ordered statistics will be discussed further in Chapter 3.  
A major advantage for correlation tests is the ease by which they can be applied to a censored 
sample by essentially restricting the portion of ṁ that matches with the observed data [42]. 
Additionally, Shapiro-Wilk has consistently demonstrated strong power across a plethora of non-
normal distributions and has become the gold standard for overall power [43]. 
2.2.3.  Moment Tests 
Normality tests utilizing the moments of the distribution in their test statistic are known as 
moment tests and have existed conceptually since at least the late 19th century [44]. Given their 
behavior in the normal distribution, the third and fourth moments are natural metrics for testing. 
These are commonly denoted, respectively, by ඥb1  and b2 and defined as: 
ඥb1 = 
1
n ∑ (xi − xത)
3
s3
   and    b2 = 
1
n ∑ (xi − xത)
4
ቀ1n ∑ (xi − xത)
2ቁ
2 -3 
ඥb1 is equivalent to the moment-based estimate of skewness (while b2 is the moment based 
estimate of excess kurtosis. As such, tests employing them are sometimes more plainly referred 
to as tests of skewness or kurtosis. Possibly the most well-known test of skewness comes from 
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D’Agostino who provides a transformation for b1 which follows a closely normal distribution 
when the sample is derived from a normal distribution [45]. Anscombe and Glynn detail a 
similar procedure for b2 [46]. Hosking utilizes L-moments to provide an alternate test for 
skewness [47]. Lin and Mudhokar base their Z2 (initially named Z) test on the first and second 
moments utilizing the property that xത and s2 are independent if and only if the sample is drawn 
for a normal distribution [48]. The Z2 test is shown to be particularly strong against skewed 
alternatives. Later Mudholkar et al. developed the Z3 statistic based on the first and third sample 
moments and demonstrates strong power against non-normal kurtosis [49]. 
The greatest advantages of moment tests are also tied to their greatest disadvantages. Since 
these test statistics typically focus on either skewness or kurtosis it is very easy to amend them 
toward one-sided alternatives. For example, a researcher may only be interested to know if the 
data is left skewed without care to the data being right skewed. But as a tradeoff the examination 
of only one aspect of non-normality leads to considerably lower power compared to other classes 
of tests that are sensitive to all aspects of non-normality. In order to improve the overall power 
and create an omnibus test, skewness and kurtosis statistics may be combined as with the K2 test 
of D’Agostino-Pearson [50], the combination of Z2 and Z3 [49], the tests by Bowman-Shenton 
[51] and that by Jarque-Bera [52]. More recently Bai and Ng present an omnibus test for time 
series data that is serially correlated [53]. These omnibus tests result in tests that are well 
powered against a wide range of distributions and the use of the individual statistics can be used 
to identify sources of non-normality [54]. However, this second point is refuted based on the 
correlation between ඥb1 and b2 being quite high even for large sample sizes [20, 22].  As a 
result, the diagnostic value of moment tests is questionable. 
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2.2.4.  ECF Tests 
ECF tests are based on upon the characteristic function, which for the normal distribution is 
 ϕ(t) = exp(itµ −
1
2
t2σ2) 
and the empirical characteristic function for a sample of size n is 
 ϕn(t, Xn)=
1
n
෍ exp(itxj)
n
j=1
 
The earliest ECF test surveyed by this review was by Koutrouvelis whose test statistic divided 
the characteristic function into real and imaginary parts [55]. Around the same time Murota and 
Takechu proposed a test based on an(t)= ቚϕ(t,
Xn sൗ )ቚ which demonstrated good power against 
symmetric distributions but not against skewed distributions [56]. Epps and Pulley provide a test 
that is robust against both skewed and kurtic alternatives and is probably the most well-known of 
ECF tests [44]. Their test statistic is 
 T= න ฬϕn ൬t,
Xn − xത
s
൰ −  ϕ෠(t,Xn)ฬ
2
dG(t)
∞
-∞
 
in which ϕ෠(t,Xn)=exp൫itxത − 1 2ൗ t
2s2൯ and dG(t) is a weight function initially suggested as 
൫√2𝜋൯
ି1
exp( −𝑡
2
2ൗ ). 
The Epps-Pulley test has been shown to have comparable power to other well-known 
normality tests with recommendation for its relatively easy computation [25]. ECF tests have 
received much praise in the multivariate realm. Whereas EDF and moment tests are criticized for 
lacking consistency [57], Csorgo’s application of the empirical distribution function to the 
multivariate setting [58] was, at the time, praised as being the only multivariate normality 
(MVN) test “genuinely” multivariate in nature [59]. Application of the ECF to testing MVN is 
still ongoing [60]. 
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2.2.5.  Other Tests 
Tests that do not clearly fit into any of the previous categories are grouped together as a 
separate category. These include tests based on Hermite polynomials [61-63] and the moment 
generating function [64]. Of particular interest to this dissertation is the test by Sigut et al. [65], 
which combines Bayesian elements with large deviation theory [66]. 
Unlike most normality tests Sigut et al., through the use of so-called experts, offers the 
ability not just to discriminate between normal and non-normal but also provide diagnostic value. 
Let C଴ be the class of any sample of size n drawn from a N(0,1) population and let Cଵbe the 
class of all samples of a non-normal population with the same size and parameters. The problem 
is then to determine if 𝑋௡ belongs to C଴ or C1. The authors introduce the notion of an expert, 
based upon the optimal decision rule under a Bayesian framework given by: 
P(C1)p(Xn|C1)
P(C଴)p(Xn|C଴)
 
in which P(Ci) and p(Xn|Ci) are the a priori probabilities and CDFs for i equal to 0 or 1. The error 
associated with such a decision rule is given by: 
E=P(C଴)E଴+P(C1)E1 
where E଴ and E1 are the errors associated with misclassifying samples from C଴ and C1 
respectively. E଴ can be rewritten as: 
P଴ ൭
1
𝑛
෍ log
n
i=1
p(Xn|C1)
p(Xn|C଴)
 ≥ 
1
𝑛
log
P(C1)
P(C଴)
൱ 
with P଴ being shorthand for the probability of the event in the case that all observations are from 
the normal class. Using Chernoff’s theorem, it can be shown that as n tends to infinity this 
probability relates to the Chernoff distance between p(Xn|C଴) and p(Xn|C1), which is independent 
of the prior probabilities and decays exponentially with the sample size. These arguments are 
43 
 
applicable to both E1 and E଴ as well establishing the expert as an asymptotically optimal 
decision rule. The authors then extend the concept to a sum of experts 
P(C11)p(Xn|C11)
P(C଴)p(Xn|C଴)
+
P(C12)p(Xn|C12)
P(C଴)p(Xn|C଴)
+…+
P(C1r)p(Xn|C1r)
P(C଴)p(Xn|C଴)
 
showing that the previous results hold for this combination. In practice care must be taken so that 
the chosen experts provide a comprehensive basis for “non-normal” as samples derived from 
non-normal populations that are not reasonably “close” to any of the experts become 
problematic. In response the Johnson family of distributions is recommended with four 
parameterizations intended to cover the plane of non-normality defined by the population 
skewness and kurtosis given, respectively, as:  
ටβ1=
Eൣ(X-µ)3൧
(E[(X-µ)2])3 2⁄
 
and  
β2=
Eൣ(X-µ)4൧
(E[(X-µ)2])2
 
Specifically, the quadrants of interest are: 
i. ඥβ1 < 0, 1 < β2 <3 
ii. ඥβ1 < 0, 3 < β2 <10 
iii. ඥβ1 > 0, 1 < β2 < 3 
iv. ඥβ1 > 0, 3 < β2 < 10 
Distributions that differ from normal in both skewness and kurtosis will be identified by the 
expert associated with a specific type of deviation. For distributions that deviate only by 
skewness, then a combination of either (i) and (ii) or (iii) and (iv) will be large, depending on 
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whether the distribution is left skewed or right skewed. Similarly, the combination of (i) and (iii) 
or (ii) and (iv) will identify distributions that are leptokurtic or platykurtic with zero skew. 
2.3. Transformation 
Data that is found to be non-normal may be altered through (non-linear) transformation to 
achieve normality. Feature transformation is actually quite common across the omic sciences 
including metabolomics. Some of the more popular transformations are shown in Table 2.1. 
Many involve a linear mechanism via centering (mean/median), scaling (variance / standard 
deviation) or both, and offer no change in distribution. This is sufficient in the typical 
metabolomics study, focusing on biomarker discovery in a sea of features with wildly varying 
abundance levels, where transformations are primarily used to remove variation within and 
between features. For example, when conducting univariate t-tests or analysis of variance 
(ANOVA) it is helpful to remove heteroscedasticity. In the case of multivariate analysis via 
principle component analysis then it may be desirable for the compounds to have equal weight 
[67].  
Although normality is not often the primary focus, some transformations (g-i) are non-linear 
and do offer the possibility to alter the distribution. Both the power and Box-Cox transformations 
are directly intended for such use and can be directly applied to metabolomic data as ion counts 
are strictly greater than 0. They do, as with the generalized log, require estimation of an 
additional parameter δ from the data. With the power and Box-Cox transformations this 
parameter can be estimated using profile likelihood and is dependent on a fully observed sample. 
The natural log transformation is frequently used to help induce normality, being in fact a special 
case of the Power and Box-Cox when λj = 0. It is a popular choice in general and evidence 
supports its value in metabolomics [68]. Unfortunately, it has the unattractive consequence of 
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greatly inflating the transformed variance in features with lower abundance. This phenomenon is 
consistent with the two-component model introduced in Section 1.7. Returning to this model, the 
ion count yji for some metabolite j and sample i is 
yji= α + cjxjie
ηji  + εji 
with η ~ N(0,ση2),  ε ~ N(0,σε2),  xji is the true concentration and cj represents the overall ionization 
efficiency of the instrument. For this exercise it convenient to combine the true concentration 
 
 Name Calculation  
(a) Centering 𝑦ij∗ = 𝑦ij − 𝑦തi 
(b) Autoscaling yij∗ =
𝑦ij − 𝑦തi
si
 
(c) Range Scaling yij∗ =
yij − yതi
𝑚𝑎𝑥 (yi) − 𝑚𝑖𝑛 (yi)
 
(d) Pareto Scaling yij∗ =
yij − yതi
√si
 
(e) Vast Scaling yij∗ =
yതi(yij − yതi)
si2
 
(f) Level Scaling yij∗ =
yij − yതi
yതi
 
(g) Loga yij∗ = loga൫yij൯ 
(h) Power yij∗ (λ𝑗 ) = ൝
yij
λ𝑗                for λ𝑗 ≠ 0
ln൫yij൯      for λ𝑗 = 0
 
(i) Box-Cox yij∗ (λ𝑗 ) = ቐ
yijδ − 1
λ𝑗
൘       for λ𝑗 ≠ 0
ln൫yij൯         for λ𝑗 = 0
 
(j) Generalized Log yij∗ (δ, α) = ln ൬(yij − α) + ට(yij − α)2 + δ൰ 
Table 2.1: Common Transformations in Metabolomics 
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and instrument ionization as µji = cjxji representing the true average ion count. When µji is large, 
the middle term dominates the expression and the distribution of yji is reasonably close to a log-
normal and the log transformation performs well. But, when µji is small the last term dominates 
and yji behaves more as a normal random variable. The mean and variance of yji follow as 
 E ቂyjiቃ = α + µji 
 Var ቀyjiቁ  = µji
2Ληଶ + σεଶ 
with Λη2 = eση(eση − 1), which is the variance of a log-normal variable with mean 0 and standard 
deviation ση (on the log scale). From the observation above µji→ 0 implies that yji
D
→  N. Using 
the delta method, the asymptotic variance when applying the log transformation must be 
converging to 
 var ቂlog ቀyjiቁቃ → ቀµji
2Λη2 + σεଶቁ *
1
(µji + α)
2 
as n goes to infinity. For the next step, recall that α is mostly regarded as a nuisance parameter 
and can frequently be ignored. However, as µji becomes small this intercept may arguably 
become non-trivial. One can either make the assumption that α is ignorable or adjust the 
transformation log ቀyji  −  αቁ. In either case, the result follows: 
 var ቂlog ቀyji  −  αቁቃ → ቀµji
ଶΛηଶ + σεଶቁ *
1
µji
ଶ 
             → Ληଶ + 
σεଶ
µji
ଶ 
Thus as µji approaches 0 the variance will increase without bound. µji → 0 will obviously occur 
when yji → 0, suggesting the variance will be high for features in which µji is small. This implies 
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low metabolites with low concentration will tend have higher variance; however, recall the ion 
count is dependent on the product of both the concentration and ionization efficiency of the 
molecule. A small concentration of a metabolite with a high ionization efficiency may produce 
more ions than a large concentration of a metabolite that is poorly ionized. 
Inflation of variances at low ion counts is problematic as it can hinder the ability to identify 
biomarkers that fall in this range. One solution is to only log transform metabolites with higher 
abundances and leave the low abundance features alone. This can work well at the extremes, i.e. 
ranges where µjie
ηji or εji dominate, but ranges in which both terms meaningfully contribute 
remains problematic. The generalized log transformation (GLOG) offered a solution to this [69].  
Although utilized for microarrays, the concept is drawn directly from the model first 
presented by Rocke and Lorenzato and natural to use with MS data [70]. As with Power/Box-
Cox, the GLOG involves estimation of a parameter, which can also be found using Maximum 
Likelihood, and is based on the ratio of σε2/Λη2 [69]. Note that with the power family the 
transformation parameter is estimated on each individual feature whereas in the GLOG a single 
parameter set is typically used for all features. Further detail on the advantages and 
disadvantages of these transformation can be found in van den Berg et al. [71]. 
2.4. Correlation 
The final item of interest in this chapter is that of correlation. For 𝒚A and yB any two 
metabolites with means µA, µB and variances σA, σB the correlation is defined as  
ρxA,xB =
Eൣ 𝒚A − µA൧Eൣ 𝒚B − µB൧
ටEൣ 𝒚A − µA൧
2
Eൣ 𝒚B − µB൧
2
 
The numerator is simply the covariance between yA and yB while the denominator is the square 
root of the product of the two standard deviations. Hence, correlation is the covariance 
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normalized against the variation of two variables and is bounded between -1 and 1. A value of ρ 
equal to 0 implies independence between the two variables, meaning that knowledge of one 
variable provides no information about the other variable. When ρ > 0 the two are said to be 
positively correlated with higher values in one variable being associated with higher values in the 
other. Negative correlations occur when ρ < 0 and higher values in one variable tend to indicate 
lower values in the other. A value of ρ = -1 or ρ = 1 will be achieved when the two variables are 
an exact linear transformation of each other.  The sample correlation is most frequently described 
using the Pearson r correlation coefficient [72], which replaces the population parameters with 
the usual sample estimates: 
Pearson's rxA,xB =
(∑ 𝒚A − xതA)(∑ 𝒚B − xതB)
ඥ∑(𝒚A − xതA)2 ∑(𝒚B − xതB)2
 
Note that in the above formula the (n-1)-1 terms cancel out. Pearson’s r shares the same boundary 
space as ρ with the interpretation also being the same. As one might expect with 𝜌 signifying a 
linear relationship, this statistic is closely related to simple linear regression (SLR). In fact, r is 
the square root of the 𝑅ଶ statistic, which measures the proportion of variation explained by the 
linear fit. It is therefore unsurprisingly that, like SLR, 𝑟 is sensitive to extreme outliers. A non-
parametric version of the correlation coefficient was developed by Spearman [72] and is in fact 
often recommended for metabolomic data due to the propensity for extremely large outliers [11]. 
The calculation of Spearman’s rank sum correlation coefficient follows exactly from Pearson 
with the exception being that values of both variables are first translated into ranks: 
𝒚A* ={rank൫yA1൯, …, rank൫yAn൯} 
yB
* ={rank൫yB1൯, …, rank൫yBn൯} 
 and so 
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Spearman's ryA,yB = 1-
6 ∑ (yA1
* − yB1
* )n1
n3 − n
 
Whereas as Pearson indicates a linear relationship between 𝒚A and yB, Spearman indicates a 
monotonic relationship. Spearman is therefore more general and able to capture a wider range of 
relationships in the two variables and is also invariant to any monotonic transformation. 
However, as an estimator Spearman is less statistically efficient than Pearson with hypothesis 
tests for ρ = 0 using Pearson being more powerful. However, in this paper interest is more on the 
coefficients rather than p-values. Correlation coefficient estimates are tabulated and examined 
for each metabolite using both Pearson and Spearman. The availability of pathway information 
for the metabolites allows for an additional layer of assessment based upon functional class. 
Details on these pathways are given in section 2.6. 
2.5. Methods 
As metabolite distributions and correlations are examined it is important to consider the 
potential impact that transformations may have. In each of the normality and correlation methods 
used, results are provided for the untransformed data, as well as data transformed by log, GLOG 
and Box-Cox. These transformations are selected given their ability to alter the distribution of 
the metabolite and the interest of this paper. It is our belief that a simple log transformation is 
effective at inducing normality within metabolites. The GLOG is a closely related function and is 
rooted in MS based analytical chemistry, making it a natural choice for consideration. The Box-
Cox transformation provides a gold standard by which to assess both log based transformations. 
Correlation is assessed by pairwise comparisons using both Pearson and Spearman statistics. 
Three approaches are used to assess normality: Shapiro Wilk, Normal Quantile-Quantile plots 
and Box-Cox λ. The Shapiro-Wilk test is among the most recognizable tests for normality. 
Among the first correlation tests, it was first described in 1965 [73]. It is regarded for being 
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among the most powerful and having high power across a large spectrum of non-normal 
behavior [33]. These reasons led to its selection here as theoretically metabolites are not 
constrained to any specific type of non-normality. Additionally, as a correlation-based test 
Shapiro-Wilk can be adapted to censored samples allowing its application to metabolites in the 
dataset that contain missing values. Additional detail for these methods follow. 
2.5.1.  Shapiro-Wilk 
For a given metabolite y𝒊 = {y1i , …, yni}
', the test statistic is: 
Wi = 
ቀ∑ aiy[j]i
n
j =1 ቁ
2
∑ (yji − yത)
2n
j =1
 
where y[j]i is the j
th ordered value of the vector yi 
{a1, …, an} = 
mTV-1
(mTV-1V-1m)
1/2 
with 
V = cov(m) 
m = (m1, …, mn) 
such that 
m௝ = E ቂy[j]i | y௜~N(0,1)ቃ 
Due to the symmetry of the normal distribution ∑ m௝, and by extension ∑ ai, is equal to 0. W௝ is 
bounded between 0 and 1 and under H଴ will be closer to 1. Censored samples are handled by 
restricting the range to cover only the observed order statistics. That is 
W௝  = 
ቀ∑ ai y[j ]iΩ ቁ
2
∑ (yji − yത)
2
Ω
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where Ω = {all j : y[௝]i is not missing}. 
2.5.2.  Normal Quantile-Quantile plots 
The normal quantile-quantile (QQ) plot is the most commonly used and recognized graphical 
approach. For 𝒚𝒋 and m as before, the QQ plot displays the pairs  
{y[j]i , m௝} 
Samples that are normal should follow closely to a straight line while non-normal behavior will 
manifest with non-linear behavior. For example, pairs of a sample from a right skewed 
distribution will tend to show an upward curve for larger values of i. Although QQ plots are easy 
to construct and straightforward to interpret, the lack of a formal decision-making structure 
causes the conclusions to be subjective. High dimensional data presents an additional challenge 
as it is infeasible to examine hundreds or thousands of features in this manner. The approach 
taken here is to consider all possible yji for i ∊ {1, …, n} and j ∊ {1, …, m} simultaneously. Each 
metabolite is mean centered and scaled by the sample standard deviation: 
yji
*=
yji − yതj
syj
 
These resulting yji
* 's are then combined into a single vector and all resulting pairs {y[k]
*  , mk} for k 
ϵ {1, …, j*i} are plotted. 
The QQ plot will be used to give a graphical assessment. To accommodate the large number 
of variables each compound will be median scaled and standardized. A single QQ plot will then 
be made for all the values of all the compounds. Because missing values are likely due to limit of 
detection and not missing at random only, compounds that are observed in all samples will be 
used. Next, normality will also be assessed using the Shapiro-Wilk test. P-values can easily be 
tabulated across all compounds and categorized based on standard significance at the 0.05 level. 
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This test is the gold standard for univariate normality and its use here is consistent with previous 
studies. 
2.5.3.  Box-Cox λ 
For a variable of interest yj, the family of power transformations introduced by Tukey [74] 
produces a variable yj(λj) that is optimally normal based on: 
yj(λj)= ቐ
     yj
λj    for λj ≠ 0 
ln ቀyjቁ for λj = 0
 
which is monotonic for all λj. Box and Cox amended this to account for the discontinuity that 
occurs at λj = 0, yielding the following definition:  
yj(λj)=
⎩
⎪
⎨
⎪
⎧ yj
λj-1
λj
for λj ≠ 0 
ln ቀyjቁ for λj = 0
 
λj is estimated using a profile likelihood based on 
൫σ√2π൯
-n
*exp ቐ
ቀyj
λj − Aθቁ
ᇱ
ቀyj
λj − Aθቁ
2σ2
ቑ 
in which A is a matrix of predictor variables and θ is an unknown vector of associated 
parameters based on the model 
 E ቀyjቁ = Aθ 
Hence Box-Cox is appropriate for transforming dependent variables of a linear model, but can be 
generalized to other variables by setting A = 1. Some definitions incorporate the geometric mean 
of untransformed variable  GM൫𝒚j൯=ටyj1*yj2*…*yjn
n  as this allows for simplification of the 
likelihood. These transformations are only appropriate for variables strictly greater than zero, and 
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so the two parameter Box-Cox substitutes yj
' = (yj + αj) in place of yj in order to ensure that all 
values are positive. For MS metabolomic data the single parameter version given should suffice 
as detectable ion-counts are strictly greater than zero. Occasionally, missing values may be 
treated as zero, but this is a very strong assumption implying the metabolite is completely absent 
from the sample. This may hold for some metabolites, such as pharmacological agents or 
xenobiotics, but unlikely to be true for the vast majority of missing values. For the most part the 
components of metabolic processes are expected to be present in all subjects to at least some 
degree (though maybe too low to be observed). Finally, notice that λj = 1 indicates the original yj 
is the optimal choice for normality and thus λj itself can serve as assessment of normality in the 
same manner as skewness and kurtosis.  
2.6. Datasets 
Three separate cohorts of human plasma, urine and CSF were profiled using LC-MS. These 
sets were part of a collaborative work between Metabolon and the Department of Molecular and 
Human Genetics at Baylor College of Medicine and were previously described in Elsea et al. 
[64]. Samples were drawn from pediatric subjects who were found to be free of any IEMs. 
Hence, these samples form a control group for which to compare suspected cases of IEMs and, 
as demonstrated in Miller, Kennedy, Eckhart, Burrage, Wulff et al. {Miller, 2015, Untargeted 
metabolomic analysis for the clinical screening of inborn errors of metabolism, have led to 
significant advancements in the diagnosis of such diseases. As a single, homogenous group these 
sample sets provide an excellent opportunity to assess metabolite properties in the absence of any 
experimental treatment or factor. Further, metabolites can be influenced by demographic factors 
in adults, such as differences in gender, race or age, these sets being a pediatric cohort implies 
such factors prevalent after puberty should be less important here. Samples were collected and 
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stored by the Department of Molecular and Human Genetics at Baylor College of Medicine and 
have previously been described in Elsea et al. [75]. Metabolomic analysis was conducted 
utilizing a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo 
Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated 
electrospray ionization (HESI) source [76]. For more specific details see Elsea et al. [75], 
DeHaven et al. [12], Evans et al. [77] and Evans et al. [76]. In addition to the tier 1 and tier 2 
[78] metabolites that were previously reported, the data here also include those features with 
unique mass spectral signatures but did not match with any available chemical standard in the 
library. 
Table 2.2 summarizes the major characteristics of the three datasets. Identified features are 
matched against an in-house library. Those features that had a match are referred to as “named”. 
Those features having a distinct MS/MS signature but no available standard in the library are 
referred to as “unknown”. Missing values are observed in around half of the metabolites within 
each set, which presents a challenge. Missing values have previously been shown to be 
associated with lower ion abundance and are thus often assumed to be related to limit of 
detection [79]. Propensity for missing values in these data are shown to be greater for lower 
abundant metabolites. Figure 2.1 plots the proportion of observed values by the median of the 
observed abundance level of the observed values. Because median abundance levels range from 
Table 2.2: Summary of metabolite data sets. 
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25 thousand up to 10 billion, it is convenient to log10 transform the medians for plotting.  
Transformed abundance level is used to model the proportion of observed value using 
logistic regression and smooth splines. Both indicate that rate of observation increases as 
abundance level increases and the two fits overlap considerably in plasma and urine. For the 
most part, almost all biochemicals with medians ion count above 107 are fully observed. There 
are a few aberrant compounds in which less than 10% of the samples are observed but the 
median abundance level is well above the 107. Predominantly these are pharmacological 
metabolites and xenobiotics. For example, in the urine plot there are two compounds with a log10 
median abundance around 8 but were observed in less than 20% of samples. These compounds 
are lidocaine and dexopanthenol. In fact, upon further inspection almost all of the biochemicals 
observed in less than 10% of samples were found to be related to pharmacological agents. For 
this reason, the plots have been restricted to show only those metabolites in which more than 
10% of samples were observed. With missing values being associated with lower abundance 
level, the observed value for a metabolite then constitute a left censored sample, which makes it 
challenging to assess normality. For simplicity, only the metabolites that were observed in every 
sample are used here, except for Shapiro-Wilk analysis which can deal with censored samples. 
Figure 2.1: Proportion of observed samples by abundance level in plasma, CSF and urine. X-axis is log10 median 
abundance level. Y-axis is the proportion of samples observed. Solid red line represents logistic 
regression fit. Dotted blue line is a splinal fit using 10 knots. Biochemicals in which less than 10% of 
the samples are observed are excluded. 
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Metabolites in which a 
standard is available in the library 
can be grouped according to their 
biochemical functions. This 
enables pathway associations using 
predetermined functional classes, 
which are shown in Table 2.3. In 
general pathway assignments can 
be somewhat arbitrary due to 
various roles metabolites play. Arginine, for example, is critical in urea cycle but also an 
important component in cellular division and also the regulation of blood pressure, among other 
functions. While the assignments given here could arguably be different in some cases, the 
overall portrait given is accurate. As the total number of biochemicals varies across the three 
sets, the overall counts can be somewhat misleading. CSF for example has the highest amount of 
amino acids as a proportion of its total, even though the raw number is less than either of the 
other two sets. Figure 2.2 shows the relative proportion of each pathway. The three most 
dominant classes are Amino Acids, Lipids and Unknown and these serve to differentiate the 
three datasets. Lipids, or fatty acids, are highest in plasma, though this class is also a large 
contribution to CSF as well. In fact, the overall the pathway distribution is rather similar between 
plasma and CSF with the former having a bit higher proportion of lipids and the latter having a 
higher proportion of amino acids. Still, the main difference between these two matrices is 
density, with plasma having nearly twice as many biochemicals as CSF. Urine is actually the 
densest of the three, with the dominant class being unknowns, the features without an existing 
Table 2.2: Pathway Designations by Matrix 
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library match, which makes up about half of all the metabolites found in this matrix. Though the 
lack of available standard to provide a chemical name is somewhat limiting, it is still useful 
when comparing against the other two matrices suggesting that nearly half of the compounds 
measured in urine are not found in the other two. It is noteworthy that such a large percentage of 
the urine biochemicals did not have an available standard in the library. At the very least this 
further reinforces that the composition of urine is quite different, while CSF and plasma are very 
similar with the latter almost being a subset of the former. To illustrate this point, Figure 2.3, 
courtesy of BioVenn [80], shows a Venn diagram of the individual biochemicals. This illustrates 
the significant overlap in biochemicals between plasma and CSF. 81.8% (428 of 523) of the 
compounds identified in CSF are also found in plasma, whereas the overlap with urine is 72.1% 
(377 of 523). Meanwhile only 56.7% (570 of 1006) of the plasma metabolites overlap with urine. 
All together this shows that the composition of plasma and CSF is extremely similar. CSF also 
has quite a bit in common with urine, while urine and plasma only share about half of their 
0
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Figure 2.2: Distribution of the eight major pathways plus unknown in plasma, CSF and urine. Unknowns represent 
distinct mass spectrum signatures but did not matching library entry preventing classification. Y-axis is 
percentage of biochemicals per matrix. 
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makeup. Note that while this shows the composition, in terms of metabolites present, is similar, 
it does imply that the concentrations of those metabolites are similar. Answering this completely 
would require running plasma and CSF samples from the same subject concurrently and using 
isotopically labeled standards to account for matrix effects. However, from the ion abundance 
levels shown in Figure 2.1, abundance levels for plasma tend to cluster more around 105.5 - 106 
whereas CSF biochemicals cluster more around 105. This suggests that concentrations in CSF are 
likely lower than that seen in plasma. 
Finally, while plasma and CSF are subject to homeostatic regulation, the concentrations of 
metabolites in urine are known to be strongly influenced by endogenous factors such as water 
intake, exercise, diet and disease state [81-83]. Creatinine normalization is often used to correct 
for such effects, though the practice of normalizing across compounds of such vastly different 
Figure 2.3: Venn Diagram of observed biochemicals in plasma, CSF and urine. 
59 
 
biochemical functions and physical properties is not well understood. Normalizations differ from 
transformations in that these are data manipulations within samples while transformations 
manipulate metabolite features. In a data frame in which the rows are the samples and the 
columns are the metabolites, normalizations operate on the rows while transformation act on the 
columns. Results are given for urine both with creatinine normalization and without (un-
normalized). For the most part normalization does not appear to be change the overall 
conclusions. 
2.7. Results 
2.7.1.  Normality 
Summary measures in all three sets suggests clear non-normality across the matrices. Figure 
2.4 shows the histograms of the sample skewness and kurtosis as well as Box-Cox λ across all of 
the biochemicals fully observed. The first notable observation is the surprising consistency of 
behavior across the four data versions. Urine is present twice, once without any normalization 
and also with a creatinine normalization. Skewness is consistently greater than 0 and frequently 
with a magnitude greater than 1, suggesting metabolite distributions have a significantly heavy 
right tail. Metabolites are also consistently lepto-kurtic, in many cases with excess kurtosis of 5 
or more. Estimated λi's for Box-Cox transformation cluster tightly and nearly symmetrically 
about 0. Since λi = 0 indicates a natural log transformation, seeing the metabolites centered on 
this value supports the natural log as a good candidate transformation for achieving normality. 
It’s useful to point out that there is no other clear peak in the λi values. One might have expected 
a significant portion of metabolites to be normal, which would cause clustering around 1. 
However, the uni-modal and symmetric shape to the λi's suggests metabolites are roughly log-
normal with no favored alternative to this behavior.  
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Results for Shapiro Wilk support the raw data being non-normal and that log transforming 
does indeed lead to more normal behavior. Table 2.4 shows the rejection rate of the fully 
observed compounds in the three matrix versions. Rates are given for the raw data as well as 
using a log, GLOG or Box-Cox transformation. Using p < 0.05 the null rejection rate is 5%. No 
Figure 2.4: Summary normality measures in raw data. Statistics are calculated on each biochemical that is fully 
observed in that respective matrix.  
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fewer than 70% of metabolites are rejected in the raw data across the four datasets, strongly 
supporting non-normal behavior. Proportions are highest in urine, where both un-normalized and 
creatinine normalized versions are over 90%. The log transformation reduces the rejection rate 
greatly, down into the mid to high 20s in plasma, CSF and un-normalized urine. So, while the 
log transform significantly improves deviation from normality, roughly a quarter of the 
metabolites are still displaying statistically significant non-normal behavior. Rejection rate for 
GLOG transformation is overall similar to the log with the log being slightly lower in plasma and 
the GLOG being a little lower in CSF and un-normalized urine. Box-Cox reduces the rejection 
rate the furthest further. In plasma the rejection rate is below the null rate. Although rejection in 
CSF and urine under Box Cox remains slightly higher than the null rate, it is still much lower 
than either log or GLOG. Rejections rates in the normalized version of urine are much higher 
than the other matrices across all transformation versions. Log transformation is rejected at 
nearly twice the rate of the other data versions and GLOG is rejected almost three times more. 
This dataset also has the highest Box-Cox rejection rate which, at nearly 10%, is twice the 
rejection rate in plasma. This is somewhat unexpected as, from Figure 2.4, the lambda values for 
both versions of urine were more closely clustered around 0 than plasma and CSF. However, 
Figure 2.4 shows that the urine data contains more skewness and kurtosis than the other two 
Table 2.4: Shapiro-Wilk rejection rate in fully observed metabolites. Rejection is 
based on p < .05 
62 
 
matrices and that creatinine transformation actually increases both metrics. 
As a visual approach to normality assessment, so called “combined” QQ plots are shown in 
Figure 2.5. These are made by taking each fully observed metabolite within the dataset, center 
and standardizing, merging together into a single variable and then plotting against the expected 
normal quantiles. The raw data demonstrates a severe right skewed distribution in all four data 
types as one might expect. Application of the log transformation significantly reduces skeweness 
in all four data types, producing a more symmetric set of values. Discrepancies from normality 
persist, mostly in the tails with the effect being strongest in plasma. These departures occur 
roughly in theoretical quantiles below -2 and above 2 and in the form of more extreme values 
Figure 2.5: Combined quantile-quantile plots. Each point represents an observed ion count of a biochemical. 
Biochemical are independently centered and scaled prior to being combined.  
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than expected. Together this implies longer tails in the lowest 5th and highest 5th percentiles. 
GLOG is extremely similar to the log, with the only noticeable deviations from log occurring in 
the normalized urine set in the form of GLOG having more extreme tails. As one would expect 
based on the Shapiro-Wilk p-values, a power transformation based on the Box-Cox induces 
almost perfect agreement with the normal theoretical quantiles throughout.  
There is one particular oddity in the QQ plots regarding Box-Cox and normalized urine. The 
quantiles for normalized urine have the strongest agreement with the theoretical quantiles for 
Box-Cox of any of the four data sets, surprising since the Shapiro-Wilk rejection (Table 2.4) was 
highest in this data type. Generally speaking, these QQ plots do not change the impression but 
serve to further reinforce information from the summary measures in visual way. However, note 
that in the QQ plots, Box-Cox generally produces less extreme tails than expected under the 
normal distribution or leptokurtosis. Recall, from Figure 2.4, that urine tends to be more 
platykurtic than the other sample types and that normalization enhances this property. Indeed, 
extreme tailing is most present in the normalized data for all transformation types. Most likely 
there are a subset of biochemicals which remain platykurtic even after transformation, but since 
Box-Cox tends to move the other features toward leptokurtosis, this dichotomy is masked when 
all the observations are plotted together.  
Next, we move on to biochemicals with missing values. The assumption here is that missing 
values are limit of detection, which would make the observed set of values for a metabolite with 
missing values a left-censored sample. Using Shapiro-Wilk, the observed values are tested for 
being a left-censored Gaussian sample. A minimum observation rate of at least 20% was 
imposed. Table 2.5 shows the Shapiro-Wilk rejection rate for these biochemicals. Box-Cox 
requires the entire sample to be observed and is not shown here. Estimation of the λi's in a 
64 
 
censored sample would attempt to transform the observed values to a normal distribution rather 
than fitting to the portion of the normal curve observable through the sample. Log and GLOG, 
when estimating a single pair (αgl , λgl) across the entire dataset, do not have this limitation. The 
rejection rates in the biochemicals with missing values have a similar profile to the fully 
observed biochemicals for both plasma and CSF. The raw data performs a little better here, 
especially in CSF, but both a log and GLOG transformation reduce the rejection rate down into 
the mid- to high 20%s. Profile in the normalized urine is also broadly similar – very high 
rejection in the raw data with the log bringing it down only to 40% while GLOG offers only 
marginal improvement over the raw data. The un-normalized urine is a bit different in these 
missing biochemicals with log and GLOG doing worse than in the fully observed biochemicals. 
The consensus from the results so far suggests that using a log-family transformation is 
largely effective at inducing normality, but some metabolites persist in being non-normal. In an 
attempt to understand why, a few variables immediately come forth as plausible candidates: 
proportion of missing values, abundance level, molecular mass and biochemical function. The 
influence of these factors on normality is examined via the Shapiro-Wilk p-values in the raw data 
with the first three examined in plots of Figure 2.6. Abundance is taken as the average of the 
(observable) ion counts. Due to the large spread in both mean abundance and p-value, a log10 
Table 2.5: Shapiro-Wilk rejection rate in metabolites with missing values. Includes 
biochemicals with 20% ≤ observed proportion < 100%. 
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transformation is used in the plots. With the rejection rate profiles being so similar between 
compounds with and without missing values, it suggests that detection does not appear to be a 
major factor in the distributional behavior. The plots, however, reveal that as the observable 
proportion decreases as the p-value increases. This negative correlation is likely the result of 
fewer samples leading to lower power, and hence explaining why the rejection rate for the raw 
data tended to be a little bit lower for the metabolites with missing values.  
Figure 2.6: P-value by various biochemical characteristics. Blue indicates biochemicals fully observed while 
pink indicates the presence of missing values. Both p-value and mean abundance are on log10 scale. 
Abundance is based upon observed values. Chemical mass is measured in grams / mol.  
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There does appear to be some slight connections with mean abundance, based on observed 
values, and the p-values. In plasma and CSF, the highest abundant compounds (mean abundance 
108 and up) tend towards higher p-values. Below this level the p-values are quite scattered 
though, and no pattern is apparent in the urine even at the highest abundance levels. It’s worth 
pointing out that in the abundance plots the blue points tend to be on the right and the pink points 
are on the left. This fits with that observed in Figure 2.1 showing that more abundant compounds 
tend to have fewer missing values. 
The final plot frame profiling the p-value against the molecular mass of the metabolite does 
not reveal much of a relationship either. There is perhaps some evidence that p-values are higher 
at mass levels around 600 Da and up, but certainly no relationship below 500 Da. One item these 
plots do show is that, unlike abundance, the proportion of missing values is not related to 
molecular mass. The blue and pink points are dispersed evenly throughout these plots in all three 
matrices. It is also apparent from the CSF plot that this matrix is made up of lower molecular 
weight compounds than either plasma or urine.  
Finally, Table 2.6 gives the proportion of Shapiro Wilk rejected biochemicals by pathway 
designation using the biochemicals that are fully observed. The idea here is to see if any pathway 
or subset of pathways behaves differently from the others. Are some pathways more normal 
others, or are do the non-normal biochemicals tend to come from certain classes? Unfortunately, 
certain pathways are rather small in these sets, such as Energy metabolism which only has 6 
members in plasma and 9 in both CSF and urine. So, the table certainly lacks for precise 
estimates of the proportions and makes formal testing challenging. But in many cases, it is still 
useful for observational purposes if nothing else. The proportion of rejected compounds, for 
example, is consistently high across all pathways and all matrix types in the raw data. There may  
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Table 2.6: Shapiro-Wilk rejection rate by Pathway. Rejection based on p < .05. 
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some specific differences, like in plasma where the difference between amino acids and lipids, 
both of whom are large members in the matrix, is nearly 20% (88.0% vs 68.9%). Similarly, in 
CSF carbohydrates (46.7%) and nucleotides (65.2%) are quite a bit lower than lipids (82.9%). 
This not only suggests some differences between the metabolite pathways but also between the 
matrices themselves, and further demonstrates that while many biochemicals may be present in 
multiple matrices, their behavior can be quite different. See the lipids, which in the raw data has 
the lowest rejection rate in plasma but the second highest rejection rate in CSF. Regardless of the 
specific pathway comparisons, the proportion of rejected compounds is quite high across all the 
raw data. In every single case, a natural log transformation reduces the proportion of rejected 
biochemicals from the raw, and Box-Cox always reduces the proportion even further. Overall 
improvement with either transformation is therefore not attributed to any specific class of 
biochemicals. All pathways see improvement and the response is consistent across all pathways. 
2.7.2. Correlation 
For the four data types, correlations were examined between each pairwise combination of 
metabolites. Three different versions of correlations are presented: (1) Pearson R using raw data, 
(2) Pearson R using natural log transform and (3) Spearman Rho. While all three versions have 
been used, (2) and (3) are recommended due to the propensity for large outliers in the data [9]. 
Data is filtered in two ways based on proportion of missing values. The first way is to restrict to 
only those metabolites that are fully observed. This still leads to a myriad of pairings with 
146,611 distinct pairs in plasma, 32,896 pairs in CSF and 119,805 pairs in urine (119,316 when 
normalizing to creatinine). The second way is to take all compounds that are at least 10% 
observed. This leads to a total number of distinct pairs in which at least two samples are 
observed in both pairs as 484,182 in plasma, 105,706 in CSF, 735,357 in un-normalized urine 
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and 734,143 in normalized urine.  
For biochemicals with missing values, correlation is based on the pairs that are present. 
Results are displayed in Table 2.7. For simplicity, only Pearson R values on the raw data are 
displayed for compounds observed in at least 10% of samples because, as seen in the table, 
correlations are very similar regardless of whether Pearson or Spearman is used or whether a log 
transformation is applied or not. Across the three datasets correlations are centered around 0.1. 
The exception to this is un-normalized urine in which a moderate correlation around 0.3 is more  
typical. Plasma and CSF are, once again, very similar and creatinine normalization causes the 
urine to look more like those two. The inner quartile range of correlation coefficients for these 
datasets is rough between -0.1 and 0.35 with urine and CSF being a little higher while plasma is 
a little lower. This shows the metabolites tend to be more positively correlated than negatively, 
and that the range of correlation for most pairs would be considered low to moderate in most 
Table 2.7: Summaries of pairwise correlations based on Pearson r. 
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situations. Instances of extreme association do occur, however. In plasma, for example, the two 
isomers of bilirubin, the Z, Z and E, E forms, are highly correlated with each other (Pearson R = 
0.958). Both are also correlated with biliverdin (ZZ Pearson R = 0.990, EE Pearson R = 0.927), 
which is the precursor metabolite to bilirubin in the breakdown of macrophages. And while 
negative correlations are less prevalent, there are still instances of strong negative associations as 
well. Note that when considering any metabolite with an observation rate of at least 10% there 
are several pairs with correlation of +/-1. This is because through the pairings some metabolites 
will have just two observed values in common, which results in a perfect positive or negative 
correlation depending on how the rankings match up. For this reason, it is more useful to focus 
on compounds that are completely observed, but from the table it is clear that considering 
metabolites with missing observations produces fairly similar values.  
Figures 2.7-2.10 visually integrate Pearson R with pathway information in the form of a 
heatmap. This is essentially a matrix in which each cell corresponds to a pair of biochemicals, 
given by the row and column intersection, and the value is a color translated from the Pearson r 
value. A value of r = 0 is white. As correlations move towards 1 the color moves toward red. The 
diagonals are thus bright red reflecting the perfectly positive correlation a compound has with 
itself. Similarly, as the correlation moves towards -1 the color becomes more and more blue. The 
biochemicals were grouped according to pathway and the cells were shaded such that 
increasingly negative correlation is more and more blue, increasingly positive. 
These maps show that though there are instances of very strong correlations, the strongest of 
which are almost exclusively positive, in general biochemicals are not strongly associated with 
each other. Furthermore, instances of strong correlations appear to be somewhat matrix specific. 
In plasma, strong, positive correlations tend to cluster around the diagonal. This is an indication  
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Figure 2.7: Plasma correlation heatmap. Coloring based on Pearson r coefficient with blue for negative values and 
red for positive.  Each row and column represent a specific metabolite, which are ordered left to right, top 
to bottom according to pathway assignment. 
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Figure 2.8: CSF correlation heatmap. Coloring based on Pearson r coefficient with blue for negative values and 
red for positive.  Each row and column represent a specific metabolite, which are ordered left to right, 
top to bottom according to pathway assignment. 
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Figure 2.9: Urine (un) correlation heatmap. Coloring based on Pearson r coefficient with blue for negative values 
and red for positive. Each row and column represent a specific metabolite, which are ordered left to right, 
top to bottom according to pathway assignment. 
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Figure 2.10: Urine (normalized) correlation heatmap. Coloring based on Pearson r coefficient with blue for 
negative values and red for positive.  Each row and column represent a specific metabolite, which are 
ordered left to right, top to bottom according to pathway assignment. 
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that strong correlations are more likely to occur between metabolites within a pathway versus 
metabolites in different pathways. Case in point, in plasma the lipids do not correlate very 
strongly with non-lipids, and in fact several have a slight negative correlation with most other 
compounds, but some of the largest and strongest intensity blocks are within the lipid class. Yet, 
in the CSF and the un-normalized urine rather strong correlations are observed throughout the 
map. Creatinine normalization noticeably lowers the correlations across the entire urine map, but 
it remains almost exclusively red with noticeable patches spread throughout the map as opposed 
to clustering within pathway.  
There is also some evidence of within pathway associations. This sub pathway behavior is 
most strongly seen in plasma where a subset of the lipids correlates strongly with each other but 
negatively correlated with most other biochemicals, including other lipids. Inspection of this 
group finds that members are comprised of medium and long chain fatty acids, branched chain 
fatty acids and polyunsaturated fatty acids. Lipid categories not found in this group include 
plasmalogens, phospholipids, monoacylglycerols and di-acyglycerols to name a few. This shows 
that even though metabolites may be chemically related, they need not share the same behavior. 
Sub setting is also seen within a group of amino acids in the top left most corner of normalized 
urine map.  
Figures 2.11-2.14 provide another pathway view for correlations. Each node is an individual 
metabolite, clustered together in a circle by pathway and the pathway circles then arranged in a 
circular pattern like the numbers on a clock face. Two metabolites are connected when the 
Pearson R between the two metabolites exceeds the minimum threshold, which here is set to 0.7 
in order emphasis the strongest relationships. Because negative correlations are rare, pathway 
figures for r < 0 are not provided. To further aid in interpretability, the unknowns and named  
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Figure 2.11: Plasma correlation network graph. Nodes are metabolites. Connecting lines indicate pairwise Pearson r 
coefficient ≥ .7. Pathways are presented a clockwise manner based on the order listed in the legend. 
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Figure 12: CSF correlation network graph. Nodes are metabolites. Connecting lines indicate pairwise Pearson r 
coefficient ≥ .7. Pathways are presented a clockwise manner based on the order listed in the legend. 
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Figure 2.13: Urine (un) correlation network graph. Nodes are metabolites. Connecting lines indicate pairwise 
Pearson r coefficient ≥ .7. Pathways are presented a clockwise manner based on the order listed in the 
legend. 
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Figure 2.14: Urine (normalized) correlation network graph. Nodes are metabolites. Connecting lines indicate 
pairwise Pearson r coefficient ≥ .7. Pathways are presented a clockwise manner based on the order listed 
in the legend. 
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metabolites without a pathway are removed. A total of 426 metabolites are available in plasma 
for this graph. Although the number of lines may seem large at first, recall there are 90,525 
pairwise combination and only 1,343 (1.5%) with correlation above 0.7. Amino acids as a whole, 
are strongly associated with lipids and nucleotides, and there is strong relationship within the 
amino acid and lipid pathways. But members of the other six pathways are not consistently 
related, and their relationships to other pathways are largely determined by individual members. 
This is probably most relevant to xenobiotics where behavior of any member is an amalgamation 
of diet, environment, microbiome, pharmacological behavior, etc. Associations with the 
metabolites may provide useful insight to the physiological function these biochemicals belong 
to.  
The pathway plot for CSF is similar to plasma. Restricting to the pathway associated 
members gives 207 metabolites with a total of 21,321 pairs, of which 945 (4.4%) are above 0.7. 
Amino acids and lipids are again strongly associated both within and between pathway 
classifications, but as with plasma the other six pathways are not that correlated internally and 
their relationships with other pathways are largely member specific. Un-normalized urine, with 
301 metabolites yielding a total of 45,150 pairs of which 1,730 (3.8%) are above 0.7, shows 
really strong association between amino acids and nucleotides. However, after creatinine 
normalization (300 metabolites – 44,850 pairs – 1,124 (2.5%) ≥ 0.7), the graph very much 
resembles plasma as far as pathway relationships are concerned. 
2.8. Conclusions 
This chapter demonstrates that ion counts of metabolites have a left skewed distribution for 
an overwhelming majority of features. The behavior is observed in three separate types of human 
material commonly used for clinical testing. A natural log transformation is largely effective at 
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removing skewness and inducing normality; however, it is not perfect with around a quarter of 
metabolites still exhibit statistically significant departures from normality. The power 
transformation can reduce this the proportion down to near the null level but requires estimating 
the λi's for each metabolite. This is somewhat of a nuisance as the semi-quantitative nature of the 
instrumentation means that these parameters are likely to change from run to run, and is 
complicated by metabolites with missing values, which may be non-ignorable. The natural log is 
a static transformation and avoids these sorts of issues. Aggregate quantile-quantile plots point to 
this departure being mostly in the extreme tails. This may be due to the reference population 
being composed of non-IEM suspects that initially suspected of having a metabolic disorder, 
implying some level of poor health and the label of “healthy” being somewhat misleading. It is 
possible that some subjects were mis-diagnosed, given the low diagnosis rate for IEMs, or that 
they have non-IEM disease which still impacts their metabolic profile. Since the subjects are 
independent with likely different diseases, only a small fraction of any given metabolite would 
be affected. Hence, it may be that metabolites truly are log-normal and intentionally censoring 
the upper and lower 5% is sufficient to adjust for diseased subjects when the diseases are not 
concentrated on a specific disorder. 
The second point of this chapter also shows that when the data are resolved in a chemo-
centric fashion, global metabolomics is not overly correlated. In general features are at most 
mildly correlated with an average Pearson correlation coefficient around 0.3 and instances of 
moderate to high correlations, consider here to be values of 0.5 and up, are rare.  An examination 
of biochemical pathways found that certain pathways are more correlated than others, most 
notably the amino acids and lipids. Thus, metabolomic datasets that concentrate on certain 
classes of biochemicals may exhibit higher correlation, but in global approach doesn’t appear to 
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elevate correlations much overall. 
These results are useful for general understanding of global LC-MS metabolomics and also 
have significant implications for statistical analysis. Because many studies employ a low sample 
size, parametric hypothesis testing is preferable to maximize power. Using a log transformation 
or other similar approach is largely helpful at satisfying this pre-requisite. Correlation is an 
important characteristic for many multivariate tests including Hotelling’s T Square and Principle 
Component Analysis as well as network methods such as Gaussian Graphical Models. 
Knowledge of how metabolomic sets structure is useful for maximizing statistical analysis.  
  
83 
 
REFERENCES 
[1] M. Vinaixa, S. Samino, I. Saez, J. Duran, J. J. Guinovart, and O. Yanes, "A Guideline to 
Univariate Statistical Analysis for LC/MS-Based Untargeted Metabolomics-Derived 
Data," Metabolites, vol. 2, no. 4, pp. 775-95, 2012. 
[2] T. Obata and A. R. Fernie, "The use of metabolomics to dissect plant responses to abiotic 
stresses," Cell Mol Life Sci, vol. 69, no. 19, pp. 3225-43, Oct 2012. 
[3] E. G. Armitage and C. Barbas, "Metabolomics in cancer biomarker discovery: current 
trends and future perspectives," J Pharm Biomed Anal, vol. 87, pp. 1-11, Jan 2014. 
[4] N. T. Quan et al., "Involvement of Secondary Metabolites in Response to Drought Stress 
of Rice," Agriculture, vol. 6, no. 2, p. 23, 2016. 
[5] P. Manini, G. De Palma, R. Andreoli, M. Goldoni, and A. Mutti, "Determination of 
urinary styrene metabolites in the general Italian population by liquid chromatography-
tandem mass spectrometry," Int Arch Occup Environ Health, vol. 77, no. 6, pp. 433-6, 
Aug 2004. 
[6] T. H. Herdt, J. B. Stevens, W. G. Olson, and V. Larson, "Blood concentrations of beta 
hydroxybutyrate in clinically normal Holstein-Friesian herds and in those with a high 
prevalence of clinical ketosis," Am J Vet Res, vol. 42, no. 3, pp. 503-6, Mar 1981. 
[7] J. D. Clarke et al., "Assessment of genetically modified soybean in relation to natural 
variation in the soybean seed metabolome," Sci Rep, vol. 3, p. 3082, Oct 2013. 
[8] A. M. Evans, M. W. Mitchell, H. Dai, and C. D. DeHaven, "Categorizing Ion-Features in 
Liquid Chromatography/Mass Spectrometry Metabolomics Data," Journal of 
Metabolomics, vol. 2, no. 3, 2012. 
[9] A. V. Frane, "Power and Type I Error Control for Univariate Comparisons in 
Multivariate Two-Group Designs," Multivariate Behav Res, vol. 50, no. 2, pp. 233-47, 
2015 Mar-Apr 2015. 
[10] H. Zou and T. Hastie, "Regularization and variable selection via the Elastic Net," vol. 67, 
no. 2, pp. 301-320, 2005. 
[11] D. Camacho, A. de la Fuente, and P. Mendes, "The origin of correlations in 
metabolomics data," Metabolomics, vol. 1, no. 1, pp. 53-63, 2005. 
[12] C. D. Dehaven, A. M. Evans, H. Dai, and K. A. Lawton, "Organization of GC/MS and 
LC/MS metabolomics data into chemical libraries," J Cheminform, vol. 2, no. 1, p. 9, Oct 
2010. 
[13] A. Kolmogorov, "Sulla determinazione empirica di una legge di distribuzione," G. Ist. 
Ital. Attuari, vol. 4, pp. 83-91, 1930. 
84 
 
[14] A. K. Bera, A. F. Galvao, L. Wang, and Z. Xiao, "A new characterization of the normal 
distribution and test for normality," Econometric Theory, pp. 1-37, 2015. 
[15] L. T. DeCarlo, "On the Meaning and Use of Kurtosis," Psychological Methods, vol. 2, 
no. 3, pp. 292-307, 1997. 
[16] Z. Liang et al., "The Statistical Meaning of Kurtosis and Its New Application to 
Identification of Persons Based on Seismic Signals," Sensors (Basel), vol. 8, no. 8, pp. 
5106-5119, Aug 2008. 
[17] A. L. Bowley, Elements of statistics, 2d ed. London, New York,: P. S. King & son; C. 
Scribner's sons, 1902, pp. viii p., 2 l.,. 
[18] R. A. Groeneveld and G. Meeden, "Measuring Skewness and Kurtosis," Journal of the 
Royal Statistical Society. Series D, vol. 33, no. 4, pp. 391-399, 1984. 
[19] M. K. Cain, Z. Zhang, and K. H. Yuan, "Univariate and multivariate skewness and 
kurtosis for measuring nonnormality: Prevalence, influence and estimation," Behav Res 
Methods, vol. 49, no. 5, pp. 1716-1735, Oct 2017. 
[20] J. C. W. Rayner, D. J. Best, and K. L. Mathews, "INTERPRETING THE SKEWNESS 
COEFFICIENT," Communications in statistics. Theory and methods, vol. 24, no. 3, pp. 
593-600, 1995. 
[21] D. Doric, E. Nikolic-Doric, V. Jevremovic, and J. Malisic, "On measuring skewness and 
kurtosis," Quality and Quantity, vol. 43, no. 3, pp. 481-493, 2009. 
[22] R. Horswell and S. Looney, "Diagnostic limitations of skewness coefficients in assessing 
departures from univariate and multivariate normality," Communications in statistics. 
Simulation and computation, vol. 22, no. 2, pp. 437-459, 01/1993 1993. 
[23] G. Abel, "Is formal normality testing a waste of time?," in Methods and Methodology, ed: 
Cambridge Centre for Health Services Research, 2013. 
[24] M. J. Campbell and T. D. V. Swinscow, Statistics at square one, 11th ed. Chichester, UK 
; Hoboken, NJ: Wiley-Blackwell/BMJ Books, 2009, pp. iv, 188 p. 
[25] L. Baringhaus, R. Danschke, and N. Henze, "Recent and classical tests for normality - a 
comparative study," Communications in Statistics - Simulation and Computation, vol. 18, 
no. 1, pp. 363-379, 1989. 
[26] H. Cramér, "On the composition of elementary errors," Scandinavian Actuarial Journal, 
vol. 1928, no. 1, 1928. 
[27] R. von Mises, "Wahrscheinlichkeitsrechnung und ihre Anwendungen," der Statistik und 
theoretischen Physik, 1931. 
85 
 
[28] A. N. Kolmogorov, "Sulla determinazione empirica di una legge di distribuzione," G. Ist. 
Ital. Attuari, vol. 4, pp. 83-91, 1933. 
[29] A. N. Kolmogoroff, "Confidence limits for an unknown distribution function," Annals of 
Mathematical Statistics, vol. 12, pp. 461-463, 1941. 
[30] N. V. Smirnoff, "On the estimation of the discrepancy between empirical curves of 
distribution for two independent samples," Bul. Math. de l'Univ. de Moscou, vol. 2, pp. 3-
14, 1939. 
[31] N. V. Smirnoff, "Approximate laws of distribution of random variables from empirical 
data," Uspekhi Mat. Nauk, vol. 10, pp. 179-206, 1944. 
[32] G. J. Filion, "The signed Kolmogorov-Smirnov test: why it should not be used," 
Gigascience, vol. 4, p. 9, 2015. 
[33] N. M. Razali and Y. B. Way, "Power comparisons of Shapiro-Wilk, Kolmogorov-
Smirnov, Lilliefors and Anderson-Darling tests," Journal of Statistical Modeling and 
Analytics, vol. 2, no. 1, pp. 21-33, 2011. 
[34] H. W. Lilliefors, "On the Kolmogorov-Smirnov Test for Normality with Mean and 
Variance Unknown," Journal of the American Statistical Association, vol. 62, no. 318, 
pp. 399-402, 1967. 
[35] T. W. Anderson and D. A. Darling, "Asymptotic theory of certain 
"goodness-of-fit" criteria based on stochastic processes," Annals of Mathematical 
Statistics, vol. 23, pp. 193-212, 1952. 
[36] O. Vasicek, "A Test for Normality Based on Sample Entropy," Journal of the Royal 
Statistical Society. Series B (Methodological_, vol. 38, no. 1, pp. 54-59, 1976. 
[37] T. Nafee et al. WikiDoc The Living Textbook of Medicine [Online]. Available: 
https://www.wikidoc.org/index.php/Anderson-Darling_test 
[38] M. de Smith, Statistical Analysis Handbook: a comprehensive handbook of statistical 
concepts, techniques and software tools. 2015. 
[39] T. P. Royston, "An Extension of Shapiro and Wilk W Test for Normality to Large 
Samples," Journal of the Royal Statistical Society. Series C (Applied Statistics), vol. 31, 
no. 2, pp. 115-124, 1982. 
[40] J. P. Royston, "Some Techniques for Assessing Multivariate Normality Based on the 
Shapiro-Wilk W," Journal of the Royal Statistical Society. Series C (Applied Statistics, 
vol. 32, no. 2, pp. 121-133, 1983. 
[41] M. M. Rahman, "A modification of the test of Shapiro and Wilk for normality," Journal 
of Applied Statistics, vol. 24, no. 2, pp. 219-236, 1997. 
86 
 
[42] S. Verrill and R. A. Johnson, "Tables and Large-Sample Distribution Theory for 
Censored Data Correlation Statistics for Testing Normality," Journal of the American 
Statistical Association, vol. 83, no. 404, pp. 1192-1197, 1988. 
[43] E. Seier, "Comparison of tests of univariate normality," InterStat Statistical Journal, vol. 
1, pp. 1-17, 2002. 
[44] K. Pearson, "Contributions to the mathematical theory of evolution, II: Skew variation in 
homogeneous material," Philosophical Transactions of the Royal Society of London, vol. 
186, pp. 343-414, 1895. 
[45] R. B. D'Agostino, "Transformation to Normality of the Null Distribution of g1," 
Biometrika, vol. 57, no. 3, pp. 679-681, 1970. 
[46] F. J. Anscombe and W. J. Glynn, "Distribution of the Kurtosis Statistic b2 for Normal 
Samples," Biometrika, vol. 70, no. 1, pp. 227-234, 1983. 
[47] J. Hosking, "L-moments: Analysis and estimation of distributions using linear 
combinations of order statistics," Journal of the Royal Statistical Society. Series B 
(Methodological), vol. 52, no. 1, pp. 105-124, 1990. 
[48] C. Lin and G. Mudholkar, Biometrika, vol. 67, no. 2, pp. 455-461, 1980. 
[49] G. S. Mudholkar, C. E. Marchetti, and C. T. Lin, "Independence characterizations and 
testing normality against restricted skewness–kurtosis alternatives," Journal of statistical 
planning and inference, vol. 104, no. 2, pp. 485-501, 2002. 
[50] R. D'Agostino and E. S. Pearson, "Tests for Departure from Normality. Empirical Results 
for the Distributions of b2 and √ b1," Biometrika, vol. 60, no. 3, pp. 613-622, 1973. 
[51] K. Bowman and L. Shenton, "Omnibus Test Contours for Departures from Normality 
Based on and b2," Biometrika, vol. 62, no. 2, 1975. 
[52] A. K. Bera and C. M. Jarque, "Efficient tests for normality, homoscedasticity and serial 
independence of regression residuals: Monte Carlo Evidence," Economics Letters, vol. 7, 
no. 4, pp. 313-318, 1981. 
[53] J. Bai and S. Ng, "Tests for Skewness, Kurtosis, and Normality for Time Series Data," 
Journal of Business & Economic Statistics, vol. 23, no. 1, pp. 49-60, 2005. 
[54] R. B. D'Agostino, A. Belanger, and R. B. D'Agostino, Jr., "A Suggestion for Using 
Powerful and Informative Tests of Normality," The American Statistician, vol. 44, no. 4, 
pp. 316-321, 1990. 
[55] I. Koutrouvelis and J. Kellermeier, "A Goodness-of-Fit Test of Simple Hypotheses 
Based on the Empirical Characteristic Function," Journal of the Royal Statistical Society. 
Series B (Methodological), vol. 43, no. 2, pp. 173-176, 1981. 
87 
 
[56] K. Murota and K. Takeuchi, "The studentized empirical characteristic function and its 
application to test for the shape of a distribution," Biometrika, vol. 68, no. 1, pp. 55-65, 
1980. 
[57] C. J. Mecklin and D. J. Mundfrom, "An Appraisal and Bibliography of Tests for 
Multivariate Normality," International Statistical Review, vol. 72, no. 1, pp. 123-138, 
2004. 
[58] S. Csorgo, "Testing for Normality in Arbitrary Dimension," The Annals of Statistics, vol. 
14, no. 2, pp. 708-723, 1986. 
[59] L. Baringhaus and N. Henze, “A consistent test for multivariate normality based on the 
empirical characteristic function," Metrika, vol. 35, no. 1, pp. 339-348, 1988. 
[60] M. Arcones, "Two tests for multivariate normality based on the characteristic function," 
Mathematical Methods of Statistics, vol. 16, no. 3, pp. 177-201, 2007. 
[61] N. M. Keifer and M. Salmon, “Testing normality in econometric models," Economics 
Letters, vol. 11, no. 1-2, pp. 123-127, 1983. 
[62] A. Hall, “Lagrange Multiplier Tests for Normality against Seminonparametric 
Alternatives," Journal of Business & Economic Statistics, vol. 8, no. 4, pp. 417-426, 
1990. 
[63] R. H. Koning and B. van der Klaauw, "Testing the normality assumption in the sample 
selection model with an application to travel demand," Journal of Business & Economic 
Statistics, vol. 21, no. 1, pp. 31-42, 2003. 
[64] T. W. Epps, K. J. Singleton, and L. B. Pulley, “A test of separate families of distributions 
based on the empirical moment generating function," Biometrika, vol. 69, no. 2, pp. 391-
399, 1982. 
[65] J. Sigut, J. Pineiro, L. Moreno, J. Estevez, R. Aguilar, and R. Marichal, "A large 
deviation approach to normality testing," Computational statistics & data analysis, vol. 
49, no. 3, pp. 741-756, 2005 2004. 
[66] G. Wainrib, M. Bachar, J. Batzel, and S. Ditlevsen, Eds. Stochastic Biomathematical 
Models: With Applications to Neuronal Modeling (Lecture Notes in Mathematics). 
Springer, 2013. 
[67] K. Dettmer, P. A. Aronov, and B. D. Hammock, "Mass spectrometry-based 
metabolomics," Mass Spectrom Rev, vol. 26, no. 1, pp. 51-78, 2007 Jan-Feb 2007. 
[68] J. W. Locasale et al., "Metabolomics of human cerebrospinal fluid identifies signatures of 
malignant glioma," Mol Cell Proteomics, vol. 11, no. 6, p. M111.014688, Jun 2012. 
[69] B. Durbin and D. M. Rocke, "Estimation of transformation parameters for microarray 
data," Bioinformatics, vol. 19, no. 11, pp. 1360-7, Jul 2003. 
88 
 
[70] D. M. Rocke and S. Lorenzato, "A Two-Component Model for Measurement Error in 
Analytical Chemistry," Technometrics, vol. 37, no. 2, pp. 176-184, 1995. 
[71] R. A. van den Berg, H. C. Hoefsloot, J. A. Westerhuis, A. K. Smilde, and M. J. van der 
Werf, "Centering, scaling, and transformations: improving the biological information 
content of metabolomics data," BMC Genomics, vol. 7, p. 142, 2006. 
[72] R. R. Pagano, Understanding statistics in the behavioral sciences, 5th ed. Pacific Grove: 
Brooks/Cole Pub. Co., 1998, pp. xxviii, 548 p. 
[73] S. S. Shapiro and M. Wilk, "An analysis of variance test for normality (complete 
samples)," Biometrika, vol. 52, no. 3-4, pp. 591-611, 1965. 
[74] J. W. Tukey, "The comparative anatomy of transformations," The Annals of 
Mathematical Statistics, vol. 28, no. 602-632, 1957. 
[75] S. H. Elsea et al., "Elucidation of the complex metabolic profile of cerebrospinal fluid 
using an untargeted biochemical profiling assay," Mol Genet Metab, Apr 2017. 
[76] A. Evans et al., "High resolution mass spectrometry improves data quantity and quality 
as compared to unit mass resolution mass spectrometry in high-throughput profiling 
metabolomics," Metabolomics, vol. 4, 2014. 
[77] A. M. Evans, C. D. DeHaven, T. Barrett, M. Mitchell, and E. Milgram, "Integrated, 
nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem 
mass spectrometry platform for the identification and relative quantification of the small-
molecule complement of biological systems," Anal Chem, vol. 81, no. 16, pp. 6656-67, 
Aug 2009. 
[78] L. W. Summer et al., "Proposed minimum reporting standards for chemical analysis 
chemical analysis working group (CAWG) metabolomics standards initiative (MSI)," 
Metabolomics, vol. 3, no. 3, pp. 211-221, 2007. 
[79] O. Hrydziuszko and M. R. Viant, "Missing values in mass spectrometry based 
metabolomics: an undervalued step in the data processing pipeline," Metabolomics, vol. 
8, no. 1, pp. 161-174, 2012. 
[80] T. Hulsen, J. de Vlieg, and W. Alkema, "BioVenn - a web application for the comparison 
and visualization of biological lists using area-proportional Venn diagrams," BMC 
Genomics, vol. 9, p. 488, Oct 2008. 
[81] J. Calles-Escandon et al., "Influence of exercise on urea, creatinine, and 3-
methylhistidine excretion in normal human subjects," Am J Physiol, vol. 246, no. 4 Pt 1, 
pp. E334-8, Apr 1984. 
[82] W. E. Mitch et al., "Effects of Diet and Antihypertensive Therapy on Creatinine 
Clearance and Serum Creatinine Concentration in the Modification of Diet in Renal 
Disease Study," American Society of Nephrology, vol. 7, no. 4, pp. 556-565, 1996. 
89 
 
[83] R. T. Rubin, "Urine creatinine excretion: variability and volume dependency during sleep 
deprivation," Psychosom Med, vol. 33, no. 6, pp. 539-43, 1971 Nov-Dec 1971. 
  
90 
 
CHAPTER 3: MISSING VALUES 
2.9. Introduction 
Much of this dissertation is a result of collaboration between Metabolon and the Molecular 
and Human Genetics Dept. at Baylor College of Medicine. Initially this partnership explored the 
diagnostic value of high throughput metabolomics for the identification of IEMs [1]. This work 
demonstrated the power of global MS-based metabolomics as a screen for IEMs detailed in 
Miller, Kennedy, Eckhart, Burrage, Wulff et al. [2] and Kennedy, Miller, Wulff, et al. [3] and 
Elsea, Kennedy, Pappan, Donti, Evans, Wulff, et al. [4]. The technology has also demonstrated 
diagnostic potential in other disease settings. Donti et al. [5] details the ability of metabolomics 
to differentiate between adenylosuccinate lyase deficiency versus other neurometabolomic 
disorders sharing a similar genotypic profile. Similarly, metabolomics sphingomyelin levels were 
found to be depressed in subjects with peroxisomal biogenesis disorder (PBD) compared to 
disease mimics [6]. Recent research offers the potential for improved detection and/or staging of 
pancreatic [7], ovarian [8], colorectal [9] cancers through metabolomics. Evidence also supports 
the use of metabolomics in motor neuron diseases, including detection of Amyotrophic Lateral 
Sclerosis (ALS) [10], monitor progression of Alzheimer’s [11], or informing treatment of 
Parkinson’s [12].  
The implications for these results and others is that metabolomics represents not just a tool 
for biomarker discovery, but offers the potential inform on disease progression and effectiveness 
of treatment at the individual patient level [13, 14]. Customization of treatment, more formally 
known as Personalized Medicine [15], Precision Medicine [16] or N-of-1 [17], has become 
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popular in recent years. For metabolomics, which has traditionally operated as a screening 
platform, the application to the clinical environment represents a significant shift for the 
technology. 
2.10. The Z-Score 
One approach to assessment at the individual level is to profile the individual’s metabolic 
profile against the overall population at large. This is particularly effective in IEMs because the 
disease generally inhibits the body’s ability to convert intermediates of important metabolic 
pathways, leading to either a buildup or depletion of metabolites in biochemical pathway 
affected. Identification of these cases amounts to outlier detection. The initial statistical analysis 
in Miller et al. [2] relied mainly on z-scores, which is equivalent to autoscaling (section 2.XX) 
and is used in metabolomic data [18, 19]. Autoscaling is attractive in metabolomics because all 
features on the same scale and hence given the same weight in analysis. The downside is that 
unit scaling may mask useful information about technical variation. For this reason, pareto 
scaling, which divides by ඥ𝜎௜ rather than σi, is sometimes preferred as it keeps a better sense of 
the original scale while still making metabolite feature more homogenous [20]. In a direct 
comparison between auto and pareto scaling, Masson et al. identified autoscaling as more 
effective for GC-MS [21]. Conversely, Gromski et al. using NMR data found kNN classification 
to be highest with pareto scaling compared to various other scaling methods, including 
autoscaling [22]. The most appropriate transformation is likely to depend on the data and 
analysis in question. 
The z-score translates the patient’s biochemical level into the number of standard deviations 
from the average value of that compound. That is, for a given subject j and biochemical i, taking 
yji  as the observed metabolite value for the subject. The z-score is then 
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zji = 
yji − µi
σi
 
with µ௜ and σ௜ being the mean and standard among healthy subjects for compound i. Cases of 
IEMs present as outliers with very high or low values in the biochemical(s) related to their 
specific dysfunction. To illustrate this outlier behavior, the z-score plots of two subjects are 
shown in Figure 3.1. In these plots the individual metabolites are plotted with the x-axis being 
the z-scores and the y-axis being the individual metabolites. The metabolites are colored 
according to major biochemical pathway and fall into 1 of 8 classes. The first plot, subject A, is 
from a urine sample and is shown to have a high level of N-acetylglucosaminylasparagine, a 
compound signifying aspartylglucosaminuria [23]. The second plot, subject B, is from a plasma 
sample and shows two high outliers. One of these is pipecolate, elevated levels of which are 
related to Zellweger syndrome, Refsum Disease 
and others peroxisomal disorders [24, 25]. The 
other outlier, which is technically the most 
extreme hit in the plot for this subject, is S-
methylcysteine. This biochemical is known to be 
associated with certain diets [26] and may be 
associated with cardiotoxicity [27], but no 
connection between this molecule and IEMs were 
found in a literature search.   
The presence of S-methylcysteine highlights 
an important reality of using z-score analysis. In 
extreme situations ion suppression may lead to 
erroneously low values whereas very high levels 
Figure 3.1: Z Score plots of suspected IEM cases. 
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in one sample may carry over to subsequent samples in run [28]. In cases of instrument error the 
biochemical may be regarded as a false positive, but note that the z-score for this subject may be 
accurate and not necessarily the result of instrument error. Genetic outliers are known to exist in 
perfectly normal, healthy subjects, with the average individual having anywhere from 60 to 200 
genetic mutations [29]. The same phenomenon could easily occur in metabolomic components as 
well, leading to natural outliers that do not inform on the disease state. One may wish to refer to 
such outliers as non-informative markers instead of false positive. However, for diagnosis 
purposes the distinction appears to be moot. Regardless of whether the values of this biochemical 
is truly high in the subject or made artificially high by the instrument, either way these points are 
analogous to type I errors and create points of investigation that require follow up. Additional 
input from a clinician familiar with the patient’s history is therefore always necessary to 
accurately diagnose a subject. Thus z-scores have a couple desirable traits. First, they are 
computationally easy. Second, they are easily interpretable by a physician. However, due to the 
natural outliers present in high through put metabolomics it is imperative to limit process 
induced outliers as much as possible. 
2.11. Alternatives to Z-Scores 
Other approaches besides z-scores are available both in clinical practice and statistical 
modeling strategies have been used extensively in the field of metabolomics. In fact, 
metabolomics is closely related to chemometrics [30-32]. Chemometrics involves a rich array of 
statistical methodology [33]. For example, partial least squares regression and principal 
component regression are have often been used in metabolomics [34]. It is, therefore, 
unsurprising to see multi-analyte or multivariate methods applied to metabolomics. Some 
examples of these are given next. 
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2.11.1. Linear Models 
Impaired Glucose Tolerance (IGT) is a hyperglycemic state associated with higher blood 
glucose levels than normal but not high enough to qualify as type 2 diabetes [35, 36]. Generally, 
someone with IGT is considered to be pre-diabetic meaning that they have difficulty absorbing 
glucose but not to the same degree as someone with diabetes. Standard diagnosis for IGT 
involves the oral glucose tolerance test (OGTT) which involves fasting for at least 8 hours, 
taking a baseline blood draw, consuming a 75 gram oral glucose solution and measuring glucose 
levels after 2 hours. Blood glucose between 140 mg/dL and 199 mg/dL after 2 hours is indicative 
of IGT as are certain level of increase over baseline.  
Demonstrating the ability of multiple metabolites to model impaired glucose tolerance (IGT) 
without the need for invasive procedures, Cobb, Eckhart, Perichon, Wulff et al. [37] used a 
logistic regression model to predict the probability of a subject being IGT. Letting p stand for the 
probability of a subject being IGT, the logit of IGT is modeled as linear combination four 
metabolites: 
log ൬
p
1-p
൰ =b଴ + b1*α–hydroxybutrate + b2*linoleoyl–glycerolphosphocholine + 
b3*4–methy–2–oxopentanoate + b4*Oleate 
The model was developed using a total 1,623 available plasma samples from two separate 
cohorts: Relationship between Insulin Sensitivity and Cardiovascular Disease Study (RISC; 
n=955)[38] and The Diabetes Mellitus and Vascular health initiative (DMVhi; n=668) [39]. 
Model development was done in RISC (AUC=.82) and then validated in DMVhi (AUC=.83). 
This model was found to perform significantly better (p < .05) than the standard OGTT in both 
the training and test cohort. 
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In the realm of continuous outcomes, glomerular filtration rate (GFR) measures renal 
function by estimating the flow of fluid through the kidney. Calculating the true or measured 
GFR (mGFR) requires an intensive regiment consisting of multiple blood draws and urine 
collections plus a continuous intravenous infusion. In practice GFR is typically estimated 
(eGFR), most commonly with creatinine levels in serum (sCR). One such formulation, the 
Modification of Diet and Renal Disease (MDRD) study equation, is given by 
eGFRMDRD=175*sCR-1.154*Age-0.203*0.742if female*1.212if black 
which is a linear regression equation (or four separate regression equations) depending on race 
and sex, on the log scale: 
log(eGFRMDRD)= log(175) −  1.154* log(sCR) −  0.203* log(Age) +  
log(0.742)*I(female) + log(1.212)*I(black) 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which is the 
current recommended standard of care for estimating GFR, involves a more complicated linear 
model: 
            log(eGFRCKD-EPI)= log(144)  + a* min ൬
sCR
k
,1൰ −  1.209* max ൬
sCR
k
,1൰  +  
log(0.993) *Age + log(1.018)*I(female)+1.156*I(black) 
where 
a= ቄ-0.329 if female-0.411 if male ቅ 
k= ቄ0.7 if female0.9 if male ቅ 
The sex and race differences in the models are due to creatinine which is known to be higher in 
men than women and higher in African Americans than non-African Americans. Recently, new 
algorithms for estimating GFR have been proposed based on metabolites beside creatinine in 
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addition to offering the potential to remove sex and race which are becoming increasingly 
undesirable [40]. 
2.11.2. Metabolite Ratios 
There are biological reasons to support the use of multiple analytes. First, individual 
metabolites could enhance one another. For example, both urea and creatinine are known to be 
related to kidney function with poor function leading to elevations of each. Therefore, high levels 
in both urea and creatinine help strengthen a conclusion of poor kidney function. When assessing 
quality of plasma samples, increases in lysophosphatidylcholines with decreases in 
phosphatidylcholines signal prolonged storage at room temperature [41]. Because these two 
classes move in different directions, taking a ratio between members of each classes provides 
better diagnostic ability for poor storage conditions. Similarly, creatinine and creatine are both 
known to be different on average between adult men and adult women with men tending to have 
higher levels of creatinine while women tend to have higher levels of creatine. Either of these 
markers are individually good discriminator of gender; however, in certain conditions the ratio of 
the two can provide an even stronger discriminator. The second advantage to using multiple 
metabolites is robustness. The number of metabolic processes and interactions in the human 
body is vast [42], allowing any given metabolite to be affected by multiple conditions. Focusing 
on either eGFRMDRD or eGFRCKD-EPI, these models associate low levels of kidney function with 
high levels of creatinine. Yet creatinine can clearly be affected by other conditions. In fact, high 
levels of creatinine are also associated with diabetes and heart disease [43]. But since creatinine 
is also associated with exercise, kidney function and other conditions, reliance on this metabolite 
can lead to increases in the false positive and false negative rates when a person’s behavior is 
outside “normal” behavior.  
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Association with multiple conditions is not unique to creatinine. Tryptophan is known to be 
positively associated with GFR [37], but as it is not synthesized by the body its levels are 
strongly related to diet [44]. For example, a person with even the poorest of kidney function 
could in theory appear healthy if they ate enough poultry or flax seeds [45].  
Vitamins are obviously important to healthy human function but are frequently taken as 
supplements for various reasons: ascorbic acid is believed to help improve immune function, 
folic acid is recommended during pregnancy to boost fetal brain development, and so on. 
Vitamin pills and other supplements often contain ingredient levels that are well above the 
recommended daily intake level. The popular energy drink Red Bull for example contains 2.5 
times the daily amount of pyridoxal (vitamin B6). The point here is that any single marker could 
easily be affected by a person’s behavior. Having multiple metabolites in the model helps to 
mitigate these problems. 
2.11.3. Decision Trees 
Another way to address the complicated nature of metabolism is with decision trees. 
Returning to the IEM scenario, pipecolate is an example of this. Peroxisomal Biogenesis 
Disorders are related to the inability to breakdown certain amino acids, particularly very long 
chain fatty acids. Presence of these diseases are characterized by elevated levels of cerotic acid  
(C26:0) and hexocosenoic acid (C26:1) as well as the ratios of long chain fatty acids [46]. Within 
this family of disorders, pipecolate is absent from single gene mutation variations but present in 
the Zellweger syndrome spectrum. As a simple example this could be described with the 
decision tree shown in Figure 3.2. The advantage to decision trees is that pipecolate does not 
factor in until after sufficiently high levels of cerotic and hexocosenoic acid have been found to 
warrant a diagnosis of PBD. Thus, an extremely high level of pipecolate, which can also occur in 
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pyridoxine-dependent epilepsy and other non PBD disorders [47, 48] would not by itself trigger 
a false identification of PBD.  This decision tree-based algorithm is possible because of the 
unique relationship between pipecolate and disorders in the Zellweger spectrum. Such 
relationships are not always present and even when they are there is still the matter of 
determining what constitutes sufficiently elevated levels of the long chain fatty acids in the first 
split and the same for pipecolate in the second split, not to mention if there are other diseases 
related to the fatty acids in question. Ultimately, any algorithm used to classify a broad range of 
IEMs could incorporate a combination of decision trees and linear models. But developing such 
a model would require a greater understanding of the relationships of the hundreds of metabolites 
measured by global MS, many of which have received little to no attention.  
2.11.4. Challenges to Modeling Rare Diseases 
Developing extensive knowledge of global metabolic interactions, particularly the disease-
metabolite relationships, may require large cohort studies. Particularly in the case of IEMs and 
other rare diseases. Consider collectively IEMs occur in roughly 1 out of 1,000 births [49-52], 
though incidence may vary considerably by region. Individually, incidence of specific disorders 
Figure 3.2: Hypothetical Decision Tree for Peroxisomal Disorders 
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within this family will be much less frequent. Alkaptonuria, which was discussed in Chapter 2, 
occurs once in every 250,000 to 1,000,000 births [53]. MCADD, the other IEM discussed in 
Chapter 2, occurs about once every 50,000 births [54]. This makes it challenging to acquire a 
reasonably sized cohort for specific disorder, let alone all disorders encompassing IEMs. On the 
other hand, a simple z-score calculated against a reference group of healthy individuals is 
sufficient to indicate outliers. Under normal theory, a z-score above 2 or below -2 indicates an 
extreme 2.5th percent. In the previous chapter it was shown that a natural log transformation is 
reasonably effective at achieving a normal distribution for most metabolites. Combination of the 
log transformation followed by z-scoring leads to a straightforward way of identifying potential 
metabolomic outliers as the first step toward rare disease identification and can also be applied to 
the emerging discipline of n of 1 or personalized/precision medicine as well. Therefore, this 
dissertation is concerned with the general detection of biochemicals with extreme levels through 
the use of univariate z-scores. 
2.12. Missing Values  
As introduced in 1.7.2, The large amount of missing values in global MS metabolomics 
require some method of missing data analysis. As missing values play a central role it is 
appropriate to review the broader topic of missing data. Missing data are ubiquitous in scientific 
research and the topic has received much attention from both the statistical community and 
researchers within individual fields and there is a vast amount of literature covering the subject 
[55-57]. Conventionally, missing data are classified into three categories based on the 
mechanism behind the missing data. The strongest of these is Missing Completely at Random 
(MCAR) under which the probability of being missing is unrelated to the true value as well as 
any level of any covariate. A step down from this assumption is Missing at Random (MAR) in 
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which the missing value is related to a covariate, but otherwise unrelated to its true value.  
Lastly, if the missing value depends on some function of the value itself, with or without regard 
to the covariate levels, then the mechanism is termed Missing Not at Random (MNAR). In the 
context of metabolomics data, imagine yj is the level of some metabolite and A is any set of 
covariates, including, potentially, other metabolites. Using the dummy variable Dj = 1 if the 
compound level is missing and Dj = 0 if the compound level is observed the three conditions can 
be written mathematically as 
MCAR  P൫Dj = 1 ห 𝒚j,A൯ = P(Dj = 1) 
MAR  P൫Dj = 1 ห 𝒚j,A൯ = P(Dj = 1 | A ) 
MNAR  P൫Dj = 1 ห 𝒚j,A൯ = P(Dj = 1 | g(𝒚j,A )) 
To illustrate examples of each of these consider the following suppositions. First, suppose a 
short in the machine causes the portion of the chromatogram in which the metabolite elutes to be 
lost in the last third of the run. This situation would be MCAR as missingness, or the manner in 
which data are missing from the data, depends on neither the true value nor any other variable 
pertinent to the experiment. Next, suppose that the biochemical in question elutes very close to 
another biochemical with massive abundance so large that the peak could cover the area of both 
biochemicals. This scenario would be MAR as missingness is tied to the size of the neighboring 
compound but otherwise unrelated to the value of the biochemical in question. Last, consider the 
LOD scenario when a value is missing because it falls below the background level of the 
instrument. It is clear that this situation is MNAR since missingness is directly tied to the sample 
level. In this case a missing value constitutes partial information, namely that the sample is 
below a certain threshold but otherwise unknown. In statistics such partially known 
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measurements are referred to as censored, with the observed values for a metabolite constituting 
a left-censored sample [58].  
2.12.1.  Regulatory Suggested Methods 
Use of global metabolomics to identify subjects with a disease, like IEMs, is a diagnostic 
screening test, and the instrumentation involved is most likely to be classified as a Laboratory 
Developed Test (LDT) [59]. At present the US Food and Drug Administration (FDA) does not 
monitor LDTs in the same fashion as pharmaceutical drugs, though FDA approval is required for 
Medicare and Medicaid reimbursement of LDTs and FDA’s current level of monitoring is under 
internal review. But for now, Federal oversight of LDTs is limited to Clinical Laboratory 
Improvement Amendments CLIA [60], which are a series of regulations to “establish quality 
standards for laboratory testing performed on specimens from humans, such as blood, body fluid 
and tissue, for the purpose of diagnosis, prevention, or treatment of disease, or assessment of 
health” [61]. The intent is to ensure a level of technical proficiency as well as a consistent 
process for generating and interpreting results. The process itself is unspecified as the law is 
intended to include all laboratories covering a broad industry of diagnostic and treatment 
activities. Missing data is mentioned only in the context of reporting results in the presence of 
missing patient records. Therefore, these do not provide suggestions for handling of missing 
(output) data. Outside of the Federal agencies, independent laboratory licensing is provided by 
the College of American Pathologists (CAP) [62]. Similar to CLIA, CAP accreditation focuses 
mainly on laboratory procedure, including things like consistency and accuracy of 
instrumentation as well as proper maintenance of patient records. It too does not offer any 
guidance on handling of missing values.  
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The FDA does provide guidance for missing values with regards to clinical trials. These 
methods include Complete Case, Single Imputation, Multiple Imputation, Full Information 
Maximum Likelihood and the EM algorithm. In the research role, metabolomics itself has come 
to rely mainly on imputation methods to handle missing values [63-65]. Various forms of single 
imputation have been used. Additional imputations include K Nearest Neighbors [22, 66], which 
is a popular machine learning algorithm and has been employed in various settings [67]. 
Imputations are also borrowed from other omic fields, including a family of imputation methods 
based on Principle Component Analysis.  These methods for handling missing values are 
detailed next. 
2.12.1.1.  Complete Case 
Complete Case Analysis involves removing observations in which missing values occur. This 
approach can be applied either to the samples, retaining only those subjects which experience no 
missing value in any of the compounds, or on the variables, removing any compound feature that 
is not completely observed. It is equivalent to completely filtering out features or samples with 
missing proportion greater than 0. After the data has been trimmed to the fully observed subset, 
routine analysis can be performed. Statistical analysis by complete cases is only unbiased if the 
missing data is MCAR, a condition that is rarely true in practice let alone for high throughput 
metabolomics. Although very simple to execute, when applied to metabolomics the loss of 
information can be staggering and often impractical. As observed by Steinfath et al [68]:  
“The following simple calculation shows that such omissions would be extremely costly 
and may render the experiment worthless. Let us assume that only 1% of all 
measurements, i.e. of the components in the data matrix, are missing. Let us also assume 
that we have 100 genotypes and 100 metabolites. Then, according to the binomial 
distribution, on average, 63% of the rows or columns must be omitted, while in the case 
of pairwise correlation, generally only one or two values must be omitted. Therefore, in 
the case of multivariate methods, an estimation of missing values is reasonable.” 
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Here, Steinfath and his colleagues recognize the fundamental problem with removing all trace of 
missing values from the data, yet the individual metabolites may contain only a few missing 
observations. The assumption posited assumes that missing values are MAR, which is likely not 
the case. However, the total amount of missing data proposed by Steinfath is extremely 
conservative [22, 66]. In the experience of this author a general rule of thumb is that roughly half 
the metabolites in a large, global analysis will be fully observed while the other half will have 
some fraction of missing values. Overall percentage of missing values can vary depending on 
instrumentation and sample type, but it is generally true that complete case will result in 
significant, often unacceptable, reduction to the data. 
2.12.1.2.  Single Imputation 
Single Imputation (SI) replaces missing observations with an identical value based on the 
observed data. As an example, a vector of 7 with four observed values is shown. In the case of 
mean imputation, the average of the four observed values is 1.5, which is subsequently filled in 
for the three unobserved values.  
1.2
2.2
0.7
1.9
   
Mean 
Imputation
ሱ⎯⎯⎯⎯⎯ሮ  
1.2
2.2
1.5
0.7
1.5
1.5
1.9
 
Choices of SI frequently used in metabolomics include mean or median [66], zero [69] and 
minimum / half-minimum [70]. Mean and median are consistent with missing at random while 
the other three are associated with missingness resulting from low values. As metabolomics is 
high dimensional it is worth noting that SI is generally applied to each individual compound or 
feature separately because the LOD could vary from compound to compound. One exception to 
this would be zero imputation. This is an extreme case of low valued assumption, implying that 
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compounds unobserved in sample are completely absent from that sample. This may be true in 
certain cases especially with drugs or other xenobiotics, but many endogenous metabolites are 
likely present to some degree. 
In clinical trials, Last Observation Carried Forward is a form of single imputation for 
longitudinal data. Repeated sampling of the same biological unit is a common experimental 
design strategy and has been used in metabolomics [71]. However, longitudinal studies in 
metabolomics could be confounded by circadian rhythm. Metabolite levels fluctuate over a 24-
hour period, responding to basic environmental changes such as sleeping, eating and physical 
activity. Understanding the relationship between metabolites and the circadian rhythm is an 
active area of metabolomics [72, 73]. Although repeated sampling is un-related to the IEM 
setting of this thesis there is diagnostic potential through monitoring of metabolite levels. This 
approach would be particularly applicable with patient monitoring for disease progression or 
treatment response. In such studies, specifying study conditions and sample collection to mitigate 
circadian variation is important for minimizing intra-subject variability. Therefore, it is important 
that the consistency of sample collection be extended, ideally, to commonalities such as the same 
time of day and/or the same fasted status for each sample draw. 
Naturally, SI is very simple to implement. Unlike complete case though, SI does not produce 
universally unbiased parameter estimates even under MCAR. For proof of this, assume that 
values are indeed MCAR. Imputation with the observed mean will produce unbiased estimates 
for the mean. However, replacement with a single value will lead to an unnatural reduction in 
variation thus providing under estimates of the variance. Next assume that missingness follows 
LOD. Imputation with zero, half minimum or minimum. When estimating parameters for the z-
score transformation, minimum imputation is almost guaranteed to be produce an inflated 
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estimate of the mean since the true will in most cases be lower than the imputed value. The only 
way this can be unbiased for the mean is if every single missing value happens to be right at the 
LOD. Through similar arguments, zero imputation is all but guaranteed to underestimate the 
mean. And of course, all will poorly estimate the standard deviation for the same reason mean 
imputation does. 
2.12.1.3. Multiple Imputation 
In contrast to SI, multiple imputation (MI) creates multiple sets of imputed data. Each 
realization contains plausible values of the missing data sampled from a Bayesian posterior 
distribution. The sets are analyzed as any complete dataset would be with final inference coming 
from a combination of the results across all the sets. MI is advantageous for a few reasons. 
Estimates are consistent and asymptotically normal under MAR or if the model of the missing 
data mechanism is correctly specified. Next, the variance of parameter estimates can be divided 
into portions due to between imputation and within imputation. Decomposition of the variance 
allows variability due to the imputation to be accounted for, unlike the single imputation case 
where variation is often artificially deflated, and that the impact of imputing can be assessed. 
Finally, MI is available in a few software packages, although most of these appear to assume 
MAR. One challenge to MI can be reproducibility due to the randomness of the draws. Also, 
there are a number of ways in which to implement MI, which may also contribute to confusion 
and inconsistency of results. Methods for simple missingness mechanisms include Linear 
Regression, Propensity Scores and Predictive Mean Matching. The first two of these are offered 
by PROC MI in SAS [74]. For more complex or data specific missingness structures there is the 
Markov Chain Monte Carlo (MCMC) approach; however, this assumes multivariate normality. 
Multiple (or Multivariate) Imputation by Chained Equations (MICE)[75], also known as Fully 
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Conditional Specification [76] or Sequential Regression [77] among others, is a popular 
extension of MI for multivariate data that has been used in a number of disciplines. 
2.12.1.4. Maximum Likelihood 
Maximum Likelihood is a statistical technique for parameter estimation involving the 
likelihood function: 
 L(θ;𝑿𝒏)= ෑ f (x௝; θ)
n
j=1
 
The formula is equivalent to the probability density (pdf) of a random sample 𝑿𝒏; however, the 
emphasis of the likelihood is to view θ as a function of the observed data. Taking the derivative 
of L with respect to θ, setting the result equal to 0 and solving for θ results in parameter 
estimates which maximize the likelihood function, giving the name maximum likelihood (ML). 
In practice a log transformation is applied along with a sign change to simplify the calculation by 
turning the product into a summation: 
− ෍
∂ log f (𝑥௝; θ)
∂θ
 = 0
n
j = 1
 
This function is known as the score equation. The negative sign follows from log f(𝑥i;θ) ≤ 0 as 
the pdf is always bounded between 0 and 1. Conceptually this approach may be thought of as 
producing the “best” estimates of θ given the observed data. In general ML tends to be efficient. 
However, the estimates may be biased and in many cases in which unbiased estimators can be 
claimed it is only done so asymptotically. Additionally, the solution to the score equation(s) may 
not have a closed form in certain settings, requiring numerical approximations to solve. 
 In relation to this dissertation, missing data due to limit of detection has two principle forms 
in ML. The first is censoring, in which an observation is recorded but there is no value to 
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associate with it due to the true value being below the detection threshold. The second is 
truncation in which values below the detection threshold are not just unknown but the 
observations themselves are unrecorded. For metabolomics, the number of missing values for a 
given compound is always known and when due to limit of detection it is appropriate to 
incorporate the partial information from these observations into the model. However, as 
discussed in Chapter 2, strictly speaking there are times when missing values will not be LOD. 
Alternative reasons for missing values are more in line with MCAR, where ignoring the missing 
values is acceptable. Truncation may offer a tradeoff over censoring, producing more accurate 
estimates when some values are actually MCAR/MAR but being less efficient when all values 
are due to LOD. As this paper focuses on the LOD assumption, the censoring approach is used 
exclusively. 
2.12.1.5. Expectation-Maximization Algorithm 
Broadly, the Expectation-Maximization (EM) Algorithm is a two-step, iterative approach 
useful for generating maximum likelihood estimates when the likelihood function is difficult to 
solve directly, such as with latent variables or missing data. The overall process is shown in 
Figure 3.3. The algorithm begins with the Expectation, or E, step in which creates a function of 
the expected log-likelihood based on current parameter estimates. This is followed by the 
Maximization, or M, step in which the derived function is maximized to obtain updated 
parameter estimates. With these updated estimates in hand the algorithm returns to the E step and 
continues cycling until some tolerance between the current and updated estimates is achieved. 
Key here is the ability to handle missing values. In this case the EM steps essentially take 
current estimates of the parameters to generate estimates of the missing values based on the 
conditional expectations. After filling in the missing values, new parameter estimates are created. 
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Primarily the purpose is to generate parameter estimates; however, a “complete” dataset can be 
found from the final E step. Overall, EM is regarded as being efficient and generally accurate 
regarding its primary goal – parameter estimation. As with ML, it does require specification of 
the likelihood function. 
2.12.2.  Common Metabolomic Imputations 
In regard to missing data, metabolomic researchers are mostly interested in a complete 
dataset. Therefore, producing plausible estimates of the missing observations is most critical. 
The previous methods suggested by FDA are not necessarily meant for this purpose and many of 
Figure 3.3: EM process flow diagram. 
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those methods require specifying a statistical model. Following Chapter 2 and 3, metabolite 
characteristics may not be known leaving researchers uneasy about specifying such behavior. 
Imputation in metabolomics has come to rely more on non-parametric methods. There does exist 
some overlap, such as SI via mean, minimum, zero, etc. But more complicated imputation 
strategies have largely been borrowed from other omic fields. This include variations on 
Principle Component Analysis, k Nearest Neighbors and Random Forest. The latter two have 
been found to perform well in comparison with other methods. Greater detail on given on these 
methods next. 
2.12.2.1. Principal Component Analysis 
Principal Component Analysis (PCA) is a popular multivariate technique with broad use in a 
number of disciplines including chemometrics and metabolomics [33, 78-81]. PCA is most 
simply a data reduction technique that reduces a set of correlated vectors into a smaller set of 
uncorrelated, or “principal”, component vectors. Intuitively, even when there are a massive 
number of variables on n observations it should take no more than n - 1 independent pieces of 
information to completely separate the subjects in an experiment. Thus, PCA has useful 
application in high dimensional data in which m ≫ n and also in data that is highly correlated. 
More precisely, for Xn×m a matrix of m metabolite features on n samples the singular value 
decomposition theorem states there exist matrices Un×n, Vm×n and Dn×n (note that in practical 
applications 𝑿 will always be of rank n) such that: 
X = UDV' 
D is a diagonal matrix with elements known as the singular values of 𝑋 satisfying 
D11 ≥ D22 ≥ … ≥ Dnn. U and V are the solutions associated with the eigenvalues of XX' and X'X 
respectively: 
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XX'U = UD2 
X'XV = VD2 
The full PCA decomposition of X is given by Y = XV. The columns of Y are orthogonal to each 
other and are referred to as the principle components of X. A useful interpretation, relating the 
singular values, is that the ith component of Y accounts for Di  ∑ Dj⁄  of the observed variation in 
X.  
Pearson and Hotelling were the first to use PCA in the early 20th century [82, 83]. It was 
introduced to missing data by Christoffersson to handle matrices with missing values [84]. Near 
the turn of the century Tipping and Bishop added a probabilistic model to PCA (PPCA), which is 
closely related to factor analysis [85]. From this Oba developed an imputation method consisting 
of three parts: principal component regression, Bayesian estimation and an EM-like algorithm 
[86]. This approach is termed Bayesian PCA (BPCA). Finally, when suspicion that missing 
values are not believed to be a linear function of latent parameters Non-linear PCA (NLPCA) 
may be used [87]. For PPCA and NLPCA, missing values are essentially ignored during the 
fitting process but can be imputed on the back end.  
2.12.2.2. k Nearest Neighbors 
Broadly speaking, k-nearest neighbors (kNN) is a simple machine learning algorithm. In 
statistical application it is a tool for non-parametric prediction. It functions much the way other 
prediction tools do: Given a set of outcomes variables on n observations with m input variables 
from which to train, outcomes for a new observation can be made based upon the inputs. When 
the output variable is categorical it is often referred to as kNN classification, while continuous 
outputs are called kNN regression. It’s worth pointing out that in metabolomic imputation, the 
neighbors are generally the metabolites with missing values for one metabolite of a sample filled 
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in based upon the observed values of the neighbors for the same sample. The alternative would 
be to fill in values of a metabolite in a missing sample based upon the observed values of the 
metabolite in another sample. Replacement by nearest sample is less likely to be successful since 
there is no guarantee that a group of randomly selected subjects would associate well. However, 
in theory certain metabolites can be very closely associated with one another based upon 
biochemical function or pathway relationship.  
The specific algorithm for kNN involves comparing the input for a new observation 
(sometimes referred to as query) to the input of the training set by some dissimilarity measure. 
This is most commonly based on one of the following distance measures:  
Euclidean = ඩ෍ ቀyji  −  y௝i'ቁ
2
n
j = 1
 
Manhattan = ෍ ቚ yji  −  y௝i'  ቚ
n
j = 1
 
Minkowski = ඨ෍ ቚ yji -  y௝i'  ቚ
q
n
i = 1
q
 
Hamming = ෍ Di  where ቊ
 yji =  y௝i'  : Di = 0
yji ≠  y௝i'  : Di = 1
ቋ 
Euclidean represent the shortest distance between two points in an 𝑛-Dimensional space and is 
the most popular distance measure for continuous values. Manhattan measures the distance 
between two points based on a grid structure. Minkowski is the generalization of the first two, 
giving Manhattan when q = 1 and Euclidean when q = 2. While these three are all appropriate for 
numeric values, Hamming is able to handle categorical variables by counting the number of 
instances in which yi and yi' disagree. Although not highly applicable for metabolomics, 
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metabolites could conceivably be dichotomized based on the ion counts being below versus 
above a certain threshold, or by an indicator variable based on presence or absence of an ion 
count. Regardless, once the dissimilarity is calculated, the k training observations with the 
smallest dissimilarity are used to formulate a prediction of the outcome variable based on some 
function of the k training outcomes. When the outcome is categorical this can be the mode of the 
k “neighbors” while continuous variables typically use the mean or median. 
The nearest neighbor concept has been extended to missing data as a method to produce 
realistic replacements for missing values and has become popular in the omic fields [88]. As an 
imputation method it is non-parametric and software packages for kNN imputation are widely 
available; however, it is not guaranteed to produce unbiased estimates under MAR or even 
MCAR.  
To illustrate how kNN works a classification example is given. Taurocholate (TC), 
glycocholate (GCC), taurochenodoexycholate (TCDC) and glycochenodeoxycholate (GCCDC) 
are the major bile acids in humans and are markers of liver health. Non-alcoholic fatty liver 
disease (NAFLD) is a form of liver disease in which excessive amounts of fat accumulate in the  
liver regardless of alcohol consumption resulting in impaired liver function. Non-alcoholic 
steatosis (NASH) is more advanced condition which can lead to liver failure. The following 
observations relate the biochemical levels of 7 hypothetical patients to fictional disease 
outcomes:  
Patient TC GCC TCDC GCCDC Condition 
1 4.2 10.4 9.7 19.1 Normal 
2 3.8 9.1 10.6 12.6 Normal 
3 5.8 9.7 11.4 17.3 NAFLD 
4 4.1 8.1 8.9 11.8 NAFLD 
5 3.1 6.5 12.8 3.2 NASH 
6 3.5 7.9 15.1 9.8 NASH 
7 4.3 9.2 12.8 7.3 ? 
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The first six with known disease conditions represent training samples while the seventh sample 
is unknown and the desire is to classify it based on the data at hand. Using Euclidean as the 
dissimilarity measure and setting k = 3 gives: 
Patient TC GCC TCDC GCCDC Euclidean Distance Rank 
1 0.01 1.44 9.61 139.24 12.26 6 
2 0.25 0.01 4.84 28.09 5.76 3 
3 2.25 0.25 1.96 100.00 10.22 5 
4 0.04 1.21 15.21 20.25 6.06 4 
5 1.44 7.29 0.00 16.81 5.05 2 
6 0.64 1.69 5.29 6.25 3.72 1 
The three smallest distances are, in ascending order, patients 6, 5 and 2. The corresponding 
conditions are NASH, NASH and Normal. With NASH being the condition of two of the three 
closest neighbors, patient 7 is predicted as being NASH. If Condition had been continuous, such 
as a severity measure, then the prediction would be either the mean or median (or some other 
function) of the three neighbors. 
The main attractions to kNN are rapid processing speed, ability to handle categorical and 
continuous variables in both the inputs and outputs, and distributional free assumptions. The 
number of user defined settings are few. Dissimilarity is generally Euclidean for continuous 
variables and Hammering for Categorical. Resolving the prediction from the neighbors is 
typically done by the mean, though median may be more appropriate when severe outliers are 
present. The biggest hurdle is determining the value of k and the optimal value will depend upon 
the data. Selecting k = 1 is analogous using Nearest Neighbor or 1NN. A rough rule of thumb is 
k = 10 and this is the default in a number of software packages; however, in metabolomics 
performance has been shown to level off around k = 5.  
Major drawbacks to kNN are that it can be harmed by the presence of non-informative input 
variables, imbalance in the output variable and ties in the prediction for classification, and 
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inconsistent scales among continuous inputs. For the first point, consider that neighbors are 
evaluated by some dissimilarity, which, for the common measures listed above, will increase in 
magnitude as more input variables are included. When a large number of the input variables in 
the training set are unrelated to those of the new variable then the dissimilarity measure becomes 
dominated by noise meaning that training sample association with a new observation is largely 
determined by chance. In essence, non-informative inputs tend to weaken the power of the 
dissimilarity measure to discriminate between values. Focusing on kNN classification, by 
increasing the number of observation of a given class the more opportunity there is to increase 
the classes’ reach due to natural variation within a population. Thus, when one class is severely 
over-represented in the training set compared to other classes the more opportunity that class has 
to be close to any new observation.  This can be overcome by condensing the training space, 
such as with subsampling, to produce a training set with equal representation of the class variable 
or alternatively by weighting the prediction so that closer neighbors have more impact on the 
prediction. A similar solution can be employed for instances of when two or more classes have 
equal representation in the k nearest neighbors. In the binary case ties can be avoided by setting k 
to an odd value; however, in the general multiclass setting there is no way to guarantee that a tie 
will be avoided. Ties must be broken somehow. Taking the value of the closest neighbor (i.e. 
1NN) or defaulting to the most prevalent class are analogous to weighting. However, random 
selection of the tied categories is also possible.  
The most relevant drawback to metabolomic data is the impact of input variables with vastly 
different scales. This can be seen somewhat in the example provided above. 
Glycochenodeoxcholate has a larger abundance than the others causing this metabolite to 
dominate the dissimilarity (under distance-based metrics at least). Scaling of variables is 
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therefore important with kNN. Section 2.1 discussed various scaling techniques for metbolomic 
data. Repeating the above example by dividing the levels of each metabolite by the median of the 
training set gives:  
Patient TC GCC TCDC GCCDC Condition 
1 1.063 1.209 0.882 1.566 Normal 
2 0.962 1.058 0.964 1.033 Normal 
3 1.468 1.128 1.036 1.418 NAFLD 
4 1.038 0.942 0.809 0.967 NAFLD 
5 0.785 0.756 1.164 0.262 NASH 
6 0.886 0.919 1.373 0.803 NASH 
7 1.089 1.070 1.164 0.598 ? 
and the associated Euclidean based ranking is:  
Patient TC GCC TCDC GCCDC Euclidean Distance Rank 
1 0.0006 0.0195 0.0794 0.9355 1.02 6 
2 0.0160 0.0001 0.0400 0.1887 0.49 2 
3 0.1442 0.0034 0.0162 0.6719 0.91 5 
4 0.0026 0.0164 0.1257 0.1361 0.53 3 
5 0.0923 0.0986 0.0000 0.1129 0.55 4 
6 0.0410 0.0229 0.0437 0.0420 0.39 1 
The three closest neighbors are now patients 1, 2 and 4, the conditions of which are NASH, 
Normal and NAFLD. This indecision is arguably more reflective of the data: the new 
observation is similar to the NASH patients in GCCDC but more similar to the Normal or 
NAFLD patients in TC and GCC. Regardless of one’s opinion, median scaling has altered the 
neighbors (though the 1NN tie breaker would keep the prediction the same). 
One final point for clarity, in the examples the patients form the neighbors and the missing 
variable is imputed from other values of this same variable. In the metabolomics setting the 
compounds become the neighbors and missing values in a compound are replaced based upon 
the values of other compounds. This further emphasizes the importance of scaling the variables. 
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2.12.2.3.  Random Forest 
Random Forest is another machine learning algorithm useful for classification and regression 
built upon decision trees. Unlike kNN, Random Forest is a supervised approach that uses the 
entire dataset. Multiple trees are created, each by randomly sampling from both the samples and 
candidate predictors. For a given tree, the samples selected for training are referred to as “in bag” 
and the unselected samples are “out of bag” (OOB). Within each random selection a tree is 
created based upon the observed outcome to classify the in-bag samples with the tree grown until 
the nodes are pure. An additional caveat to growing the tree is that at each node separation is 
based on the best split from a subsampling of the predictors rather than the best predictor. This 
approach to splitting protects against overfitting and is shown to boost performance [89]. The 
Final prediction for each sample is then aggregated over all the sets in which the sample was out 
of bag. Forests created for continuous outcomes are referred to as regression forests, and use 
regression trees rather than classification trees, with the final prediction being the mean or 
median predicted value. Categorical outcomes are termed classification forests with final 
predictions based on the mode.  
The usual advantages and disadvantages from such ensemble approaches hold for Random 
Forest. Namely, the use of several (up to several thousand) trees significantly improves accuracy 
but sacrifices interpretability. Additional advantages are the ability to assess predictive 
performance by comparing out of bag predictions against the true value as well as the ability to 
assess the contribution of the individual predictors. The latter feature is helpful for biomarker 
identification as more influential variables are good candidates for further investigation. For an 
excellent review of Random Forest see Liaw and Wiener [90].  
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2.13. Methods 
This paper seeks to evaluate the performance of common imputation methods versus more 
clinically accepted missing data methods in regard to estimating the mean and standard deviation 
from a single “control” population. The common imputation methods selected are (1) None – no 
imputation of the data, (2) Mean – single imputation with the observed mean/average on a 
feature to feature basis, (3) Min – single imputation with the observed minimum, (4) kNN – k 
Nearest Neighbors using metabolites as the neighbors and (5) RF – Random Forest regression. 
The two competing clinical methods are (6) rankit regression (RR) which involves regression the 
observed order statistics against their corresponding expected values under a standard normal 
distribution and (7) Maximum Likelihood (ML) for left censored data.  (1)-(3) were chosen 
because they are common to metabolomics and are acceptable for use in clinical trial evaluation. 
(4) and (5) were selected over others because previous studies have found them to generally have 
better performance than other methods [22, 66, 91].  
These alternatives were selected based on the results of chapter 4 which found that 
metabolites have strong normal tendency following a natural log transformation. Invoking this 
property allows for the use of maximum likelihood or other parametric models which can be 
combined with left censoring following the LOD assumption. Both methods do this. As EM is a 
ML based approach, inclusion of this method felt redundant. Finally, MI has many attractive 
properties, but it has already been explored in metabolomic data where its performance was 
found to be poor [66].  
2.13.1.  Rankit Regression 
For X a normal variate with mean µ and variance σ 2 and Z the standard normal with mean 0 
and variance 1, the distribution of X is related to that of Z by the following relationship: 
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X ~ µ + σZ 
This can be recognized as a linear regression problem. Given a random sample Xn drawn from an 
unknown normal distribution, estimates of µ and σ 2 can be found by regression the ordered 
values of Xn against the corresponding expected values under a standard normal. Notationally, 
let x(i) be the ith ordered value of Xn and z(i) be the ith ordered value of sample of size n drawn 
from the standard normal. Additionally, let zi* = E(z(i)). These are known as the rankits of the 
normal distribution. In general, the expected value of an ordered statistic is non-trivial. However, 
it is possible to show the expected value of x(i)'s are in fact a linear transformation of the 𝑧(i)'s: 
(3.3.1-1) 
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(3.3.1-5) = μ + σzi* 
Step 2 follows from a property of exponential families. Step 3 comes from the change of variable 
u = (x-μ) σ⁄ . The first resulting integral in step 4 is equivalent to the probability density function 
of the ithordered rankit of a standard normal, which over the entire real line has probability equal 
119 
 
to 1. The second integral is equivalent to the expected value the 𝑖௧௛ ordered rankit from a 
standard normal. Returning to the so called rankit regression model of interest: 
൥
x(n)
⋮
x(1)
൩ = a + b ቎
E (z(n))
⋮
E (z(1))
቏ 
The least squares estimate of 𝑎 and 𝑏 are: 
 a = xത  −  bz̅* 
 b = 
∑ (n1 zi *  −  z̅*)(x(i)  −  xത)
∑ (zi*  −  z̅*)
2n
1
 
Next, consider any subset of U ⊆ {1, …., n} and the expected value of the linear coefficients are: 
(3.3.1-6) 
 E(b)=E ൥ 
∑ (zi*  −  z̅*)(x(i)  −  xത)U
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(3.3.1-8) 
=
∑ (U zi *  −  z̅*)({μ + σzi*} − {μ + σz̅})
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(3.3.1-9) 
=
σ ∑ (U zi*  −  z̅*)(zi*  −  z̅})
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2
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(3.3.1-10)  E(b)=σ 
And 
(3.3.1-11)  E[a] = EൣxതU  −  bz̅U* ൧ 
(3.3.1-12) = ൛μ + σz̅U* ൟ − z̅U* E[b] 
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(3.3.1-13) = μ + σz̅U*  −  σz̅U*  
(3.3.1-14)  E[a]=μ 
The substitution made in (3.3.1-8) and (3.3.1-12) follows from the result in (3.3.1-5). Hence the 
regression coefficients are unbiased estimators of 𝜇 and 𝜎 for any subset of the ordered values 
{x(1), …, x(n)}, including the full set X(n). In fact, when all the ordered values are used z̅* = 0 due 
to the symmetry of the normal distribution implying: 
a = xത  −  bz̅*= xത 
 b = 
∑ (n1 zi*  −  z̅*)(x(i) −  xത)
∑ (zi*  −  z̅*)
2n
1
 = 
∑ (௡1 zi*)(x(i)  −  xത)
∑ (zi*)
2n
1
 
So, in the complete case the estimate of the mean is identical to the sample average while the 
estimate of the standard deviation is the ratio between the sum of the observed ranks, after 
centering, and the rankits over the sum of the rankits squared. 
In terms of this thesis, rankit regression is relevant as it can easily be adapted to left-censored 
data by ignoring the unobserved values and regressing only with the observed values, treating 
them as the highest ordered values in the data. This approach is straightforward as many software 
applications have the capability to perform simple linear regression. The biggest challenge is 
finding values of 𝑧௜∗ as the rankits are not trivial to calculate. However, numerical 
approximations are readily available [92]. 
2.13.2.  Maximum Likelihood and Left-Censoring 
The general likelihood function for a sample in which there are 𝑛 total observations and 𝑘 
values are missing due to begin below a certain value Ti is: 
 L൫θi ; yi൯=
n!
ki!(n −  ki)!
P(x < Ti)
ki * ෑ P(x <  yji | yji > Ti)
n
ki+1
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The likelihood above is in two parts. The first part, P(x < Ti)
ki, represents the probability 
associated with the unobserved values, while the second part, P(x <  xji | xji > Ti), relates to the 
probability of the observed values.  Under a normal distribution with parameters µ and σ the 
likelihood is: 
 L ቀµj, σi ; yiቁ  = 
n!
k!(n-ki)!
ቈ(σi√2π)
-1
න exp ቈ
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2
n
ki+1
2σi2
൙ ቏ 
Here the j subscripting of the metabolomic framework is used to emphasize that there are several 
features with each having their own distribution (θi), point of truncation (Ti), and number of 
missing values k௜. However, the total number of samples, n, is the same. For simplicity the i 
subscripting is removed in the following sections, but the emphasis on individual metabolites 
remains. The log-likelihood gives: 
 l= log ൬
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Using the transformation ξ = (T-µ) σ⁄  the likelihood can be simplified to: 
 l = log ൬
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 The score functions follow as: 
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Setting these equal to 0 and solving gives: 
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Due to the symmetry of the standard normal distribution φ(t) = φ(-t) and ϕ(t) = 1 −  ϕ(−t). This 
relationship is used to maintain some consistency with the estimating equations in the truncated 
case: 
y ഥ −  µ = 
k
n −  k
σ*
φ(−ξ)
1 −  ϕ(−ξ)
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k
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቉ =
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n −  k
+(yത  −  µ)2 
2.13.3.  Maximum Likelihood and Left-Truncation 
In the normal truncated case the likelihood function is  
 
 L(µ,σ) = ෑ ቆ1-ϕ ൬
 T -µ
σ
൰ቇ
-1 1
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T, as before, represents the point of truncation giving the probability of a value being unrecorded 
as ϕ(( T-µ) σ⁄ ). The term in the first part of the likelihood relates to this probability of being 
observed and normalizes the area over the space [T,∞) to a total probability of 1. ML estimators 
for µ and 𝜎 have previously been shown [93-95]. Rewriting by expanding the product and using 
the transformation ξ= (T-µ) σ⁄  produces: 
 L(µ, σ) = (1 −  ϕ(ξ))ିn(σ√2π)
ିn
exp ቌ− ෍
ቀyj  −  µቁ
2
2σ2
ቍ 
Taking the natural log gives: 
 l(ξ, σ) = − n* log൫1 −  ϕ(ξ)൯ −  n*log൫σ√2π൯ − ෍
ቀyj  −  µቁ
2
2σ2
 
The resulting score equations are: 
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Solving for each parameter gives: 
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These equations produce a system of two equations with two unknowns (recall ξ is a function of 
µ and σ) which can be approximated using the Newton Raphson method [96]. 
2.13.4. Maximum Likelihood vs. Rankit Regression  
As stated above, one challenge with rankit regression is estimation of the rankits themselves. 
Much work has been devoted to the approximation of these values for items that include the 
normal quantile plots and Shapiro-Wilk Test [97-99]. As the x-variable in the rankit regression, 
any bias in the estimation of the rankits can lead to spurious conclusions. To illustrate this, a 
simple simulation of a normal random variable Xn with mean µ = 10, standard deviation σ = 3 
and n = 30 is conducted. The variable is censored by removing low values three at a time, 
beginning with three smallest and progressively increasing up until only the three largest values 
remain. At each level of censoring both maximum likelihood and rankit regression are used to 
estimate the value.  
To evaluate different approaches to estimating the rankits themselves, rankit regression was 
conducted in three different ways. The first uses the qqnorm function from R, which is used 
create normal quantile plots in that software. Estimates generated by qqnorm come from the 
function points, which, for n > 10, the default is to take the quantiles corresponding to ϕିଵ ቀj-0.5
n
ቁ 
for j ϵ {1, …, n}. This decent approximation to the rankits is not exact, leading to systematic bias 
in the estimates. To address this bias, the second approach simulates a N(0,1) variable, referred 
to as Zn, with Xn regressed on the ranks of Zn. On average, the ranks of Zn will be equal to the 
desired ranks, leading to less bias. But since each individual realization is not the true rankits, 
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higher variance in the estimates are expected. In essence, this second approach does not remove 
error in rankit estimation but allows it to balance out over the simulations. Third, 100,000 
realizations of Zn are created, sorted and the ranks averaged to produce the independent variable 
Znavg. This third way should have the least systematic bias due to error in the rankits while 
minimizing variance in the estimator. 
Figure 3.4: Parameter estimates from Maximum Likelihood versus Rankit Regression, part I. Individual estimates in 
black with average values in red. Rankits based on qqnorm function in R.  
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Simulations results found that maximum likelihood does indeed exhibit bias in both the mean 
and standard deviation while rankit regression generally performs as expected. These results are 
summarized in Figures 3.4-3.5, which show the individual parameter estimates as a function of 
the proportion of missing values in the sample. Trend lines for the average parameter estimates  
Figure 3.5: Parameter estimates from Maximum Likelihood versus Rankit Regression part II. Individual estimates 
in black with average values in red. Rankits based on simulated standard normal and average of 100,000 
standard normal simulations. 
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Table 3.1: Estimates of Population Parameters in Maximum Likelihood versus Rankit 
Regression. Results based on simulations of normal random variable with true mean 10 
and true standard deviation 3. 
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are indicated in red. Maximum likelihood shows 
steadily increasing bias towards over-estimates in 
the mean and under-estimates in the standard 
deviation over the range of proportion missing.  
The bias appears to inflate at around 60% missing 
values.  
Rankit regression using qqnorm is less biased, 
but an inspection of the average estimates, shown 
in Table 3.2, reveal a similar trend towards 
overestimates in the mean and under-estimates in 
the SD. Impact is most apparent in the SD 
parameter where rankit regression by qqnorm is 
seen to consistently underestimate the parameter 
through all proportions of missing values. While 
the bias in RREG is around .5-1 unit less than 
maximum likelihood, the variability of the 
estimates is much greater. This result is to be 
expected as maximum likelihood methods are 
generally very efficient. Bias in rankit regression 
using Zn demonstrates more variability than 
qqnorm, as expected, at all levels of missing values. The variability of these estimates is 
tremendous in both parameters at 80-90% missing values. However, Zn does tend to be slightly 
less biased than qqnorm, especially in the standard deviation, up to 70% missing values. Lastly, 
Table 3.2: Difference in Rankit Estimates 
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rankit regression by Znavg demonstrates little evidence of bias at any parameter level while having 
variance that is roughly equivalent, if a little bit higher, than when using qqnorm. The specific 
rankit estimates for the qqnorm and Znavg approaches are displayed in Table 3.2. Magnitudes 
between the two are largest in the tails, which fits with the bias under qqnorm being most 
noticeable at 80-90% missing. With this much of the data gone, estimation is entirely dependent 
on these most extreme values which happen to be the most off. 
The evaluations that follow, the expectation is that maximum likelihood will generally 
perform well. However, being only asymptotically unbiased there is the possibility that in certain 
circumstances, such as very large proportions of missing data or small sample sizes, rankit 
regression will prove to be less biased. However, the findings here support maximum likelihood 
for left censored data as being clearly more efficient. The variability of rankit regression 
estimation is an item to pay attention to in further assessment. 
2.13.5. Assessment 
Selected methods will be evaluated in chemocentric metabolomic data using the same three 
data sets evaluated in Chapter 4. Using only those metabolites which were completely observed 
in all samples, the data is first log transformed, and then observed values are removed in left-
censored fashion. Each method was applied to censored data to produce estimates of the mean 
and standard deviation, which were then compared against the corresponding sample values of 
the fully observed data. Error in the method can be described as the difference between the fully 
observed parameter value τ and the estimate of that parameter τ̃. Comparison involves taking the 
so called relative error, which is error as a proportion of the fully observed value: 
Relative Error = 
 τ̃  − τ
τ
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In order for relative error to be defined τ must be non-zero. This should not be a problem here 
since the standard deviation is always non-zero and ion counts are always positive values that 
are, even at the lowest level, in the thousands. The primary reasoning for relative error is that by 
viewing error as a percentage of the original parameter value it makes results comparable 
between features and between parameters. That is, we can not only equate relative error in the 
mean between two features, but also compare relative in the mean against that of the standard 
deviation for the same feature. Error is also closely related to bias, which is an important concept 
in statistics and one of the most, if not the most, important ways to evaluate estimators. By 
aggregating relative error across all features, some estimate of bias can be achieved.  
Before experimenting with these data sets, simulation experiments were conducted to test the 
performance of the methods under ideal circumstances and their sensitivity to the normality and 
left censored assumption. These theoretical results will be a point of reference in which to 
consider the results in the real datasets and to understand the importance of the assumptions to 
performance. Simulations experiments are described fully in section 5.4.  
Briefly, a series of relatively small datasets were created in which the columns are based on 
either a normal or a chosen representative non-normal distribution. Observations will then be 
removed from a portion of the dataset, with the methods being applied using the assessment 
approach outlined above. Use of kNN and RF necessitate simulating an entire dataset since both 
of these methods use the fully observed features to impute missing values. Naturally, correlation 
between the features is important to these methods and is included as part of the simulation 
experiments. Finally, since performance of kNN is known to suffer when the variables are on 
different scales, and metabolomic sets easily qualify this definition with average feature 
abundance ranging from the tens of thousands to the hundreds of millions, median scaling is also 
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including in the simulation workflow. Scaling is selectively used in the field and median scaling 
was chosen due to the propensity for large outliers in metabolomic data [18, 100]. Indeed, results 
using kNN were observed to be much poorer without any scaling. The other methods, including 
RF, were largely unaffected. Scaling is thus optional, for the other methods. Fortunately, median 
scaling has no effect on relative error for NONE, MEAN, MIN, ML and RR. It is important to 
realize that in practice such scaling can of course only be performed on the observed data. Thus, 
to best imitate the process in real data variable scaling is performed after variable censoring. 
2.14. Simulation Experiments 
2.14.1.  Workflow 
The proposed methods, ML and RR, assume normality and that missing values are due to the 
ion count falling below the instruments level of detection. Goals of the simulation experiments 
are as follows (i) evaluate performance of the methods when both assumptions are true, (ii) 
evaluate change in performance when one of the two assumptions fail and (iii) evaluate the 
impact of correlation on kNN and RF. Besides kNN and RF, the other five procedures are 
univariate, since they act on each feature separately, meaning it would be sufficient to asses these 
using simulations of a single variable. However, since kNN and RF operate from a dataset with 
fully observed variables it was necessary to simulate a full dataset. For this reason, these 
experiments involve 1,000 simulation runs of a multivariate dataset Yn×m=[y1 y2 … ym] 
where the yj's are identically distributed random variables. A value of n = 30 is selected as the 
standard since it is consistent with the sample sizes of the datasets discussed in Chapter 4. A 
value m = 114 is chosen with the variables y1, …, y14  censored such that the lowest 2*j values 
are removed for j ϵ {1, …, 14}. Variables y15, …, y114  are uncensored and represent the fully 
observed data available to kNN and RF for imputing. The methods are then applied to produce 
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estimates {yത෨1, …, yത෨14}  and {s̃1, …, s̃14} of, respectively, the censored sample means and standard 
deviations. These estimates are compared back to the usual sample mean and standard deviation 
without censoring the variable.  
Beginning with the hypothesis that the assumptions of normality and LOD are correct, Yn×m 
is first simulated as multivariate normal. It is presumed that the correlation between metabolites 
is a highly influentially characteristic that will impact the performance of both kNN and RF. 
Metabolite correlation will vary depending on instrumentation. For example, ion-centric data is 
known to be highly correlated due to a single parent metabolite producing multiple related 
fragmentation features [101], but in Chapter 4 it was shown that the majority of feature pairs 
have at most only a moderate level of correlation. Incorporating this correlation can be 
accomplished by beginning with a multivariate normal Zn×m having mean vector 𝟎 and variance 
covariance matrix In. Let Yn×m be as follows: 
Yn×m = Zn×m*Chol(Ʃ)+µ 
where Chol(.) is the Cholesky root. Yn×m will be normally distributed with mean µ and variance-
covariance Ʃ. These simulations use the compound symmetry structure, namely: 
Ʃρ = σ2
⎣
⎢
⎢
⎢
⎡
1 ρ
ρ 1 ⋯
ρ ρ
ρ ρ
⋮ ⋱ ⋮
ρ ρ
ρ ρ ⋯
1 ρ
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⎥
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Let YN
 ρ designate the multivariate dataset with mean vector µ and variance-covariance Ʃρ. Within 
each simulation a single random draw of Zn×m is made from which the datasets YN
 ρ for ρ = ቄ0, 1
3
, 
1
2
, 2
3
, 9
10
ቅ are created. The complete workflow of this simulation is shown in Figure 3.6.  
The two proposed methods are expected to perform well under normal and LOD simulations 
with performance degrading as the amount of missing values increases. One curiosity is whether 
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performance is linked to the number of values that are missing or the proportion of values that 
are missing. To examine this the normal LOD simulations are repeated using n = 10 and n = 600 
in addition to the standard n = 30. The smallest sample setting is particularly interesting with ML 
since this method is known to be only asymptotically unbiased. 
The first assumption to be tested is the LOD assumption. Aside from LOD, potential sources 
of missingness are largely independent of the true value, i.e. lost scans or swamping from 
another peak, implying missing at random. Therefore, simulations with normal are conducted by 
removing values completely at random instead of in a left censored fashion. This will inform 
how critical the LOD assumption is and the possible impact of the methods on minor, but 
Figure 2.14.16: Feature set simulation workflow. Each experiment comprises 1,000 simulations. Znxm is a 
multivariate standard normal from which Xρ is constructed with pairwise (spearman) correlation ρ for all 
vectors. Normal simulations involve Xρ being multivariate normal while the non-normal simulations consist 
of log-normal and uniform. In all cases, values removed are done so by taking the lowest from the variables 
selected. For the normal simulation case, simulations are also performed by removing values at random. 
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plausible sources of missing values. 
The next assumption to be tested is normality. There are numerous ways in which non-
normality can manifest. The approach taken here is to create non-normality through skewness 
and kurtosis. The results of Chapter 4 showed that metabolites, particularly when untransformed, 
are prone to large outliers leading to a significant right skew. The log-normal distribution is 
useful at producing such right tailed data and has the added benefit of indicating what happens 
when a log transformation is not applied to a feature that does have strong log-normal behavior. 
Noting that metabolites can sometimes be rather evenly distributed within a tight range, we turn 
to the uniform distribution which is a non-skewed platykurtic distribution with excess kurtosis -
6/5. In addition to both distributions having some basis for being used, data can also be simulated 
using the same workflow by transforming YN
 ρ. In the log normal case this is done by simply 
taking the exp(YN
 ρ) = YLN
 ρ . Similarly, any random variable can be made uniform using the 
cumulative distribution function from the target variable. Thus, for the uniform we have 
YU
 ρ = FY(YN
 ρ). Being able to create non-normal variables from YN
 ρ allows for the correlation 
structure to be somewhat preserved. Since both transformations are monotonic and one-to-one, 
the spearman correlation will be unaffected, though the Pearson correlation will vary.  
Table 3.3 summarizes all conditions of the simulation. In the real dataset the average ion 
count abundance level of metabolites was around 
15 in the compounds that were fully observed 
after a log transformation (plasma = 15.09, CSF = 
15.33, and urine = 16.75) while the standard 
deviation ranged from just less than 0.5 to over 0.9 
(plasma = 0.50, CSF = 0.48, urine = 0.91). Based 
Table 3.3: Conditions of simulation 
experiments. 
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on this, in the normal simulations µj = 15 and σj = 0.6 for all j ϵ {1, …, 114}. For the log-normal 
case, µj = 2.65 and σj = 0.3 so that the resulting exponentiated variable has mean of 14.8, close to 
that in the normal case, along with skewness of 0.94. With the uniform µj is 0 and σj is 1, treating 
a standard normal 𝑌j
 ρ=Ф-1൫𝑍j
 ρ൯*2+14. This produces a uniform distribution with mean 15 and 
standard deviation of 0.57. 
2.14.2.  Results 
2.14.2.1. Normal Distribution and LOD 
To begin, one simulation run from YN ଴ is presented. Tables 3.4 and 3.5 show the estimated mean 
and standard deviation for each method as well as the corresponding uncensored parameter  
value. A clear result from these tables is that median scaling considerably alters the original 
parameter value, shown in uncensored column. Each variable begins as N(15,0.62) and the 
impact of median scaling when no values are missing move each variable towards a 
N(1,0.62/152). Dividing the variable by an average of 15 centers the distribution around 1. 
However, as low values are removed from the data the observed median steadily increases 
Table 3.4: Estimates of mean in one simulation. Distribution is normal with missing values 
censored below and ρ=0. 
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further and further above 15 as more and more of the lower values are removed. Thus, as the  
amount of missing values increases the target mean is being driven up. This effect of median 
scaling presents a challenge. For example, examining the eighth line of Table 3.4, in which 16 
values have been censored (corresponding to j = 8) the five common metabolomics methods are 
all very close to 1. On other hand, ML estimates a mean of 0.980 while RREG gives an estimate 
of 0.982. These estimates are actually closer to the true uncensored level of 0.970 after scaling. 
Although the standard deviation does not display a systematic trend with regards to missing 
proportion, the uncensored values are prone to shift noticeably ranging from a high of 0.056 to a 
low of 0.031. From Table 3.5, when 14 values are missing NONE estimates the standard 
deviation as 0.04 while both ML and RREG estimate just over 0.06. NONE may seem better as 
the theoretical standard deviation (without censoring) is 0.6/15=0.04. However, the uncensored, 
scaled sample standard deviation is actually 0.056 for the variable in question. Figures 3.7 and 
3.8 plot the results of the estimated mean and standard deviation against their corresponding 
uncensored values for the seven methods. Each dot corresponds the estimated mean or standard   
Table 3.5: Estimates of SD in one simulation. Distribution is normal with missing values 
censored below and ρ=0. 
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Figure 3.7: Estimated mean versus sample mean in one simulation of normal data where values are censored from 
below and ρ=0. 
Figure 3.8: Estimated standard deviation versus sample mean in one simulation of normal data where values are 
censored from below and ρ=0. 
139 
 
deviation from one of ൛Y1 ଴, …, Y14 ଴ ൟ and the solid red line represents line y = x, indicating 
agreement between the uncensored value and the estimated value. All five common 
metabolomics methods over predict the mean parameter while under predicting the standard 
deviation. In the mean parameter especially, the estimated value appears to have little correlation 
with the uncensored value. In contrast, both of the proposed methods spread around the line y = 
x, particularly in the mean parameter where higher values of the uncensored parameter are 
approximated well. Of course, this is just one simulation with pairwise correlation 0. Figures 3.9 
and 3.10 plot the results for the mean and standard deviation of all 1,000 simulations for all 
seven methods at each level of ρ. As expected the value of ρ does not affect any of the five 
univariate procedures. Focusing on the mean, NONE, AVG and MIN always over predict. This 
result fits with what one would expect as the observed values are always higher than the full 
sample when missing values are censored from below. In fact, NONE and AVG are identical in 
the mean parameter since imputing with the average does not change the average. MIN 
demonstrates somewhat better behavior at higher values of the parameter. Again, due to the  
scaling after censoring higher values of the uncensored mean imply fewer missing values, so 
performance in this range is expected. As the proportion of censored values decreases the 
observed min is approaching the lowest the sample, meaning fewer values are having to be 
imputed and those that are being imputed are being approximated with a value closer to their true 
level. As with NONE, AVG and MIN, kNN and RF almost always over predict the mean. kNN 
sees some improvement with greater correlation between the variables, but even at ρ = 9
10
 there is 
a still a bias toward lower values. RF improves only marginally with increasing correlation. At 
ρ = 0 the profile for random forest is very similar to NONE or AVG, while at ρ = 9
10
 the profile is 
similar to MIN. RREG and ML share very similar profiles and both over and underestimate in  
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Figure 3.9: Error in mean under Normal and LOD simulations. X-axis is uncensored sample mean. Y-axis is 
predicted mean. Columns represent pairwise correlation between variables in data set. Red line is y=x. 
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Figure 3.10: Error in SD under Normal and LOD simulations. X-axis is uncensored sample SD. Y-axis is predicted 
SD. Columns represent pairwise correlation between variables in data set. Red line is y=x. 
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roughly equal measure, suggesting less bias. Accuracy again tends to be better at the larger 
parameter values / lower proportions of missing values. The variation within the estimates for 
RREG and ML is quite large compared to the other methods as well. Across both profiles the 
estimates range from 0.75 to 1.01, while the other methods are largely confined to 0.95 to 1.03. 
The larger spread indicates that while RREG and ML are less biased, they are more variable as  
the amount of missing values increases. Bias in the standard deviation is present for the five 
common methods as well, but in this case the methods consistently under estimate the 
uncensored parameter. On occasions NONE does overestimate the standard deviation, but these 
are rare instances in which the variable is sufficiently right skewed. Notice that this behavior is 
absent from AVG. This is because imputed missing values with the observed average will 
always lower the standard deviation, effectively increasing the sample size while holding the 
variation constant. MIN and AVG are very similar in this regard, though MIN does tend to 
provide better mean estimates in variables that have higher means. Both kNN and RF behave 
similarly to AVG when the correlation is low. As correlation increases, RF more closely 
resembles MIN which is identical to the relationship observed in mean parameter. kNN displays 
two interesting qualities compared to the others in the standard deviation. First is a unique trait in 
which standard deviation estimates never decrease much below .01 while all the other methods 
have instances of basically reaching 0. Values of zero in the standard deviation imply imputation 
with a near constant value. That kNN avoids near 0 estimates of the standard deviation indicates 
the neighbors are producing distinct values to replace the missing observations. Second, as the 
correlation increases the variance in the estimates becomes tighter and less biased. At the highest 
levels of correlation this consistency is important, because while RREG and ML appear to be 
unbiased, both exhibit greater variability than the other methods. Estimated standard deviation 
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values for the five common methods over the entire experiment are generally between 0 and 
0.06. Estimates for RREG, however, range from 0 to 0.26 – more than four times all the other 
methods. The spread for ML isn’t as extreme as RREG with but does exhibit estimates well 
above 0.08.  
Figures 3.11 and 3.12 plot the relative error for the mean and standard deviation, 
respectively, by the percentage of missing values. The results indicate a similar pattern as that 
seen in the previous set of plots showing the uncensored values against the estimated values; 
namely, that the five common metabolomics methods over predict in the mean parameter and 
underestimate the standard deviation. Unsurprisingly, relative error steadily increases for all five 
of these methods as the proportion of missing values increases, with a minimum at 100% which 
is, of course, the maximum percentage any estimator bounded by zero can decrease by. In the 
mean parameter NONE, AVG and MIN all have similar profiles with MIN showing slightly less 
relative error for moderate and high levels of missingness. Regardless of the value for ρ, kNN 
and RF are virtually indistinguishable from those methods in the mean parameter, with 
performance somewhat in between MIN and AVG/NONE. In contrast, error for RREG and ML 
remains centered around 0 for even large proportions of missingness. However, the variation in 
the errors increases dramatically as the proportion of missing values approaches 1. Both are 
prone to severe underestimates when the amount of missing values exceeds 80%, especially 
RREG. In the standard deviation, NONE performs better than AVG and MIN. This is the result 
of single imputation eliminating variation across the samples. RF continues to track closely with 
AVG and MIN regardless of ρ. KNN, however, shows great improvement for even low 
correlation of ρ = 1
3
 and continues to improve as the correlation increases.  
144 
 
  
Figure 3.11: Relative error in mean under Normal and LOD simulations. X axis in the proportion of missing values. 
Y axis represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.12: Relative error in SD under Normal and LOD simulations. X axis in the proportion of missing values. Y 
axis represents percent change from uncensored sample value. Red line represents y=0. 
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There is a curious behavior with kNN such that with ρ = ଽ
ଵ଴
 the standard deviation estimate 
with the highest amounts of missing values are predicted better than those with moderate levels 
of missingness. As the proportion of missing values increases, the imputed variable under kNN is 
becoming more and more a reflection of the neighbors. Since the variables are on the same scale 
this results in the imputed variable becoming more and more like another random variable. 
However, the median scaling following variable censoring causes the neighbors to be shifted 
slightly upward, systematically shifting the imputed values high compared to the original values.  
Simultaneously, the weighted average over the k neighbors reduces the overall variability in 
the imputed values. The result for high proportion of missing values is an imputed variable that 
is slightly higher on average and with lower variation than the original variable. In short, kNN is 
systematically replacing the censored variables with values that is slightly shifted due to the 
scaling and less variable as a result of aggregating across the neighbors. Meanwhile, RREG and 
ML have similar profiles with over and under estimates occur, just as they did in the mean 
parameter. Both of these methods display noticeably higher variance than the other methods as 
the amount of missing data becomes very large. However, the most dramatic errors in these two 
methods tend to be over-estimates rather the underestimates seen in the other five methods.  
Bias plots, shown in Figures 3.13 and 3.14, take the average relative error as a function of 
the missing proportion for all ρ in {0, 1
3
, 1
2
, 2
3
, 9
10
}. On average the five common methods 
overestimate the mean and underestimate the standard deviation, as expected. When ρ = 0, 
average relative error profiles for kNN (green) and RF (gray) are similar to that of AVG (red), 
though kNN does a little better with the standard deviation at higher levels of missingness. As 𝜌 
increases the profile for RF moves closer and closer towards that of MIN (yellow) in both 
parameters. kNN does the same in the mean parameter, but in the standard deviation it performs  
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Figure 3.13: Bias in mean parameter under Normal and LOD simulations. X-axis represents percentage of missing 
values. Y-axis is average relative error. 
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Figure 3.14: Bias in SD parameter under Normal and LOD simulations. X-axis represents percentage of missing 
values. Y-axis is average relative error. 
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better than other four common methods even when the correlation is as little as ρ = 1
3
.  Average 
relative error for ML (purple) and RREG (blue) remain close to zero in both parameter up until 
missing rates of 80-90%. When the proportion of missing values reaches 80% and beyond, which 
in these simulations implies 6 or fewer observations, deviation from zero becomes noticeable 
with clear bias of over-estimation in the mean and under-estimation in the standard deviation. 
Though it is most evident at over 80% missing, the trend begins to emerge around 60%. Recall 
that ML is asymptotically unbiased and comes with no guarantee in small sample situations. 
These simulations suggest that noticeable bias begins for ML when the number of observed data 
points is around 10. RREG on the other hand remains unbiased in both parameter over the entire 
missing proportion range. Increasing variability does manifest for RREG, however, at around 
80%.  
An additional point, which can be extracted from the relative error plots, is that across all the 
seven methods used the relative error is much greater in the standard deviation than in the mean. 
On average increase in the mean is never more than 10% for any of the seven methods, but 
average decreases of 20% are rather common in the standard deviation. Such under estimates can 
have important consequences to outlier detection methods that rely on variance related measures 
to detect outliers. In the z-scores, the standard deviation is the denominator, meaning that a 
decrease of 50% would lead to a doubling of the z-score. Such decreases are common in the  
standard deviation for the five common methods when more than half of the 30 observations are 
missing. Such errors can lead to a large inflation of false positive rate. For example, in the 
normal distribution a value of 1.96 represents the upper 2.5% of the distribution. If one were to 
take this as a cutoff for identifying an outlier, then under estimates of 50 percent in the standard  
deviation would lead to any true z-score of 0.98 being classified as an outlier. Theoretically, such 
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an increase would lead to a false positive rate of 16.3%, more than six times the assumed rate. 
Technically, error will also be present in the mean parameter; however, error in the mean tends 
to be much lower, as a percentage of the true value, than error in the standard deviation. For 
example, at around 50% missing, average error in the mean is only 2-3% for the five common 
methods. So, it is reasonable to consider mainly the standard deviation when assessing impact on 
the z-score). An inflation of the false positive rate may be acceptable in certain situation. 
Screening tests for example may trade a higher false positive rate for increased power. However, 
in reality, there is a cost involved to investigating any subject flagged as a possible case. At some 
point the cost associated with an excessive number of false positives renders the test impractical. 
Finally, the last item considered here is the variation of the methods. Tables 3.6 and 3.7 show 
the bias for the seven methods at each proportion of missing values as well as the variance 
Table 3.6: Relative error averages and variances in Mean parameter from normal simulations 
with missing values left-censored. Correlation coefficient ρ=1/3. 
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associated with the proportion. For simplicity only, the values are shown for ρ = 1
3
 as this level is 
consistent with the average correlation seen in the real metabolomic sets in Chapter 2. These 
tables confirm that while ML and RREG are more consistent on average with the sample 
parameters these methods also demonstrate more variability when missing proportion is above 
60%, and this variation is much greater when the proportion is above 80%. Variance of the 
estimates under the five common methods steadily increase as missing proportion increases, but 
tend to stay around or under 1 up to the most extreme missing proportion of 93.3%. The variance 
in ML and RREG approaches a value of 1 around 60% missing values and increase rapidly from 
then on. 
2.14.2.2. Large Sample Normal Simulations and LOD 
To examine the influence of sample size, the same simulation was repeated using n = 600. The 
number of samples censored is increased proportionally according to 20*j for j ϵ {1, …, 14}. 
Table 3.7: Relative error averages and variances in SD parameter from normal simulations with 
missing values left-censored. Correlation coefficient ρ = 1/3 
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This way the proportion of values missing is identical to the previous simulation, but the number 
of available samples remaining is twenty times greater. Maintaining the same missing proportion 
while also having a large sample size will help answer whether results are dependent on the 
proportion of data available or on the number of samples available. Given that normal-LOD 
simulations have already been explored, only the relative error and bias plots are shown for the 
large sample setting (Figures 3.15-18). The same y-axes ranges were kept for comparison, and 
the general trend remains the same for all methods. However, it is easy to see that variation in the 
estimates is greatly reduced. The bias plots show that both ML and RREG remain almost 
completely unbiased in both parameters throughout the entire range, implying that the number of 
available samples is more important that the percentage of available values. 
2.1.1.1.Small Sample Normal Simulations and LOD 
Analogous to the large sample simulation, a small simulation with 𝑛 = 10 is conducted next. 
Due to the number of available samples, the number of samples being censored was modified to j 
for j ϵ {1, …, 8}. For this simulation only, the bias plots are shown. These are shown in Figures 
3.19 and 3.20. There a couple notable results in this simulation. First is that in the mean 
parameter, bias is not found to be as extreme in any of the methods. This is because these 
simulations end when 8/10=80% of the values are missing as opposed to 28/30=93% in the 
simulations with n = 30. In those simulations ML was found to deteriorate quickly when more 
than 80% of the values were missing. The deterioration is stronger here, and more noticeably in 
the standard deviation with average under-estimates of 20% when 5 of 10 values are missing.  
Combined with the results of the large sample simulation, the accuracy of ML is tied most 
strongly to the number of available samples rather than proportion of missing values. RREG 
continues to be unbiased in both parameters.  However, the estimates produced by this method  
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Figure 3.15:  Relative error in mean under large sample Normal-LOD simulations. X axis in the proportion of 
missing values. Y axis represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.16:  Relative error in mean under large sample Normal-LOD simulations. X axis in the proportion of 
missing values. Y axis represents percent change from uncensored sample value. Red line represents y=0. 
155 
 
  
Figure 3.17: Bias in mean parameter under large sample Normal-LOD simulations. X-axis represents percentage of 
missing values. Y-axis is average relative error. 
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Figure 3.18: Bias in standard deviation parameter under Normal and LOD simulations. X-axis represents percentage 
of missing values. Y-axis is average relative error. 
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Figure 3.19: Bias in mean parameter under small sample Normal-LOD simulations. X-axis represents percentage of 
missing values. Y-axis is average relative error. 
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Figure 3.20: Bias in standard deviation parameter under small sample Normal-LOD simulations. X-axis represents 
percentage of missing values. Y-axis is average relative error. 
% missing values 
%
 re
la
tiv
e 
er
ro
r 
159 
 
continue to show much higher variability than ML or any other method. 
2.1.1.1.Normal Simulations and MAR 
The following simulations explore sensitivity to the maximum likelihood and rankit 
regression assumptions. Here we begin by removing values at random instead of in a left 
censored fashion. Multivariate normal datasets are simulated and processed as before, with the 
only exception being that the 2*j values removed from Yj are chosen randomly rather than by 
being the 2*j lowest values. Results are displayed using the same plots and tables for error, 
relative error and average relative error as before. Figures 3.21 and 3.22 plot the error by the true 
parameter for normally distributed data with missing values removed at random. In evaluating of 
methods at estimating the mean, none of the methods display much of a pattern with regard to 
true parameter value. NONE, AVG, kNN and RF give estimates that cluster around the true level 
(red line). MIN overestimates the mean in the rare occasion that the values removed at random 
happen to favor the lowest values in the set. In general, though, underestimates are more 
common because MIN is a biased estimate of a randomly remove value and is best suited to the 
left-censored scenario. Over estimates occur in the rare instances that the values removed 
happened to be among the lowest in the variable, in which case minimum imputation is 
appropriate. But in most cases, replacing values removed at random with the observed minimum 
will result in a lower value for the imputed observation, and thus an under estimate.  
When applied to simulated data sets with observations MAR, kNN shows little association 
under low correlation, but as correlation increases, true mean values tend to be predicted with a 
mean above 1 while true mean values below 1 tend to be predicted being below 1. Under low 
correlation RF again behaves very similarly to NONE and AVG, but as correlation increase its 
profile becomes more like kNN. RREG and ML have similar profiles to MIN, generally 
underestimating the mean, though in a more extreme manner. The smallest estimate produced by  
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Figure 3.21: Error in mean under Normal and MAR simulations. Columns represent pairwise correlation between 
variables in data set. Red line represents y=x. 
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Figure 3.22: Error in SD under Normal and LOD simulations. Columns represent pairwise correlation between 
variables in data set. Red line represents y=x. 
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MIN was above 0.85, while ML produces estimates below 0.4 and RREG gives estimates below 
0.2.  
In the standard deviation, NONE over and underestimates that appear randomly distributed 
around the true value. AVG always produces lower estimates of the standard deviation, again the 
further result of imputing with a static value that is equal to the sample average and therefore 
only serves to depress the observable variation in the dataset. KNN and RF again match very 
well with AVG under low correlation. MIN, unlike AVG, produces over and under estimates of 
the standard deviation routinely. While this too imputes with a static value, using the observed 
minimum can add variation to the imputed variable as a value that is on average equal to the 
mean is being removed and replaced with a relatively extreme (and low) value.  
As the correlation increases RF continues to perform about the same whereas kNN 
demonstrates a clear linear fit between its estimated standard deviation and the true standard 
deviation. Meanwhile both RREG and ML continue to display a more extreme form of minimum 
imputation. Both methods will over and under estimate the standard deviation, but frequently 
produce extreme over estimates with values of .2 for ML and 0.3 for RREG. 
Next, Figures 3.23-26 show the relative error and average relative error against the 
proportion of missing values. NONE, AVG, kNN and RF indicate they are unbiased estimators 
of the sample mean while MIN, RREG and ML tend to underestimate. In the standard deviation, 
NONE appears unbiased while AVG increasingly underestimates the variation in the data as the 
proportion of missing values increases. MIN tends to overestimate, but as the proportion of 
missing values increases and resulting variable becomes more and more imputed the standard 
deviation begins to lower. At higher amounts of missing values MIN underestimates as a result. 
When there is no correlation between the variables, kNN and RF behave much like AVG, but  
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Figure 3.23: Relative error in mean under Normal and MAR simulations. X axis in the proportion of missing values. 
Y axis represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.24: Relative error in SD under Normal and MAR simulations. X-axis in the proportion of missing values. 
Y-axis represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.25: Bias in mean parameter under Normal and MAR simulations. X-axis represents percentage of 
missing values. Y-axis is average relative error. 
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Figure 3.26: Bias in SD parameter under Normal and MAR simulations. X-axis represents percentage of missing 
values. Y-axis is average relative error. 
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become less biased as ρ increases. KNN appears roughly unbiased at ρ = 0.9 and the estimates 
are generally contained within 20% of the true sample value. Though through RF estimates 
improves over MEAN imputation by becoming less biased at correlation increases, the method 
never becomes completely unbiased even at ρ = 0.9. Contrasting with the others methods, RREG 
and ML are biased upwards in the standard deviation and do so in an extreme fashion consistent 
with MAR results thus far. Overestimates of 100-200% are not uncommon when the proportion 
of missing values is around 50%. The other methods are generally contained to 50-60% for the 
same amount of missing values. The final items in the assessment of normal data with values 
missing at random are Tables 3.8 and 3.9 showing the average relative error at each proportion of 
missing for all seven methods when the correlation is one third. These tables reveal a picture that 
is reversed from left-censored missingness in the mean parameter with the five common 
imputation approaches being nearly unbiased while the two proposed methods are increasingly 
Table 3.8: Relative error averages and variances in Mean parameter from normal simulations. 
Missing values are MAR and ρ = 1/3. 
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biased towards underestimates. However, as with left-censored missingness, this bias, as a 
proportion of the sample mean, does remain relatively small at less than 10% for moderate to 
intermediate amounts of missing values.  
With regard to the standard deviation, none of the methods are revealed to be unbiased as the 
five common methods underestimate the standard deviation on average while both proposed 
methods overestimate. This is not entirely unexpected for AVG and MIN, due to the nature of 
single imputation, nor for KNN and RF which under correlation of 0.33 have thus far functioned 
similarly to AVG. It is somewhat surprising that NONE underestimates with increasing 
magnitude as the amount of missing values increases since the remaining values reflect the true 
population. As such, one might expect this method to be an unbiased estimator of both the mean  
and the standard deviation when values are removed at random. The reason for this is the 
distribution of the sample standard deviation follows a scaled chi-square distribution. 
Table 3.9: Relative error averages and variances in SD parameter from normal simulations.  
Missing values are MAR and ρ = 1/3. 
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Asymptotically this distribution approaches a normal, by which the symmetry of the distribution 
allows the relative error to equally balance out. However, as the number of missing values 
increases, the chi-square creates a more and more right skewed data. The asymmetry causes the 
relative error to be below zero on average. Aside from this issue, NONE arguably shows the best 
performance when missing values are MAR, having the least average relative error, although the 
variance becomes quite large compared to the other methods for moderate to large amounts of 
missing values. RREG and ML show the worst performance, overestimating the standard 
deviation by 10% when just two values are removed. Bias in these two methods are routinely 2 
to 10 times higher than the five common methods and variation of these estimators is enormous 
in comparison. Neither of the two proposed methods, which assume left-censored missing 
values, handle the MAR data even when the distributional assumption is satisfied. Mistakenly 
applying these left-censored techniques to data which violate this missing assumption can lead to 
poor estimates. The damage is most apparent in the standard deviation where over-estimates of 
50% or more become common for even moderate amounts of missing data. 
Conclusions from the MAR simulation is that when values are missing at random NONE 
appears to be the best option overall, though it will systematically underestimate the standard 
deviation when the number of observed values gets very small and the variance of this estimate 
becomes quite large when more than 50% of the data is missing. K nearest neighbors is also 
effective when the variables in the dataset are moderately correlated, when ρ ≥ 0.33 or higher, 
but will still have issues underestimating the standard deviation once the proportion of missing 
values nears 50%. In these simulations, random forest did not perform any better than kNN and 
for the most part is very similar to imputation with the observed average except when the 
correlation is very high, ρ = 0.9.  
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2.1.1.2. Log-Normal 
 The first examination of non-normality 
involves the log-normal distribution. The main 
purpose of using a log-normal distribution is to 
examine the impact of violation in normality due to 
right-skew. Since metabolomic datasets often 
contain extreme values, right skewness is a 
reasonable possibility. Further, the results of 
Chapter 2 showed that untransformed ion counts 
are frequently right skewed. Performance of the missing value methods in log-normal data will 
elaborate on the potential consequences of not log transforming the data prior to parameter 
estimation. Datasets were constructed in the same fashion as the normal simulation scheme, but 
then exponentiated to produce a log-normal dataset: 
YLN
 ρ  = exp൫Zn×m*Chol൫Ʃρ൯+µ൯ 
The untransformed values µj = 2.65 and σj = 0.3 for j ϵ {1, …, 114}. are used as this produces a 
variable with transformed mean: 
µLN, i = e
ቀ2.65+0.092 ቁ=14.8 
and is similar to that of the normal simulations. The standard deviation was chosen as this 
produces a skewness of: 
𝛾 LN,i =  (e0.09 + 2)ඥe0.09  −  1  = 0.94 
This makes for a moderately right skewed variable as indicated by Figure 3.27. The transformed 
standard deviation however is quite different at a value of: 
Figure 3.27: Probability density function of 
variables used for lognormal simulation. 
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σLN, i = ඥ(e0.36  −  1)e2*2.65 + 0.36 = 5.2. 
However, it is necessary to accept a larger standard deviation than that used in the normal 
simulations in order to get the skewness near 1 and maintain a mean around 15.  
Results of the log-normal simulations are presented in the same manner as previous simulation 
results. Figures 3.28 and 3.29 show the estimated parameter against the uncensored sample 
values. Patterns for the mean parameter are rather like those of the normal simulation when 
missing values are left-censored 
. Mean estimates from NONE and AVG almost appear random except that neither, naturally, 
ever underestimates from the true uncensored value. MIN somewhat tracks with the true value, 
predicting levels above .5 well but performance degrades the lower the true value is and is 
noticeably worse when the true level drops below .2. Recall that under the LOD mechanism, 
lower levels of the true parameter are associated with larger amounts of missing values, while 
higher levels are associated with lower amounts of missing values. RF is very similar to AVG 
(and NONE) when variable correlation is low, and the pattern moves closer to that of MIN as the 
correlation increases. Similarly, kNN estimates are also very similar to MIN and AVG under low 
correlation but, unlike RF, estimation improves as ρ increases. The improvement brought to kNN 
by higher correlation doesn’t produce a patter the same as MIN though, as kNN begins to show 
unbiasedness around .2 or less.  
ML and RREG are shown to underestimate and overestimate at all levels of the true 
parameter, though of course the accuracy is better at higher levels of the true parameter. While 
this general pattern is consistent with simulations of normally distributed, left-censored data, the 
range of the estimates for both parameters is much greater when log normal data is used. In the 
normal, left censored simulation the mean estimates were always above 0.75, whereas here the  
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Figure 3.28: Error in mean under Log-normal simulations. X-axis is uncensored sample mean. Y-axis is predicted 
mean. Columns represent pairwise correlation between variables in data set. Red line represents y=x. 
173 
 
  
Figure 3.29: Error in SD under Log-normal simulations. X-axis is uncensored sample SD. Y-axis is predicted SD. 
Columns represent pairwise correlation between variables in data set. Red line represents y = x. 
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lowest estimates for ML are below 0 and for RREG are below -0.5. The wider range of estimates 
suggests lower accuracy for log-normal data.  
Patterns for the standard deviation are quite different. NONE shows evidence of being 
unbiased but suffers more variability and the occurrence of large outliers compared to the other 
traditional methods. RREG and ML show similar patterns to each other though with a greater 
degree of variability as estimates regularly reach up to .7 while most others are confined to 
below .45. This suggests, as seen in the mean, a lower level of accuracy for the two parametric 
methods. Profiles for AVG, MIN, KNN and RF closely resemble each other indicating a similar 
 level of accuracy that appears better than the other three methods. Once again, the value of 𝜌 
does not appear to be RF as profiles of standard deviation estimates by this method remain 
largely unchanged from ρ = 0 up to ρ = 0.9. The standard deviations calculated using kNN to fill 
in missing values do change as 𝜌 increases, becoming less biased for lower values of the 
standard deviation.  
Figures 3.30 and 3.31 show the relative error in the estimation of mean and standard 
deviation respectively as a proportion of missing values. Profiles in the mean parameter for 
NONE, AVG, MIN, KNN and RF are rather consistent, showing over estimates that increase as 
the proportion of missing values increases. MIN has less error at the higher levels, peaking at 
around 2.2 times the uncensored mean level while AVG and NONE peak around 2.5 times. 
Estimates from kNN show slight improvement as 𝜌 increases, whereas RF does not improve in 
any meaningful way. ML and RREG produce under and over estimates of both parameters but 
are prone to extremely low mean estimates. The magnitude of these underestimates of the mean 
are, once again, most acute in RREG. There is evidence that underestimates of the mean are 
favored as the amount of missing values increases, and the magnitude of the relative error is  
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Figure 3.30: Relative error in mean under Log-normal simulations. X axis in the proportion of missing values. Y 
axis represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.31: Relative error in SD under Log-normal simulations. X axis in the proportion of missing values. Y axis 
represents percent change from uncensored sample value. Red line represents y = 0. 
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extremely large when the proportion of missing values is above 80%.  
Some remarkable differences between the five traditional methods are exhibited in the 
profiles of standard deviation estimates. NONE generally underestimates the standard deviation 
but extreme overestimates begin to appear around 40% missing and increase in frequency and 
magnitude as the proportion of missing values increases. AVG and MIN are rather similar, 
attributed to the right-skew pushing the observed average and minimum closer together. RF 
continues to track with both AVG and MIN with no meaningful improvement seen with 
increasing correlation. KNN has the most unusual pattern. When the correlation is low kNN  
underestimates, though not to the same degree as AVG / MIN / RF. As ρ increases, the bias in 
kNN standard deviation estimates decrease, showing relative error to shrink substantially from ρ 
= 0 to ρ = 0.9. However, as the proportion of missing values rises above 50%, kNN tends to 
overestimate the standard deviation. At ρ = 0.9, kNN appears roughly unbiased for low amounts 
of missing values, biased towards lower values at intermediate to moderate levels of missing 
values, and then biased toward overestimates for high amounts of missing values. RREG and ML 
standard deviation estimates remain similar those of the normal, left-censored simulation with 
the exception of being even more variable and producing even larger overestimates, particularly 
when the missing proportion is above 80%.  
Next, the average relative error plots, given in Figures 3.32 and 3.33, show that on average 
the five common methods (NONE through RF) overestimate the mean parameter with a 
magnitude that is greater magnitude than the two proposed methods. NONE and AVG have 
about 5-10% more bias than MIN. In a familiar theme KNN and RF fluctuate, being similar to 
NONE and AVG when the correlation between variables is zero and moving closer to MIN as 
correlation increases.  ML and RREG are biased towards lower estimates of the mean, though as  
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Figure 3.32: Bias in mean parameter under Log-Normal simulations. X-axis represents percentage of missing values. 
Y-axis is average relative error. 
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Figure 3.33: Bias in SD parameter under Log-normal simulations. X-axis represents percentage of missing values. 
Y-axis is average relative error. 
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a percentage the average error is generally contained to around 20% even as the percentage of 
missing values exceeds 90%. ML fairs better than RREG at high levels of missing values. The 
other five methods reach 20% error when the amount of missing values is between 50% to 70% 
and increase rapidly thereafter.  
For the standard deviation, average relative error is similar in magnitude for all seven 
methods. RREG and ML are biased upwards while the five common methods are biased 
downward. NONE shows a little less bias compared to AVG and MIN. RF again matches closely 
to AVG and MIN, as has been typically observed in these simulations. Performance of KNN is 
similar to AVG and NONE at low levels of missing values but deviates as the missing proportion 
increases from 50% to 100%. When correlation is low this deviation is minor but as the 
correlation increases KNN deviates more strongly towards zero as the proportion of missing 
values increase. In fact, when ρ > 0, KNN fully reverses to a bias of overestimates between 80% 
and 100% missing values. Similar to the mean parameter, ML outperforms RREG in the standard 
deviation as well. 
Finally, Tables 3.10 and 3.11 show the average relative error and variance for the seven 
methods when ρ = 0.33. These show that while RREG and ML are less biased estimators of both 
sample parameters than the other five methods, but that once again the variability in these 
methods becomes extremely high as the proportion of missing values increases. Even for 40% 
missing values these two methods have variance that is 3-4 times higher in the mean and 2-4 
times higher in the standard deviation.  The simulation results for log-normal data reveal that 
none of the seven methods to be unbiased in either parameter when variables are left-skewed. As 
with the previous normal simulations, relative errors in the mean parameter tend to be less than  
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Table 3.10: Relative error averages and variances in Mean parameter from log-normal 
simulations. Missing values are left-censored and ρ=1/3. 
Table 3.11: Relative error averages and variances in SD parameter from log-normal simulations. 
Missing values are left-censored and ρ=1/3. 
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those in the standard deviation, but the overall magnitudes are much more similar. Both of the 
proposed methods are less biased on average than the five common methods; however, once 
again the variability in these methods is much higher, leading to a degree of unreliability.  
2.1.1.3.Uniform Simulations  
The second attempt to examine non-normality involves the Uniform(14,16). As with the 
simulation of log-normal distributions, missing values are removed in a left-censored fashion. 
Results are shown in Figures 3.34-39. Error plots show the five common methods to have a 
similar pattern in both parameters to those of the normal simulation when missing values are also 
left-censored. One minor difference is that here NONE never overestimates the standard 
deviation. Both proposed methods show notable differences compared the simulation results 
using the normal distribution with left-censored missingness. Both proposed methods almost 
exclusively overestimate the mean parameter and neither produces the severely overestimated 
standard deviations seen in the normal, left-censored simulations.  
As with data simulated using other distributions, the range of both parameter estimates from 
RREG and ML compared to the others suggests that these methods are more variable. In the 
relative error plots, the mean is consistently over-estimated by the five common methods and at a 
similar percentage, which ranges from 2% at low to intermediate proportions of missing values 
up to 8% at high levels of missing values. While RREG and ML both produce estimates with 
similar errors, these methods also produce estimates that are close to the original, uncensored 
sample mean. One unusual observation, compared to the previous simulations, is the variation in 
RREG estimates are comparable that of ML. All previous simulations experiments have shown 
the opposite. In the standard deviation, NONE, AVG and MIN show similar patterns of 
underestimation in which the bias consistently increases as the percentage of missing values  
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Figure 3.34: Error in mean under Uniform simulations. X-axis is uncensored sample mean. Y-axis is predicted 
mean. Columns represent pairwise correlation between variables in data set. Red line represents y=x. 
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Figure 3.35: Error in SD under Normal and MAR simulations. X-axis is uncensored sample SD. Y-axis is predicted 
SD. Columns represent pairwise correlation between variables in data set. Red line represents y=x. 
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Figure 3.36: Relative error in mean under Uniform simulations. X axis in the proportion of missing values. Y axis 
represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.37: Relative error in SD under Uniform simulations. X axis in the proportion of missing values. Y axis 
represents percent change from uncensored sample value. Red line represents y=0. 
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Figure 3.38: Bias in mean parameter under Uniform simulations. X-axis represents percentage of missing values. Y-
axis is average relative error. 
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Figure 3.39: Bias in SD parameter under Log-normal simulations. X-axis represents percentage of missing values. 
Y-axis is average relative error. 
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increases. RF is virtually indistinguishable from NONE, AVG and MIN even as the correlation 
between variables in the dataset increases. KNN on the other hand once again improves 
substantially in terms of bias as this correlation increases. RREG and ML continue to over and 
under estimates in both parameters, but, like the other five methods, the greatest magnitudes of 
the error are overestimates of the mean and in underestimates of the standard deviation. The 
average relative error plots are interesting as roughly all seven methods are shown to be quite 
similar in both parameters. This is particularly true with the mean parameter as all methods 
steadily increase from roughly unbiased when the proportion of missing values is close to 0 to 
overestimates of about 6% as the proportion of missing values approaches 1. MIN tends to be a 
little bit better than AVG / NONE while RF and KNN are closer to AVG/NONE when the 
correlation is low and migrate towards MIN as the correlation improves. RREG and ML do a 
little bit better than the other methods, most notably when the proportion of missing values is 
between 50-70%, but the performance of all methods in the mean parameter is fairly close 
throughout.  
Average profiles in the standard deviation are also similar across the methods. All seven 
methods are biased towards underestimation and, with the exception of KNN, the profiles move 
from near unbiased to standard deviations that are basically zero as the proportion of missing 
values approaches 1. Variance estimates approaching zero is expected for the single imputation 
methods, but it is notable that the phenomenon also occurs in both parametric methods. AVG has 
the worst bias followed closely by RF, which is generally different by only a few percentage 
even when ρ = .9. NONE and MIN demonstrate very similar performance and do 10-20  
percentage points better than AVG and RF when the missing proportion is between 20% and 
80%.  RREG and ML have less bias than the other five methods up to missing proportions of 60 
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to 70%. Between 60-70% missing values, kNN becomes the least biased and bias actually 
decreases for this method as the missing proportion increases further.  
The final item for the uniform simulations are Tables 3.12 and 3.13 giving the average 
relative error and associated variance of the seven methods in both parameters when the between 
correlation is 0.33. Estimates of the mean with RREG and ML are about 1-2% better than the 
other methods on average while the variance of their estimates is anywhere from two to ten times 
higher than other methods. Both the bias and variance increase steadily in all methods as the 
proportion of missing values increases. Table 3.13 indicates that RREG and ML have anywhere  
from a one-quarter to one-third the bias that NONE, AVG, MIN and RF do for the most part. 
Table 3.12: Relative error averages and variances in Mean parameter from uniform simulations. 
Missing values are left-censored and ρ=1/3. 
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However, bias for these methods still reaches about 20% when around half of the values are 
missing. ML also degrades more quickly than RREG as the missing proportion increases. kNN 
becomes biased very quickly, underestimating the standard deviation parameter by more than 
20% with only 20% of the  values are missing. But, the bias in the standard deviation parameter 
levels off quickly at just under -40 and becomes less biases above 70% missing values while 
RREG and ML continued to degrade. 
2.1.2. Conclusions 
These simulations show the five common methods consistently underestimate the standard 
deviation and with magnitude that, relative to the original parameter, is much greater than the 
Table 3.13: Relative error averages and variances in SD parameter from uniform simulations. 
Missing values are left-censored and ρ=1/3. 
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error in the mean parameter. This result is not surprising for the single imputation methods AVG 
and MIN, which underestimate in every condition considered here, since the replacement of 
missing values with a constant value naturally decreases variability in the imputed feature. No 
imputation of the data at all is arguably preferable to these methods for this reason, producing 
less biased estimates of standard deviation and having a similar amount of relative bias in the 
mean.  
In every simulation experiment, RF estimates in both parameters proved to be little better 
than average imputation except when inter-variable correlation was the very high (ρ = 0.9) and 
missing values were left-censored, in which case average relative errors in this method were 
closer those of minimuvm imputation. The strong resemblance to average imputation implies 
that the algorithm employed by random forest imputation has little effect except when the 
correlation between the missing variable and the neighbors is very high. In the left-censored 
case, close correspondence to MIN further signals that RF correctly associates missing values 
with low values; however, the imputed values estimated by RF remain at a near constant value. 
The performance of RF in these simulations is surprising given the success of the method in 
other studies [22, 65]. The main difference between these simulations and those studies is that 
here the dataset consists of a single, homogenous population. Datasets examined by others 
involved multiple groups which were found to be statistically significant by hypothesis testing or 
separate by the first two components in a PCA analysis. Such strong group differences are likely 
to enhance the correlation of the data set as within group samples are more similar than between 
group samples. The implication of this is that random forest is effective at picking out averages 
between different populations but does not do well at discriminating between individual values 
within a single population.  
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The best performer of the five common methods is kNN. Similar to random forest, kNN 
always overestimates the mean, being close to average imputation when ρ = 0 and close to 
minimum imputation when ρ = 0.9. However, kNN preserved the standard deviation much better 
even under “weak” inter-variable correlation of ρ =  0.33. This performance in weakly correlated 
data suggests kNN does better than RF at producing an imputed variable whose distribution is 
closer to that of the censored variables.  
Both proposed methods do well when values are left-censored. When the distribution is 
normal, maximum likelihood and rankit regression are nearly unbiased for both the mean and 
standard deviations up to a missing proportion of 80%. In the leptokurtic setting, represented 
here by the uniform distribution, the methods exhibited bias in both parameters, but the 
magnitude of this bias was less than the other methods. Finally, under a log-normal distribution, 
which here was both left skewed and platykurtic, both proposed methods had less bias, in terms 
of magnitude, in the mean while similar bias in the standard deviation.  
It is notable that in the log-normal case maximum likelihood overestimates the standard 
deviation while the other methods underestimated this parameter. The one condition in which 
ML and RREG were shown to struggle was when values were removed randomly rather than 
from the lower tail. Overestimates of the standard deviation by ML and RREG were more severe 
than the underestimates seen in the other methods. This suggests that ML and RREG are more 
sensitive to LOD assumption than to the normality assumption. Another notable observation for 
both proposed methods is that they consistently show higher variance in their estimates than the 
other methods which could lead to a loss of confidence in the methods. Though error estimates 
may be close to zero on average, if the errors vary widely from data set to data set clinicians may 
not feel comfortable relying on the patient z-score results. Confidence is needed for each 
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individual instrument run. As the variance of both parametric methods degrades quickly at high 
proportions of missingness, it seems wise to restrict estimation to only those features with a 
maximum of 70% or 80% missing. 
2.2. Metabolomic Datasets 
2.2.1.  Data Summary 
Metabolomic datasets utilized in this paper consist of the three same sets used in Chapter 2: 
plasma (n = 31), cerebral spinal fluid (CSF; n = 31) and urine (n = 40). Relevant characteristics 
to these experiments are summarized in Table 3.14. The proportion of metabolites containing 
MVs varies between 46% and 60%, fitting with the authors’ previous experience that, as a 
general rule of thumb, roughly half the metabolites have some level of missing values while the 
other half are completely observed. 
2.2.2. Evaluation 
To assess performance of the considered methods in the three metabolomic sets, all 
metabolites with missing values are first discarded. Then, known values from the remaining 
metabolites are removed in a left-censored fashion. Each method is then applied to the artificially 
censored dataset, from which the error between the original sample parameter and the estimated 
value is found. Continuing with the simulated work, “full” datasets are created in order to 
provide data to kNN and Random Forest for which to fill in missing values.  Such mimic datasets 
Table 3.14: Summary of metabolomic data sets indicating the number of samples, metabolites 
and amount of missing data per set. 
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are created by taking those metabolites that are fully observed and randomly selecting half 
(rounding down) to be censored. For each one of the selected metabolites the lowest k values are 
removed with k ~ U(1, n – 2). This process was repeated 500 times for each matrix.  
Following results from Chapter 2, metabolites are log transformed in order to help induce 
normality. Following censoring, metabolites are also median scaled in order to maintain 
consistency with the simulations. The complete steps in order are as follows beginning with fully 
observed data, (1) log transform, (2) randomly sample metabolites for censoring, (3) metabolites 
scaled based on median of “observed” values, (4) estimated parameter value and compare to 
uncensored parameter, (5) repeat steps 2 thru 4 five hundred times. 
To illustrate the value of variable scaling for kNN, Figures 3.40-43 show the estimated 
parameters and their percent bias versus the corresponding sample values in the seven methods. 
There is a pronounced association between error and average metabolite abundance level under 
kNN. The effect is subtle in the mean but more pronounced in the standard deviation. 
Metabolites with high mean values tend to be under predicted in the mean while metabolites with 
lower mean values tend to be over-predicted in the standard deviation. Association between 
performance and metabolite abundance is a result of there being fewer metabolites at the extreme 
margins. For example, in the plasma there are only five metabolites with a mean log abundance 
level above 22. Thus, when one of these metabolites has missing values some of the neighbors 
must be of lower average ion abundance, causing these high abundance metabolites to be 
imputed with lower abundant ones and thus much lower values, dragging down the imputed  
average.  Conversely, the lowest abundant metabolites are forced to rely on metabolites with 
larger ion counts to replace their missing values, but since kNN generally over imputes missing 
values the effect is indistinguishable. A similar problem is seen in the standard deviation, where,  
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Figure 3.40: Estimated mean by true mean after natural log transformation and no further scaling of the 
metabolites (Plasma). 
Figure 3.41: Percent bias in mean parameter by average log abundance without median scaling. kNN under 
predicts highest abundant metabolites due to neighbors generally being of lower abundance. (Plasma) 
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Figure 3.42: Estimated standard deviation by true standard deviation after natural log transformation and no 
further scaling of the metabolites. Plasma data set. 
Figure 3.43: Percent bias in standard deviation parameter by log standard deviation without median scaling. 
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due to the different scaling, it is relatively easy to manufacture a 2- to 3-fold increase. However, 
the other methods are shown to be consistent across the range of the uncensored parameter 
values and, as seen in the subsequent results, variable scaling helps to remove this phenomenon 
in kNN as well.  
The methods considered will be evaluated by examining the error, as described in section 
3.6, between the estimated mean and standard deviation versus their original, uncensored 
parameter values. The intention of viewing the results in this manner is to address the concept of 
bias, which relates the expected value of an estimator against the parameter it is trying to 
estimate. However, direct comparison to the population level mean and standard deviation for  
the metabolites is challenging for two reasons. First, knowledge of metabolite behavior at the 
population level may not be readily available. The Human Metabolome Database [42] does 
provide references to normal levels for many metabolites, but when performing a global profile 
of a sample there is no guarantee that out of the many hundreds detected a reference range will 
be available for all metabolites given the patient demographics and sample type being profiled. 
Second, the semi-quantitative nature of the instrumentation implies that the ion counts in any 
batch do not directly infer a concentration from which population knowledge can be translated. 
Use of the dataset leads to comparisons with the fully observed sample mean and standard 
deviation, which are themselves unbiased estimators of their respective population values. How 
the methods compare to these statistics thus provides some inference about bias while also 
informing how well these methods compared to the fully observed data.  
Lastly, all elements of data pre-processing and processing are worthy candidates for 
influencing the results of data analysis. However, these items work is beyond the scope of this 
dissertation. Instead, we use the best available practice, which in the case of urine involves 
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normalization [100, 102-104]. While plasma and CSF are homeostatic, metabolite concentrations 
in urine are known to be closely associated with creatinine levels and as a result creatinine is 
frequently used to adjust for dilution effects and was previously performed in this data [3]. A 
creatinine factor was created by dividing each sample’s creatinine level by the overall average 
creatinine level and then normalizing by this factor prior to log transformation. This way the 
overall ion counts of the features have roughly the same abundance level after normalization as 
they did before. Maintaining the original abundance scale in the urine prior to log transformation 
retains consistency with the processing steps in the other matrices. 
2.2.3.  Results 
Results of NONE estimating the Mean parameter in one simulation from the plasma dataset 
are shown in Figure 3.44. Each point represents a metabolite selected for censoring with the x-
axis being the proportion of samples removed, kj n⁄ , an  d the y-axis being the relative error. 
Points below the line y = 0 indicate estimated mean for that metabolite was more than the true 
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Figure 3.44: Percent bias under NONE from one image of plasma. Each point represents a biochemical selected for 
censoring in the image. 
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mean while positive values indicate the estimate was lower. For this particular method and 
parameter, all the points are negative as the mean of the observed values will always be more 
than uncensored mean when values are removed from below. As expected, error increases as the 
proportion of values removed increases, though clearly some metabolites are more impacted than 
others. When comparing all seven methods it is most convenient to examine the relative error as 
a function of kj n⁄ , similar to the simulated result average bias plots using in the simulations. 
Performance was remarkably similar across the different datasets. The two parameters are first  
2.2.3.1. Mean Parameter 
Figures 3.45-53 displays the error, relative error and average relative error plots, just as the 
simulations, in the mean parameter for all seven methods across the three datasets. These figures 
are rather consistent across the three matrices, indicating that the five common methods 
consistently overestimate the mean parameter while both proposed approaches are less biased. 
The pattern is similar to those of the normal simulation when missing values are left-censored. 
One exception is that the two proposed methods sometimes demonstrate a notable bias towards 
over or under estimates across the three sets. The magnitude of the errors is consistent with the 
normal, left censored simulations though the relative percentage does appear a bit higher in 
urine.  
Random Forest and kNN track very closely to NONE/AVG indicating that, as expected, the 
low correlation in chemo-centric sets is not sufficient to strengthen these methods very much. A 
series of splinal plots are shown in Figures 3.54-56 representing a smoothed curve for relative 
error as function of kj n⁄ .  The solid black line gives the smooth spline of the average, while the 
dotted bands are the 1st and 3rd quartiles, essentially represent Inner Quartile Range as a function 
of x. Average bias most commonly manifests as over-estimates of the true value. All five of the  
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Figure 3.46: Percent error of mean parameter in Plasma. Each point represents an individual biochemical selected 
for censoring. Red line represents y=0. 
Figure 3.45: Estimated by uncensored mean in Plasma. Each point represents an individual biochemical selected for 
censoring. Red line represents y = x. 
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Figure 3.47: Percent error of mean parameter in CSF. Each point represents an individual biochemical 
selected for censoring. Red line represents y=0. 
Figure 3.48: Estimated by uncensored mean in CSF. Each point represents an individual biochemical selected for 
censoring. Red line represents y=x. 
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Figure 3.50: Estimated by uncensored mean in Urine. individual biochemical selected for censoring. Red line 
indicates y=x. 
Figure 3.49: Percent error of mean parameter in Urine. Each point represents an individual biochemical selected for 
censoring. Red line represents y=0. 
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Figure 3.51: Average relative error of missing data methods for mean parameter in Plasma. 
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Figure 3.52: Percent bias of missing data methods for mean parameter in CSF. 
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Figure 3.53: Percent bias of missing data methods for mean parameter in Urine. 
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Figure 3.54: Trend plot for percent bias of mean parameter in Plasma. Trend lines are based on splinal fits. Solid 
line is the average while dotted are first and third quartiles. Red line indicates no error. 
Figure 3.55: Trend plot for percent bias of mean parameter in Plasma. Trend lines are based on splinal fits. Solid 
line is the average while dotted are first and third quartiles. 
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common metabolomics estimators have similar patterns, with the amount of bias steadily 
increasing as the amount of censored data increases. Both kNN and RF have strong similarity 
with the single imputation methods implying the observed data is not very useful at informing on 
the unobserved portions. In comparison both parametric methods were found to be unbiased up 
until the proportion of missing values reaches 80%. However, for all methods the bias is 
generally small, being no more than 2-5% for even moderate amounts of missing data. Variance 
is also notable. These plots make clear another similarity between the simulated output and the  
real data, namely the increased variability of the proposed methods as the proportion of 
missingness increases. The IQR bands dramatically increase as the missing proportion reaches 
80%, which in these datasets implies 6 or fewer observations, and this behavior is strongest for 
RREG. 
Figure 3.56: Trend plot of percent bias of mean parameter in Urine. Trend lines are based on splinal fits. Solid line 
is the average while dotted are first and third quartiles. 
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2.2.3.2. Standard Deviation Parameter 
Plots for the standard deviation are given in Figures 3.57-68. As with the mean parameter, the 
results are very similar across the three matrices and are consistent with the normal, left-censored 
simulations. The five methods consistently underestimate the true variation in the metabolites. 
AVG, MIN and RF appear as the most biased with magnitudes reaching around 50% for missing 
proportions between 30-60%, and the error nears 80% when the proportion of missing values 
exceeds 80%. kNN demonstrates slightly better behavior with higher levels of missing values, 
indicating the neighbor approach can be useful at extracting structural information in extreme 
circumstances, but overall the standard deviation has been significantly decreased. Of the 
common metabolomics approaches, NONE yields as the least bias. In contrast to the common 
methods, both ML and RREG are practically unbiased throughout. ML is roughly unbiased on 
average up through 80% missing values, at which point it begins to underestimate the standard 
deviation. Conversely, RREG begins to show bias towards over estimate beyond 50% missing 
values in the plasma and CSF. However, in urine this RREG shows less bias than ML throughout 
the range of missing values. 
2.3. Summary 
This paper demonstrates the usefulness of parametric approaches to handle missing data in 
metabolomics, specifically a Gaussian model for the metabolites. Following a natural log-
transformation, maximum likelihood and rankit regression are shown to produce estimates of 
population parameters that are, for all practical purposes, unbiased up to even large proportions 
of MVs. The ability to produce accurate population estimates in the presence of missing values  
has direct value for diagnostic screening, including the identification of IEMs. Additionally, 
these results were observed in three different types of human material following a log  
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Figure 3.57: Estimated by uncensored SD in Plasma. Each point represents an individual biochemical selected for 
censoring. Red line represents y=x. 
Figure 3.58: Percent error of SD parameter in Plasma. Each point represents an individual biochemical selected for 
censoring. Red line represents y=0. 
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Figure 3.59: Estimated by uncensored SD in CSF. Each point represents an individual biochemical selected for 
censoring. Red line represents y = x. 
Figure 3.60: Percent error of SD parameter in CSF. Each point represents an individual biochemical selected for 
censoring. Red line represents y=0. 
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Figure 3.62: Percent error of SD parameter in Urine. Each point represents an individual biochemical selected for 
censoring. Red line represents y=0. 
Figure 3.61: Estimated by uncensored SD in Urine. Each point represents an individual biochemical selected for 
censoring. Red line represents y = x. 
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Figure 3.63: Percent bias of missing data methods for SD parameter in Plasma. 
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Figure 3.64: Percent bias of missing data methods for SD parameter in CSF. 
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Figure 3.65: Percent bias of missing data methods for SD parameter in Urine. 
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Figure 3.66: Trend plot for percent bias of SD parameter in Plasma. Trend lines are based on splinal fits. Solid line 
is the average while dotted are first and third quartiles. 
Figure 3.67: Trend plot for percent bias of SD parameter in Plasma. Trend lines are based on splinal fits. Solid line 
is the average while dotted are first and third quartiles. 
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likely to have a severe impact but a 50% reduction in the standard deviation would double 
transformation, implying metabolites derived from plasma, CSF or urine samples of human 
subjects can be reasonably regarded as log-normal.  
Among data processing steps the log transformation is straightforward as it does not require 
estimating any tuning parameters, such as λ for Box-Cox or δ and α for the generalized log 
(Chapter 2.3). The log, therefore, is invariant to the removal or addition of any samples or ion-
features. Relative comparisons between the two mean and standard deviation indicate that 
imputation is most impactful on the variance of the metabolites. This is highly relevant to z-
scores, as a 5-10% change in the mean, which is about the worst seen in this parameter, isn’t the 
magnitude of a metabolite’s z-score.  
Figure 3.68: Trend plot for percent bias of SD parameter in Plasma. Trend lines are based on splinal fits. Solid line 
is the average while dotted are first and third quartiles. 
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Both kNN and random forest showed weak performance, particularly the latter which was 
virtually indistinguishable from average imputation in the real datasets. Yet both have previously 
been identified as strong performers [22, 64, 66, 105]. It is important to remember that individual 
datasets may have vastly different characteristics and the most effective method is likely to 
depend on the analysis of interest. As previously assessed datasets have focused on identifying 
group differences in the presence of missing values, those datasets have come with an artificial 
group structure. The datasets here consist of a single population, implying that kNN and random 
forest may be effective at picking up differences between groups of samples but weak at 
discriminating between individual values of a homogenous population. Meanwhile both 
maximum likelihood and rankit regression demonstrate near unbiased performance for the mean 
and standard deviation up to a missing rate of 70%. Consistency is another matter as the 
variability of these methods is roughly twice that of the traditional approaches, consequences of 
which are most pertinent at moderate to high levels of missing values. In the three metabolomic 
data sets, maximum likelihood estimates were found to be more stable in general and especially 
for missing proportions above 50%. Lower variation in ML estimates compared to RREG was 
also consistently observed in the computer simulations. Therefore, between the two ML is the 
preferred method. 
Another advantage to the proposed methods is that they can easily be adapted to handle right 
censored values as well. Erroneous values could occur in the upper tail of the distribution with 
ion suppression, in which heavily abundant features are observed but with ion counts that do no 
reflected the true concentration [106]. In certain situations, it may be advisable to ignore values 
above a certain point. More generally, metabolomics data can be subject to extreme high outliers. 
219 
 
Intentionally censoring a certain amount of the highest values, say 1-5%, may be useful in large 
studies to avoid the impact of such outliers or extreme subjects. 
A major untested assumption is that missing values are due to limit of detection. While this is 
a common assumption in the field, our search of the literature returned no papers investigating 
the veracity of this assumption. Further work is required to fully understand the sources of MVs, 
the prevalence of these sources and, ideally, the ability to identify the source of specific missing 
observations. However, when a missing value can reasonably be attributed to LOD, Gaussian 
models are an advisable approach to handling MVs in metabolomics. 
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CHAPTER 4: MERGING METABOLOMIC DATASETS 
4.1. Introduction 
The LC-MS workflow requires periodic maintenance that requires turning off the machine. 
These periods in which the machine is actively processing samples is referred to here as a “runs” 
or “batches”. Instrument performance can vary from run to run. A major obstacle in global LC-
MS based metabolomics is drawing comparisons between samples processed across different 
instrument runs or different instruments. There are several reasons for wanting to compare 
samples from different instrument runs or different instruments. Before being analyzed on a mass 
spectrometer, samples are prepared and a portion is then transferred to an analysis well in a 
multi-well plate. The number of wells available depends on the type and size of wells used but is 
generally some multiple of 6 [1]. Even instrumentation that can accommodate large plates or 
multiple small plates are generally restricted to at most a few hundred wells [2]. Large 
epidemiologic studies with thousands of samples can easily exceed this capacity. In another 
example, a longitudinal clinical experiment or cohort study may not have all samples available at 
one time for analysis. In particular, the clinical environment is analogous to these situations as 
new patients are regularly being admitted and evaluated.  
Mass spectrometry itself is inherently semi-quantitative, with the observed variable returned 
by the instrument being the number of ion counts associated with the feature, i.e. “ion peak”, 
which depend not just on the concentration in the sample but also biochemical and instrument 
characteristics. For a given weight, a compound with higher molar mass will have fewer 
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molecules than a compound with a lower molar mass. Fewer molecules implies fewer ions, 
but the ionization efficiency, which relates the number of ions formed to the molecules available, 
varies by compound as well as with instrument performance. Hence the number of ions 
measured relates to the amount in the sample but is not sufficient to determine concentration. 
Instead, biochemical and instrument calibration are fixed for a given instrument run, which 
allows for inference of relative concentrations for samples within the run. One sample, for 
example, may have 30% more ions than another sample for a given biochemical. While the exact 
amount of the biochemical cannot be determined, assuming the sample types are the same and 
the concentrations are within the linear range of the instrument, one can infer that whatever the 
concentrations may be the first sample is 30% greater than the second. An implicit assumption is 
that ion recovery is linear over the concentrations being measured, which is explained in the 
following paragraph. 
Exact concentrations are derived though calibration curves, aka standard curves, in which 
known concentrations of the target compound are included to provide a reference point for the 
ion counts and calculate the levels in samples of interest according to their position on the curve. 
For a thorough review of calibration curves see the five-part series by Dolan [3-7], but 
calibration curves are most conveniently treated as a linear function. In a dataset consisting of m 
features and n samples, let cji be the true concentration of the ith subject and jth analyte. For yji 
the ion intensity associated with the same sample and ion, the assumption under the linear 
calibration is that 
yji = β0j + β1jcji+ εji 
which is a simple linear regression model. The parameters β0j and β1j, which vary by analyte, are 
estimated via a set of cji's with known concentration. β1j is strictly greater than 0 while the 
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intercept β0j is largely a nuisance parameter and generally close to 0 for any concentration range 
that extends well above the limit of detection of the instrument. In fact, single point calibration 
curves, in which all cji's have the same concentration, remove β0j entirely and can perform well 
when the concentration level is chosen appropriately [8]. Multi-point calibration curves involve 
multiple concentration levels and are better suited for examining the linear assumption. When 
results suggest non-linearity, polynomial models or other non-linear function may be used [9]. 
Alternatively, analysis may be restricted to limits of quantitation in which the assay is found to 
be linear. Producing a sample of known concentration obviously requires being able to measure 
the exact quantity of target metabolite. This will usually require being able to obtain a purified 
amount of the metabolite to measure that, because of chemical reactions that can occur in 
solution, occupies a well. Allocating an entire well to a single compound is clearly infeasible in 
an untargeted analysis as (1) the metabolites to be captured may not all be known a-priori and (2) 
the number of metabolites totals hundreds or even thousands and easily exceeds the available 
sample wells per instrument run. Lacking full quantitation, one must find some way to relate the 
ion counts in different batches to each other. 
This problem is not unique to metabolomics as similar LC-MS instrumentation is used in 
proteomics as well. Normalization is popular in proteomics and represents a potential solution 
for metabolomic data [10-12]. Normalization attempts to correct each individual sample for 
systematic effects due to collection, processing and instrumentation. In theory such correction 
would adjust for instrument effects as well, although metabolites span a much wider range of 
physical properties and chemical classes than seen in proteomics, leaving the effectiveness of 
normalization in global MS metabolomics unknown.  
An alternative to normalization is to include related samples, referred to as anchoring, across 
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multiple instrument runs by which metabolite specific adjustment can be performed. Doing so 
provides a reference point with which to orient the batches to one another. Similar approaches 
have been shown to perform well against standard normalization schemes in GC-MS data [13].  
Through a mix of targeted and untargeted data, this chapter examines the concept in LC-MS 
data. The results show that addressing metabolites individually generates global data that is more 
consistent with targeted concentration and less variable over the whole metabolome versus 
typical normalizations which tend to ignore the breadth of physical properties spanned by global 
LC-MS metabolomics. Furthermore, the number of anchors required to perform this approach is 
investigated and shown to be minimal for the vast majority of metabolites and is therefore not 
burdensome to instrument time and resources. 
4.2. Traditional Normalization 
Normalization is a commonly used method to remove a significant portion of sample to 
sample variation from the data. This purpose distinguishes normalizations from transformations, 
which are used to manipulate quantitative characteristics of metabolite features. In a practical 
manner, in a metabolomics set where the samples are the rows and the features are the columns, 
normalization acts on the rows while transformation acts on the columns. The most common 
normalization is total ion count (or total ion current) normalization (TIC) in which all 
metabolites in a sample are divided by the total number of ions observed in the sample [12]. 
Although commonly used, TIC is susceptible to being overly influenced by a small number of 
features with very large ion counts. Various adjustments to this basic premise include median 
normalization, MS-total useful signal (MSTUS) [14], median absolute deviation [15], 
probabilistic quotient normalization (PQN) [16] and cyclic locally weighted regression (Cyclic 
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Lowess)[17] among others [18, 19]. However, most of these normalizations are built on the 
assumption that on “average” the ion count of each sample should be more or less equal.  
In this paper normalizations are separated into three classes depending on the mechanism of 
action. The first class involves dividing ion intensities by a function of the sample’s ion spectra. 
The second class of normalization relies on Minus-Average (MA) plots. The third class are those 
normalizers that do not fit into either of the first two classes. 
4.2.1. Class I – Spectral Division 
Normalizers of the first class are defined as the ratio of the sample’s raw intensity values and 
a function of the sample spectra. That is to say, letting yj = ቄ yj1 , … , yjm ቅ  be the vector of 
observed ion counts and y j
 Ɲ the resulting normalized vector, the relationship is such that: 
yj
 Ɲ = ቊ
𝑦௝ଵ
ƒ௝(𝒚௝  )
, … ,
𝑦௝௠
ƒ௝(𝒚௝ )
ቋ
ᇱ
 
where ƒj(⦁) is some function. Table 4.1 summarizes ƒj for the first class of normalizations.  
Several of these methods are variations on TIC, such as MSTUS which restricts the summed 
signal to only those features that are common to all samples. Vector Normalization takes TIC 
into two dimensions by measuring the Euclidean distance of the observed vector from the origin 
0, and for this reason is sometimes referred to as Euclidean Norm. Both TIC and Vector 
Normalization are specific versions of the more general form ටΣ y ji
 pp . Mean is simply TIC 
adjusted for the number of features. Median Absolute Deviation (MAD) takes median a step 
further by finding the absolute deviations from the median within a sample and using the median 
of these to normalize. Some Spectral Division normalization methods use a baseline or control 
spectrum correction. Such spectra can be determined a-priori or chosen from the available 
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samples such as the sample with the median TIC. Linear Baseline scaling (LB) and PQN are 
examples of this. In LB, each sample is normalized so that the TIC of the resulting normalized 
sample is equal to that of the “baseline”. LB assumes a constant linear relationship between the 
sample and the baseline. Non-linear extensions are available. Although the name includes 
“scaling”, the intent is consistent with normalization which seeks to adjust all spectrum of each 
sample to the same level in some sense and the computation is consistent with the Class I 
definition. PQN, which involves a four-step process, is the most computation intensive of Class I 
normalizers listed here. In the first step TIC normalization is performed. Second, a control 
spectrum is calculated – this may be based upon a designated sample or the median spectra from 
 
  
TIC ƒ𝑖 = ෍ 𝑥𝑖𝑗
𝑚
𝑗 =1
 
 
MSTUS 
ƒ𝑖 = ෍ 𝑥𝑖𝑗
𝐴
 
𝐴 = {𝑘} 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝑥𝑖𝑘  𝑛𝑜𝑡 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 ∀ 𝑖 ∈ {1, … , 𝑛} 
 
Vector ƒ𝑖 = ቆ෍ 𝑥𝑖𝑗
2
𝑚
𝑗 =1
ቇ
1/2
 
 
Mean ƒ𝑖 = ෍
𝑥𝑖𝑗
𝑛
𝑚
𝑗 =1
 
 
Median ƒ𝑖 = 𝑚𝑒𝑑𝑖𝑎𝑛(𝑌𝑖)  
MAD ƒ𝑖 = 𝑚𝑒𝑑𝑖𝑎𝑛(|𝑌𝑖 − 𝑚𝑒𝑑𝑖𝑎𝑛(𝑌𝑖)|)  
LBa ƒ𝑖 =
𝑚𝑒𝑑𝑖𝑎𝑛(𝑌𝑖)
𝑚𝑒𝑑𝑖𝑎𝑛(𝑌𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )൘  
 
PQNb 
ƒ𝑖 = 𝑚𝑒𝑑𝑖𝑎𝑛{𝑞𝑖1 … 𝑞𝑖𝑚 } 
𝑞𝑖𝑗 =
𝑥𝑖𝑗𝑇𝐼𝐶
𝑥𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ,𝑗𝑇𝐼𝐶
൘  
 
a,b  Baseline / Control spectrum may be taken from a designated sample or calculated from available data, such as 
sample with median TIC. 
Table 4.1: Class I Normalizers 
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all samples may be used. Third, for each feature the ratio, i.e. quotient, of the TIC normalized 
intensity of the sample and control spectrum is found. The final normalizer is then the median of 
all quotients. Most class I normalizers are straightforward to calculate and are not 
computationally time intensive. Hence, these are popular and common choices for normalizing.  
4.2.2. Class II – Minus Average (MA) normalizers 
The second class of normalizers involve the plot of the minus versus average, which are 
essentially Altman-Bland plots on the log scale [20, 21]. For any two samples j and j' the MA are 
the scatter plot where each feature has coordinates ቀminusji , avgjiቁ given by:  
minusji=log2 ቀyjiቁ − log2 ቀyj'௜ቁ 
avgji=
log2 ቀyjiቁ +log2 ቀyj'௜ቁ
2
 
The minus (M) can be viewed as being the log of the ratio while average (A) is the log of the 
product. Orienting the two spectra in this way is intended to magnify systemic effects, both 
linear and non-linear. From this plot a curve can be fit to the data to determine normalized values 
for the two samples. Cyclic Locally Weighted Regression (Cyclic Lowess) and Contrast 
Normalization [22] (CN) are normalizers of this type. Under Cyclic Lowess, a non-linear local 
regression curve (lowess) is fit to the MA plot for a given pair of samples. The process is then 
repeated for all possible pairwise combinations of samples in the dataset. Following a complete 
iteration over all samples, a model tolerance parameter is calculated and the cycle is repeated 
until some tolerance is achieved between the latest cycle and preceding one. The complete set of 
all ion features for all samples can be expressed as 
 Yn×m = ൦ 
y1
y2
⋮
yn
 ൪ 
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in which is  yj=൛y1i, …, ymiൟ is the vector of ion intensities for the 𝑗
௧௛ subject. Under CN, 𝒀n×m is 
log transformed such that  
log(Y)  = 
⎣
⎢
⎢
⎡
 
log( y1)
log( y2)
⋮
log( yn)
 
⎦
⎥
⎥
⎤
 
with log(yj)= ቄlog(yj1), …, log(yjm)ቅ then linearly transformed using a m by m orthonormal 
matrix M to produce a new set of orthogonal vectors: 
YO = log(Y) M. 
The first row of M is the repetition of the constant 1 √𝑚⁄ . The other rows of M are not uniquely 
defined, except in the case of m = 2 which gives 
 M2 = 
1
√2
ቂ 1 11 -1 ቃ . 
For m  > 2, M is not unique which requires some consideration in the next step in which 𝒚1𝟎, the 
first row of YO, is used to predict the remaining rows yj
𝟎 for j = 2, …, n. Referring to these 
predictions as yොi
 𝟎, using loess regression with weighted least squares produces yොi
𝟎’s that are 
invariant to the choice of M. Estimation of yොi
𝟎's is iterated until some tolerance between the 
previous and newest estimate is achieved. The final normalized matrix is then given by  
 Y Ɲ = 
⎣
⎢
⎢
⎢
⎡
 
y1
0
y2
0 −  yො2
0
⋮
yn
0 −  yොn
0
 
⎦
⎥
⎥
⎥
⎤
 . 
From this point the dataset may be analyzed or mapped back to the original space by taking the 
anti-log transformation of each element of Y ƝM. The similarity to cyclic lowess may not be 
immediately obvious; however, notice when m = 2 the contrast matrix M coupled with the log 
236 
 
transformation is analogous to the orientation of the MA plot. Contrast normalization essentially 
generalized the MA concept to higher dimensions. From here, both methods utilize lowess to 
smooth out the normalized values.  
4.2.3. Class III – Other 
Normalizations that don’t fit the criteria of Class I or Class II are considered. One example of 
this is Quantile Normalization (Quant) which rescales the dataset so that the distribution of 
intensities within each sample is the same across all samples. Let yj, ord be the ordered set of 
intensities for sample j: 
 yj, ord = ቄyj[1] , …,   yj[m]ቅ . 
Consider next the vector of average ordered statistics across all yj, ord's: 
 yതord = ቄyത[1], …, yത[m]ቅ  = ቐ෍
yj[1]
n
n
j=1
, …, ෍
yj[m]
n
n
i=1
 ቑ   
This process essentially orders the intensities from lowest to highest within each row of the 
dataset and then takes the average of each rank. The normalized value of any given sample and 
feature is then  
 yji
Ɲ = yത[௤] 
where q ϵ {1, …, m} is the rank of yji among all the intensities for sample j. Notice that the set of 
normalized values is the same for all j. Standardizing the spectra is one advantage to Quant in 
that it directly puts the intensities of each sample on the same scale, making sample-to-sample 
comparisons easier. A significant drawback is that features with missing values must be removed 
or imputed. Second, biochemicals that are significantly more abundant than all other features, 
such as oleate in plasma or creatinine in urine, may be normalized to a near static state. The same 
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problem would occur in metabolites that are significantly lower in abundance than all other 
metabolites; however, this case is uncommon in untargeted metabolomics because a significant 
proportion of features have intensities approaching the instrument’s LOD.  
4.3. Proposed Alternatives for Instrument Run  
This chapter is concerned with alternatives to adjusting for instrument runs that involve 
correcting each metabolite separately. The methodology for such adjustment is accomplished 
through the use of common samples included in each instrument run, or batch, being combined. 
Samples in the same batch are normalized against these common samples, called anchors. 
Computationally, this anchor normalization approach is similar to performing LB but with 
normalization taking place within each batch and acting on the biochemicals rather than on the 
samples. As a result, the proposed method is more accurately classified as scaling rather than 
normalization since the manipulation is performed on each feature (i.e. column) in the data 
independently disregarding any sense of overall spectral equivalence. The intent is not to induce 
any sort of equivalence between the features, such as scaling each metabolite against its own 
mean to put each feature on the same scale or performing log / GLOG transformation to induce 
constant variance. Instead, the purpose of this anchoring approach is to account for systematic 
changes in the samples due to instrument run. The term “normalization” is used for the 
application of the following proposed methods to make clear that the intent of these methods is 
to adjust for instrument variability which has traditionally been the role of normalizations. 
The main challenge to this anchoring approach is finding a baseline between samples across 
different batches. Solutions to such a reference point are considered here in two approaches. The 
first approach, referred to as anchor normalization, uses pooled technical replicates which are 
incorporated each time a new batch of samples is analyzed. The second approach, here referred 
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to as batch normalization, involves balancing the experimental design equally across all 
instrument runs. It should be pointed out that batch normalization described here is not the same 
as Batch Normalizer described by Wang et al. [27], which utilizes the total ion count in its 
normalization of the dataset. Both approaches are described in the subsequent sections. It is 
useful to emphasize once more, that in either case the adjustment is taking place on the 
metabolites (i.e. columns) of the data rather than on the samples (i.e. rows), as is the case with 
typical normalizations. 
4.3.1. Anchor Normalization 
Returning to the linear calibration model, consider two separate instrument runs in which k 
technical replicates of the same sample are run in both batches. The ion intensity of the ith 
metabolite of batch b ϵ {1, 2} for any replicate j ϵ {1, …, k} is given as 
 yjib = βibxie
ηjib  + εjib. 
The subscript of the sample concentration, xi, is dependent only on the biochemical since these k 
samples are technical replicates and thus have the same concentration. Recall that ηib ~ N(0, σηib
2 ) 
and  εib ~ N(0, σεib2 ) so that both terms depend on the batch and metabolite, but not the individual 
replicates. The expected value of any such replicate is then: 
µ௜௕ = E ቂyjibቃ  = βibxie
σεib
2 /ଶ. 
Rearranging these terms gives 
µib = E ቂyjibቃ  = ቀβibe
σεib
2 /2ቁ xi. 
As both the IE factor 𝛽௜௕ and the term resulting from log-normal error component eσεib
2 /2 are both 
fixed, but unknown, parameters depending only on the batch and metabolite, they can be  
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combined into a single parameter term. Letting βib
*  = βibe
σεib
2 /2 it is easy to see that mean ion count 
for the batch is proportional to true concentration level: 
µ௜௕ = 𝛽௜௕∗ xi 
Hence, the mean ion count for the two batches are proportional: 
µ௜ଵ
𝛽௜ଵ∗
=  
µ௜ଶ
𝛽௜ଶ∗
 
By the central limit theorem, there exists a k such that average of the replicates within a batch 
𝑦തib = ෍
𝛽௜௕𝑥௜𝑒ఎೕ೔್+ εjib
𝑘
 
௞
௝ୀଵ
  
is reasonably close to 𝛽௜௕∗ xi.  
Consider experimental samples analyzed on two independent instruments or over two 
batches of the same instrument. Assuming a sufficient number of replicates are used, dividing 
each batch by the average of the batch’s technical replicates will anchor the samples to a 
common scale, namely the relative concentration to the replicate. Hence the term anchor 
samples. 
Anchor normalization is appropriate for batches with small number of experimental samples, 
when the experimental design is unknown, or when the experimental design prevents all sample 
types of interest from being available at the same time, such as a time course or longitudinal 
study. Of course, finding a source of material to use for the inter-batch technical replicates can be 
non-trivial. QC samples, which are included as part of many metabolomic workflows to monitor 
instrument performance [23, 24, 25, 26], are convenient sources of material when available to 
serve as anchor samples. Another option would be to pool a small amount of each sample in the 
first batch, and then inserting aliquots of these into each batch to be combined. Aliquoting into 
each batch requires a-priori knowledge of the situation and requires significantly more material 
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depending on the number of batches forecasted, however.  
4.3.2. Batch Normalization 
Consider a large number of samples drawn from the same experimental design and randomly 
assigned to separate instrument runs. The ion intensity of the ith metabolite of batch b ϵ {1, 2} for 
any replicate j ϵ {1, …, nb} is given as 
yjib = βibxjibe
ηjib  + εjib 
with nb the number of experimental samples in the batch. In this situation the concentration xjib 
depends on the metabolite, sample and batch, since each sample in the experiment represents a 
different individual being tested. However, since each batch is composed of the same 
experimental design and contains a large, randomly selected subset of samples, it follows from 
the Law of Large Numbers that the average concentration of the ith metabolite should be roughly 
the same and equal to the mean concentration of the metabolite µxi. Hence, a similar technique 
can be employed as before for the expected average ion count µyi in terms of the mean batch 
concentration µxi: 
 µyi = E൫𝑦തjib൯ = βibe
σεib
2 /2?̅?jib = 𝛽௜௕∗ µxi. 
This leads to a similar result as in anchor normalization. In a sense, the use of technical replicates 
has been replaced with experimental samples at the cost of requiring for larger sample sizes and 
identical batch designs, which are required to connect the two ends in above equation. 
 In many settings, batch normalization may be more feasible than obtaining enough material 
for technical replicates to serve as the anchor samples for anchor normalization. Additionally, 
analysis of anchor samples increases the number of samples per batch, increasing the cost and 
time required for large experiments. Thus, batch normalization can be considered appropriate for 
large experiments that replicate the study design across multiple batches. Therefore, this 
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approach may be preferable as being more cost effective. And while it does require large 
numbers of samples, the concept can be extended to groups of samples within the batch. For 
example, suppose an experiment of control and stage I disease subjects are run on the first 
instrument batch. After some time, a second batch comparing the same type of control subjects 
to stage II disease subjects. Although the entire experimental design differs between the two 
runs, one could conceivable normalize the two sets based on the common control group. It is 
important to emphasize that when saying the controls are the same “type”, this requires more 
than simply being from the same population. It involves all facets of analysis, including sample 
collection, sample storage, additional preanalytical methodology, and instrumentation. 
Replicating so many stages of the metabolomics workflow could be impractical in many 
situations. Therefore, when all samples of a large study are not available for analysis at once and 
the entire design cannot be replicated at a later date or is too detailed to , the anchor 
normalization approach should be considered. 
4.4. Methods 
The goal of this chapter is to compare anchor (ANCH) and batch (BAT) normalization to 
standard -omic normalizations that might be considered for a metabolomic dataset. The available 
data, which is described in the following section, contains technical replicates of pooled plasma 
included in each batch which serve as the anchor samples. ANCH was performed by median 
scaling each metabolite of each batch against the anchor samples. BAT was performed by 
scaling each batch against the median of the experimental samples contained within that batch. 
In general, the sample mean is more a consistent estimator than the sample median, but the mean 
can be impaired by skewed distributions when the number of samples in small. The results of 
Chapter 2 indicate metabolite ion counts tend to be heavily right skewed; thus, the median was 
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chosen instead out of precaution. 
Normalization methods compared in this section include: total ion count (TIC), median 
absolute deviation (MAD), probabilistic quotient normalization (PQN) and cyclic lowess 
(CLOW). This list includes a representative mix of commonly used Class I and II normalizers.  
4.4.1. Relative Standard Deviation 
All considered normalizations were applied and the relative standard deviation (RSD) was 
compared for each biochemical between the raw (un-normalized) and normalized data. RSD, 
also known as coefficient of variation (CV), calculates the observed variance in an experimental 
group as a percentage of the group average and is often used in clinical chemistry to judge the 
performance of an assay. The total variance will be a combination of biological and instrument 
effects. In theory, lower instrument error should lead to lower RSDs. 
4.4.2. Variance Components of Experimental Samples 
A variance components model using instrument run as a random effect was also performed 
on the experimental samples in the various normalized versions of the data. This model, which 
was fit to each metabolite, is given by 
yjib=µi + D௜௕ + εjib 
in which µi is the overall mean ion count of the i
th feature, Dib ~ N(0,σDi2 ) is the random error 
associated with the bth instrument batch and εjib ~ N(0, σi2) is the error associated with the 
individual measurement representing the population variation where Dib and εjib are independent. 
The variance of an individual sample is then 
 var ቀyjibቁ  = σDi
2  + σi2 
By finding estimates σොDi and σො, the proportion of the overall variance due to the instrument batch 
can be estimated as  σොDi
2 ൫𝜎ොDi2 +𝜎ොi2൯ൗ . Normalizations that effectively address batch-to-batch 
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variation in instrument performance should, ideally, reduce this variance component close to 0. 
4.4.3. Variance Components of Anchor Samples 
 A useful result of decomposing the variance into batch and instrument error components is 
the ability to quantify the number of anchor samples needed to reduce the overall error below an 
acceptable threshold. By fitting a variance component model on the anchor samples gives 
yanch j, ib = µanch, i +  Danch, ib + εanchj, ib 
with µanch, i ,  Danch, ib  and εanchj, ib the parameters specific to the anchor samples but analogous to 
the previously described components model. The variance of the batch anchor average is  
 var ቀyതanch, ibቁ  = σanch, Di
2  + 
𝜎௔௡௖௛,௜ଶ
𝑘
 
where k is the number of anchor samples used in batch b. By increasing k, the contribution of 
batch component to the variance can be reduced to an acceptable level. Reducing this error as 
much as possible is ideal and it is the total variance, which depends greatly on  σanch, Di2 , which 
may be most important. However, acceptable limits of variation are not immediately available 
across the entire metabolome relative to the ion-count levels of a given batch.  
As an alternative, limiting the total variance to within a certain percentage of  σanch, Di2  is 
considered. The formula to determine the minimum size k which keeps the variance of the 
anchor batch average within p% of the instrument error is 
σanch, Di2  + 
σanch,i2
k
 ≤ (1 + p)σanch, Di2  . 
Solving for k gives 
 k  ≥ 
100
p
σanch,i2
σanch, Di2
 . 
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There is no clinically accepted or otherwise immediately obvious value of p from which to 
investigate, but values of 5-20% appear to be a reasonable place to start. 
4.4.4. Global vs. Targeted 
Quantitative measurements using stable isotope dilution LC-MS/MS assays for the true 
concentration of 7 biochemicals detected in the global profiling dataset are also available. 
Normalized versions of the global dataset were compared to the targeted results using Pearson’s 
Rଶ and mean square error (MSE). For the MSE comparisons, both the global and untargeted data 
were centered and scaled to account for the different scales between the ion counts and 
concentration.  
4.5. Data 
Plasma samples from participants enrolled in the Insulin Resistance Atherosclerosis Study 
(IRAS) were obtained for metabolomic profiling. IRAS was a seventeen-year multicenter, tri-
ethnic observational study sponsored by the National Heart, Lung and Blood Institute to examine 
the relationship between insulin resistance and cardiovascular disease [28]. The initial IRAS 
cohort enrolled 1,625 African Americans, Hispanics, and non-Hispanic whites between the ages 
of 45 and 65 in four regions across the country with baseline entry from 1992 and 1994 and a 
five-year follow up. The IRAS Family Study enrolled approximately 1,280 additional family 
members of selected Hispanic and African American members from the original IRAS cohort 
with baseline enrollment between 1999 and 2002 and proceeded by another five-year follow up 
period [29]. The total number of participants for IRAS Family Study was about 1,440 with ages 
ranging from 18 to 81. Material from 1,718 plasma samples collected during IRAS and IRAS 
Family Study were analyzed with global LC-MS/MS metabolomic profiling.  
These samples, which are primarily used for monitoring performance of the instrument, serve 
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as the anchor samples. The entire instrument platform contains four arms, two versions of both 
positive and negative ion modes. The two positive ions modes split the chromatogram in half and 
thusly designated Pos Early and Pos Late. Both negative modes survey the entire chromatogram 
with one specifically intended for polar compounds. These arms are designated Neg and Polar.  
Accommodating the number of samples in the study required between 13 and 15 instrument runs 
per arm. Between 6 and 24 aliquots of pooled plasma were included on each batch. TIC was 
performed on each arm of the platform separately, while the other normalizations were 
performed across the combined arms. 
The resulting analysis measured 1,780 features across the four arms yielding 1,276 unique 
metabolites. Features included for study here are limited to those that were observed in at least 
99% of participant samples, a criterion satisfied by 767 features. Since anchor normalization is 
dependent on measurement of a feature in the anchor matrix, and can be unreliable if not well 
detected, a detection requirement of at least 2/3 in the anchor samples was imposed in order to 
include a feature in this normalization process. Under this requirement, an additional 24 features 
were lost because the anchor samples did not reliably measure these features. Three features 
were lost because the anchor was insufficiently filled in every instrument run, while the other 21 
features were lost due to low fill in at least one but not all runs. 
Seven analytes had previously been shown to be markers for impaired glucose tolerance as 
described by Cobb, Eckhart, Perichon, Wulff, et al. [30]. The markers in question are α-
hydroxybutyrate (AHB)(Polar), β-hydroxybutrate (BHB)(Polar and Pos Early), 4-methyl-2-
oxopentanoic acid (4MOP)(Neg), 1-linoleoylglycerolphosphocholine (LGPC)(Neg, Polar, Pos 
Late), oleic acid (Neg), pantothenate (Neg and Polar) and serine (Neg, Polar, Pos Early). These 
analytes were measured quantitatively using a separate quantitative mass spectrometric assay in 
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all 1,718 subjects. 
4.6. Software 
All analysis was performed in R version 3.4.3 [31]. The following packages were used: 
limma package [32], nlme package [33] and Data Normalization R-script by Hochrein et al. [34]. 
4.7. Results 
4.7.1. Global data 
Results from the variance components model, shown in Table 4.2, show that standard -omic 
normalizations do not effectively reduce the impact of instrument run. Across the 743 features, 
on average 35% of the observed variation is attributed to instrument run. MAD, PQN and 
CLOW do not improve upon this number much whilr MAD actually increases, though only 
slightly and likely to be random noise level, in instrument effect. Overall profiles of the five-
number summary for MAD, PQN and CLOW are more or less the same as the profile of the raw 
data as well. TIC does manage to address instrument variation somewhat, lowering the average 
contribution across the metabolites down to 24% and the five-number summary also shows TIC 
Table 4.2: Variance components in global metabolites. Five-number summary of variance 
proportion due to instrument run across all 743 metabolites. 
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to be consistently lower than Raw. ANCH and BAT on the other hand dramatically reduce the 
variation due to instrument run. This is not surprising for BAT which centers based on the 
participant samples from which the Dib's are calculated. Thus, the variance component is not 
highly insightful in terms of what to expect in a future dataset for this method. ANCH, on the 
other hand, is completely independent of participant samples, and the average instrument 
component here is just 7.3%. Additionally, half of the metabolites in this experiment have a 
component proportion ≤ 3.6% and three quarters have a component proportion below 10%.  
Next, RSDs of participant samples across all metabolites are shown in Table 4.3. Strictly 
speaking, lower RSD need not, as a general rule, automatically signal more effective removal of 
instrument effect. This is because ion counts for the experimental samples include both 
biological and instrument variation, as opposed to technical replicates which contain only 
instrument variation. However, with around one third of the ion count variation being due batch 
effects on average, it seems reasonable that normalizations effectively removing instrument run 
will generally be lower. On average the overall standard deviation is roughly 63.5% of the 
Table 4.3: Coefficient of Variation in global metabolites. Five-number summary of RSDs 
across all 743 metabolites.  
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metabolite mean in the uncorrected data. All of the normalization methods generally reduce the 
RSD, both on average and across the quantiles of the five-number summary. The standard -omic 
normalizations show a small, but consistent decrease in the RSD with an average value around 
59%. ANCH and BAT are even lower, with ANCH less than 55% on average and BAT less than 
53%. 
Moving on to the variance components model in the anchor samples, the five-number 
summary for the proportion due to the batch component, σොanch, Di , in the raw data is as follows: 
Minimum = 8.3%, 1st Quartile = 75.8%, Median = 87.9%, 3rd Quartile = 93.3%, Maximum = 
98.9%. The average σොanch, Di is 82.5%. So, as expected variation between instrument runs account 
for a great deal of variability, with an average 82.5% of the variation in the raw ion counts of the 
anchor samples being due to this batch effect. Figure 4.1 plots the individual σොanch, Di's against 
their respective σොanch,i's. Interestingly, the estimated standard deviations of the two components 
are somewhat similar in scale, though batch component does tend to be larger the replicate 
component, which fits with the average percentage due to batch being so high. The plot is also 
populated with several outliers in both components. Taking a log transformation helps to better 
Figure 4.1: Instrument run variation versus instrument error variation. Based on estimates from variance 
components model  
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see the individual standard deviation estimates and reveals a weak, positive correlation between 
the two components. Table 4.4 shows the five-number summary across all metabolites for 
sample size required to minimize instrument error to no more than 5% of the batch component. 
On average the metabolites require just over 10 replicates, but this is inflated by the presence of a 
few metabolites requiring extremely large sample sizes. Three quarters of the metabolites 
surveyed actually require just over 2 replicates and 86.4% require 5 or less (not shown). 
4.7.2.  Targeted Versus Global  
For the 7 metabolites measured by both the quantitative and semi-quantitative assays, raw ion 
counts are plotted against their concentration levels from the targeted analysis in Figures 4.2 and 
4.3. Individual points are colored by instrument run and there is noticeable banding of colors in 
most of the features. Among the metabolites that are measured on multiple arms, instrument 
effect can vary by arm. Plots for LGPC for instance indicate a handful of rather poor performing 
batches in Polar and Pos Late, but in Neg batch differences are less pronounced. Similarly, serine 
has clear differences between instrument days on Neg and Polar, but such effects are not as 
apparent on Pos Early. Thus, neither arm is likely to be superior overall, but certain arms may 
perform better for certain metabolites. Table 4.5 and Figure 4.4 show the R2 between the 
clinically measured concentrations and raw intensities by normalization method. Certain 
metabolites correlate better than others. Oleate has raw Rଶ of 0.777 while 4MOP has a raw R2 of 
0.584 for instance. Additionally, for metabolites observed on multiple arms the performance may  
Table 4.4: Summary of minimum anchor replicate limiting instrument error to 5%. Based on 
estimates σොanch, i
2  and σොanch, Di
2  from variance components model. 
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Figure 4.2: Targeted vs raw ion counts. Points are colored to highlight separate instrument runs. 
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Figure 4.3: Targeted vs raw ion counts continued. Points are colored to highlight separate instrument runs. 
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Table 4.5: R2 in targeted metabolites. Targeted concentrations from clinical assay versus 
global ion counts. 
0.000
0.200
0.400
0.600
0.800
1.000
Raw TIC MAD PQN CLOW ANCH BAT
Figure 4.4: R2 in targeted metabolites. X-axis are individual biochemical versions listed in ascending order of raw 
R2. Platform names have been shortened such that N = Neg, P = Polar, PE = Pos Early and PL = Pos Late. 
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Table 4.6: MSE for targeted metabolites. Targeted concentrations and global ion counts are mean 
centered and scaled against the standard deviation. 
Figure 4.5: MSE for targeted metabolites. X-axis are individual biochemical versions listed in ascending order of 
raw MSE. Platform names have been shortened such that N = Neg, P = Polar, PE = Pos Early and PL = Pos 
Late. 
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better on certain arms than on others, which is consistent with the plots in Figures 4.2 and 4.3.  
This phenomenon is most evident in LGPC, where the raw ion counts have an R2 on the Neg arm 
of .396 while the other two arms for this biochemical are just above .06. Similarly, serine has a 
R2 in the raw data on Pos Early of nearly 0.8 while the Neg and Polar versions are below 0.5. 
Some versions are more prone to instrument effects and higher instrument effect will introduce 
more variation. In extreme cases, as with LGPC on Polar and Pos Late, the instrument’s ability 
to measure the biochemical is lacking to the point that the version of this compound is not 
trustworthy. Examining the normalized versions of the data, it is often the case that typical 
normalizations actually result in a lower R2 compared to the raw version of the data. MAD 
consistently has the lowest R2 of any data version. TIC, PQN and CLOW occasionally have a 
higher R2, but, as Figure 4.4 clearly shows, for the most part typical normalizations provide no 
obvious improvement to this measure. Anchor and Median normalization on the other hand 
always have a higher R2 than the raw data. Furthermore, with the exception of LGPC, the R2 
levels are consistently around 0.9, which represents a very strong improvement for AHB, 4MOP 
and serine (Neg version).  
Examination of the MSE, shown in Table 4.6 and Figure 4.5, is consistent with the R2 
results. While MSE levels vary by biochemical and platform arm, traditional normalizations 
generally increase the amount of error between global and targeted versions. In contrast, ANCH 
and MED have consistently lower MSE over the raw version and in some cases, most notably 
AHB and serine, the decrease is quite large.   
The various versions for each analyte are plotted in Figures 4.6-4.18. These help to illustrate 
visually the superior performance of ANCH and BAT at reducing the instrument run effect. 
Color bands associated with the separate run days collapse together while the points tighten  
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Figure 4.6: Normalization comparisons to targeted levels in 3-hydroxybutyrate (Polar Platform). 
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Figure 4.7: Normalization comparisons to targeted levels in 3-hydroxybutyrate (Pos Early). 
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Figure 4.8: Normalization comparisons to targeted levels in 4-MOP. 
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Figure 4.9: Normalization comparisons to targeted levels in L-GPC (Neg). 
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Figure 4.10: Normalization comparisons to targeted levels in L-GPC (Polar). 
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Figure 4.11: Normalization comparisons to targeted levels in L-GPC (Pos Late). 
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Figure 4.12: Normalization comparisons to targeted levels in Oleate. 
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Figure 4.13: Normalization comparisons to targeted levels in Pantothenate (Neg). 
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Figure 4.14: Normalization comparisons to targeted levels in Pantothenate (Polar). 
264 
 
   
Figure 4.15: Normalization comparisons to targeted levels in Pantothenate (Pos Early). 
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Figure 4.16: Normalization comparisons to targeted levels in Serine (Neg). 
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Figure 4.17: Normalization comparisons to targeted levels in Serine (Polar). 
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Figure 4.18: Normalization comparisons to targeted levels in Pantothenate (Pos Early). 
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across the whole range of clinical concentrations. Relationships between untargeted and targeted 
data is fairly linear. The exception to this observation is oleate which displays concavity in the 
form of higher values being increasingly depressed. This pattern is consistent with ion 
suppression, but curiously the non-linearity is present in normalized versions only, particularly 
TIC, and not the raw values. Other analytes from the same arm as oleate (Neg) do not display 
this behavior, implying that while normalization is over-correcting oleate the problem is not due 
the arm itself. 
4.8. Conclusions 
Results in both the global and targeted data support that normalization based on anchor 
samples or experimental samples themselves at the individual compound level are much more 
effective at reducing variation due to instrument run. In every instance of the 7 metabolites with 
available clinically derived concentrations, anchoring improved the R2 and MSE over the raw 
data. The standard omic normalization frequently resulted in little to no improvement, and on 
occasion would worsen the association between the global and targeted values. Across all global 
metabolites, anchoring consistently lowered the observed variation in the data more so than the 
omic methods. There is some evidence that scaling based on the experimental samples 
themselves does better than anchoring from the independent set of technical replicates. However, 
in practice this may be difficult due to the number of samples available at the time of each 
instrument run or the number of experimental groups that must be randomized. The results 
presented here suggest Anchor normalization with as few as 5 technical replicates was extremely 
effective and can be feasibly accomplished through the use of quality control samples which are 
already available in many metabolomic workflows. 
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CHAPTER 5: SUMMARY 
The chapters comprising this dissertation have practical and immediate implications to 
challenges of applying untargeted, global MS metabolomics to the clinical environment, and also 
to the field in general. Chapter 2 informs on basic metabolite characteristics across three 
common human matrices: plasma, urine and cerebral spinal fluid. Across all three of these 
matrices, raw ion counts of the chemo-centric approach to metabolomics displayed a consistent 
right skew that was largely corrected using a natural log transformation. Furthermore, 
correlations between features using a chemo-centric approach are generally moderate at most, 
with average correlations of around 0.3. This knowledge is helpful when simulating metabolomic 
data when examining feasibility of experimental designs or estimating sample size from power 
calculations.  
Building upon this, Chapter 3 presents new parametric methods for handling missing data in 
metabolomics when values are left-censored due to the true value falling below the instruments 
level of detection. Compared to standard imputation approaches in the field, both methods are 
shown to produce more accurate estimates of population parameters. This is most critical to 
estimates of variance, which can be severely under-estimated in imputed data. Conversely, both 
proposed methods remain largely unbiased in both the mean and standard deviation even when 
up to 70-80% of metabolite values are missing. This has clear value for establishing reference 
ranges of healthy populations, but also for every day metabolomic studies as the problem of 
missing values is inherent to global MS and researchers often employ designs with few sample 
sizes due to cost and availability. Parametric approaches can help to maximize power while also 
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providing more robust results. 
 The final chapter demonstrates typical omic normalizations that more or less treat all 
features the same, disregarding the various types of chemical classes present in a global 
metabolomics set, is deeply flawed. When addressing instrument run effects, such approaches 
are no better, and often worse, than using the raw ion counts alone. Adjusting for instrument run 
at the metabolite level, rather than sample level, via a group of anchor samples included in the 
run or balancing the experimental design across the instrument runs is far more effective at 
reducing batch effects. Further, when using technical replicates to anchor the batches together, 
the number of replicates required can be quite low implying minimal cost of instrument 
resources. This is useful both for clinical practice, which is continuously evaluating new 
samples, and for large metabolomics studies requiring multiple instrument runs.  
While each of these chapters address key elements of metabolomics for clinical practice, 
truly implementing these techniques requires doing so simultaneously. Handling missing values 
across multiple merged sets presents a complication as metabolite detection may vary from batch 
to batch. Assuming different levels of LOD per batch, maximum likelihood is capable of 
handling this whereas rankit regression is not. However, in anchored data missing values may 
occur because the metabolite was not detected in the anchor samples. For samples in these 
batches, it may be more appropriate to treat them as MAR. This gets at the larger issue that a key 
assumption in these paper, that missing values are due to LOD, is left untested. Although it is 
generally assumed, it is also believed that some proportion is due to other reasons. An 
examination into the sources of missing values and their relative contribution to the overall 
missingness would be highly valuable. If a significant proportion of missingness is MAR, 
maximum likelihood with truncated rather than censored samples may be more advisable.   
